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Abstract to Thesis 
 
Mutations in the RAS-RAF-MEK-ERK (MAPK) pathway give rise to a range of 
developmental disorders collectively referred to as the RASopathies. De novo germ-
line mutations in patients suffering from these syndromes promote similar 
phenotypes, which include heart abnormalities, characteristic facial features, 
cutaneous malformations, gastrointestinal malfunctions, failure to thrive and a 
spectrum of mental retardation. Although many RASopathies patients show a 
propensity to develop early-onset benign and malignant tumours, Cardio-facio-
cutaneous (CFC) syndrome patients do not seem to share this predisposition, with the 
exception of an increased number of naevi.  
 
CFC syndrome is caused by mutations in BRAF, MEK1 or MEK2, with the majority 
of patients harbouring BRAF mutations. Intriguingly, both kinase-activating and 
kinase-impaired mutations have been identified in CFC patients. Here, I use the 
zebrafish system to address the activity of the CFC syndrome alleles and the MAPK 
pathway in a developmental context and test the potential of small molecule 
inhibitors to restore normal development. 
 
I established an assay for the activity of CFC, melanoma and engineered BRAF and 
MEK human mutated alleles in vivo.  Using zebrafish as an animal model organism, 
a panel of 31 mutant and wild-type BRAF, MEK1 and MEK2 alleles were expressed 
in early zebrafish embryos to assess their role in development. Irrespective of the 
predicted kinase activity, all embryos expressing BRAF and MEK mutant alleles 
reproducibly manifested the cell movement phenotype during gastrulation. 
Consistent with aberrant fibroblast growth factor (FGF) signalling and defective 
gastrulation, in situ hybridisation against convergence-extension markers showed 
misregulated convergence-extension movement patterns in CFC zebrafish embryos. 
Finally, I performed whole embryo RNA expression microarrays to identify genes 
regulated downstream of the CFC mutations, and I discuss the potential for a 
possible link to some of the phenotypes associated with a CFC zebrafish model. 
 
 
I established that the CFC, BRAF and MEK mutant embryos are sensitive to 
inhibition of MEK signalling by small molecules. Importantly, a time-window of 
treatment was identified which was sufficient to restore normal gastrulation 
movements and to prevent the developmental side effects promoted by the inhibitors 
at later stages of development. In order to begin considering the therapeutic potential 
of small molecules in developmental disorders (at least in our model system), the 
effect of low concentrations of the inhibitors in the normal formation of diverse 
tissues was thoroughly examined during zebrafish development. From these studies, 
I identified a concentration of MEK inhibitor that could be administered in a 
continuous fashion to prevent CFC-associated cell movement defects during 
gastrulation, without additional later developmental defects. 
 
Finally, I addressed the role of MEK-ERK signalling in a specific behavioural 
phenotype in zebrafish. Many RASopathies patients suffer from mental retardation 
and experience learning and attention difficulties. Research in our laboratory has 
identified a novel zebrafish behaviour induced by enhanced cAMP signalling, where 
the zebrafish seek shaded areas in their environment and exhibit frequent defensive 
shoaling behaviour. I used western blotting to establish that enhanced cAMP 
signalling activates the MAPK signalling pathway and, in collaboration with 
members our laboratory, that this phenotype can be suppressed by administration of 
the PD325901 MEK inhibitor. While we do not yet know the effect of CFC 
syndrome mutations on this behaviour, we suggest that altered MEK-ERK signalling 
may underlie important features of vertebrate behaviour. 
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1.Chapter 1 – Introduction 
 
“The past is the beginning of the beginning and all that is and 
has been is but the twilight of the dawn”  





1.1. The MAPK pathway 
 
Cells are constantly exposed to a plethora of conditions and have developed the 
capacity to monitor and respond to their environment. Signals such as hormones, 
growth factors, stress and inter-cellular communications activate membrane 
receptors and their tethered signalling cascades. Such integral pathways control cell 
fate decisions by promoting genetic and physical changes. The 
RAS/RAF/MEK/ERK cascade is one of those cascades and is conserved from yeast 
to plants and animals (reviewed in Widmann et al., 1999). Triggered by extracellular 
stimuli, mitogen-activated protein kinases (MAPKs) transduce multiple intracellular 
signals (reviewed in Yoon and Seger, 2006) that control cellular growth, 
differentiation, proliferation, senescence and apoptosis (reviewed in Pearson et al., 
2001). The structure of each canonical MAPK pathway is based on the function of 
three sequentially activated kinases: a MAPK kinase kinase (MAP3K), a MAPK 
kinase (MAP2K) and a MAPK.  
 
To date, six distinct MAPK pathways have been identified, each of which promotes 
downstream signalling via different kinases; namely, ERK1/2, ERK3/4, ERK5, 
ERK7/8, JNK1/2/3 and p38// (ERK6)/, respectively (reviewed in Chang and 
Karin, 2001). ERK5 is specifically regulated by MEK5 signalling, the p38 isoforms 
are directly activated by MEK3 and MEK6 and the JNK kinases are phosphorylated 
by MEK4 and MEK7 (reviewed in Bogoyevitch et al., 2004; Garrington et al., 
1999). Interestingly and unlike the other pathways, the ERK3 and ERK7 MAPK 
cascades are constitutively active (reviewed in Coulombe and Meloche, 2006) with 
the mechanism of activation of ERK8 still remaining largely elusive (Abe et al., 
2002) and the role of ERK4 only recently beginning to be deciphered (Rousseau et 
al., 2010). The present thesis, however, is focused on the activity of ERK1/2 MAPK 
signalling, whose frequent association with various human cancers and identification 
of cascade components as prominent oncogenes (reviewed in Kolch, 2005) have 




1.2. Working with zebrafish 
 
1.2.1. Advantages of the zebrafish model organism 
Knockout studies on mice have been informative on the importance of MAPK 
components expression in cancer and development. However, the physiological role 
of individual MAPK pathway component mutations in vivo has not been explicitly 
tested in the framework of an animal system. Zebrafish studies provide the advantage 
of exploring the developmental effects of an allelic series and as embryos develop ex 
utero, they are readily observed in detail from the very first stages of development. 
 
Zebrafish (Danio rerio) are small cyprinids, native to the banks and shallows of low-
current rivers, ponds and paddy fields of southern and south-east Asia. They are a 
carnivorous species feeding mainly on small insects on the surface of the water 
(reviewed in Miller and Gerlai, 2011; Spence et al., 2008).  
 
Zebrafish are amongst the smallest vertebrate animals with a fully developed innate 
and acquired immune system and have been established as a system for genetic, 
developmental, behavioural and pharmacological investigations. They provide a 
good platform to model human diseases both in genetic and functional assays and as 
such, they are not only an efficient complement to other mammalian models but have 
additional advantages over other them. 
 
The nature of embryonic zebrafish provides key advantages from a methodological 
perspective and has facilitated the development of a number of technologies. Firstly, 
embryos are small, are fertilised ex utero and remain translucent throughout 
organogenesis. These factors together have assisted in developing sophisticated 
imaging that has widened our understanding of organ development and function 
(Auman and Yelon, 2004; Kimmel et al., 2001) as well as allowed image-based 
high-throughput screening of cancer therapeutic drugs (Evensen et al., 2010). Their 
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optical transparency has been their most exploited feature as it permits visualisation 
of internal organs as well as targeted tissues and single cells. For instance, expression 
patterns of genes with GFP-tagged promoters can be readily tracked in individual 
tissues via fluorescence microscopy in transgenic live embryos (Figure 3.2.2). 
Similarly, RNA in situ hybridisation allows for similar gene expression analysis in 
fixed samples (Figure 2.2.5).  
 
Secondly, larvae younger than 5 dpf are fully permeable to small molecules. This 
allows for effective pharmacological treatment and whole body staining through 
passive diffusion of the molecules. Thus, zebrafish are well suited for large- and 
small-scale library screens, especially for those designed to identify modifiers of 
developmental processes. A large number of chemical screens have already been 
carried out in zebrafish, some of which have identified new used for established 
drugs (White et al., 2011; Yeh et al., 2009; reviewed in Taylor and Patton, 2010). 
Additionally, smaller screens have been able to shed new light on the mode of action 
of small molecules by elucidating their specific targets (Ishizaki et al., 2010). More 
importantly, the timing of small molecule addition and therefore the inactivation of 
their targets can be tightly controlled. This level of control can provide insight into 
the spatiotemporal regulation of individual target proteins and can deepen the 
understanding of normal developmental processes. The temporal control of small 
molecule inhibition is further explored in Chapter 3.  
 
Thirdly, the prolific nature of zebrafish allows a single pair of adult fish to breed 
once in four to five days and produce an average of 100-300 embryos per mating. 
Thus, high-throughput experiments greatly benefit from abundance of progeny.  
 
Moreover, embryonic development is fully completed at 5 days postfertilisation (dpf) 
and their rapid embryonic maturation rate allows for quick screening of embryonic 
phenotypes. This provides a vast array of developmental information that can be 
easily assessed by direct observation. Finally, establishment of adult transgenic lines 
is relatively fast as individuals reach adulthood within 3 months. In addition, the size 
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of adult zebrafish, smaller than 4 cm, and low cost allow thousands of fish to be 
maintained in a relatively small space. 
 
1.2.2. Genetic and transgenic models  
Large-scale genetic screens and more recently chemical modifier screens have been 
carried out to generate a large number of transgenic and knockout animals (reviewed 
in Amsterdam, 2006). In the last decade, the zebrafish community has increased in 
size allowing for the development of a large collection of publicly available 
resources. Such tools include an annotated zebrafish genome sequence, gene 
expression atlas, microarray platforms and central sources of mutant and transgenic 
lines. 
 
Gene knockout technology in zebrafish has been more challenging than in 
mammalian models due to the absence of homologous recombination. However, both 
temporary gene silencing and permanent gene disruption are available options. A 
simplistic and effective approach to gene silencing in developing embryos is via the 
use of morpholino oligonucleotides (MOs). The latter are short oligonucleotides 
injected at the single cell-stage embryo and are designed to hybridise with mRNA, 
either impeding its translation (translation block MO) or its proper splicing (splice-
site MO).  
 
Generation of stable knockout lines can be achieved both by genetic and chemical 
approaches. Zinc finger nucleases (ZFNs) act by specifically binding to zebrafish 
DNA and creating double strand breaks in the sequence of interest (Miller et al., 
2007). However, the cost, difficulty of design and time dedicated to optimisation are 
significant and limit the use of this technique.  
 
A different technology aiming to create knockout lines is chemical mutagenesis. 
Mutagenesis screens are easily and cost-effectively carried out. This approach 
induces random point mutations in the genome and identification of specific 
mutations relies on sequencing of genes of interest. High-throughput ENU 
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mutagenesis (Solnica-Krezel et al., 1994) and TILLING (targeting induced local 
lesions in genomes) projects (Stemple, 2004) are ongoing and have, to date, 
established tens of knockout lines, available upon request.  
 
A final way to study of the effect of individual mutations in a physiological 
framework is through zebrafish transgenics. Zebrafish represent an ideal model to 
transiently express a mutant gene of interest to assess its role during development in 
the context of a wild-type or mutant individual. Direct injection of the coding mRNA 
into a single cell-stage embryo promotes ubiquitous expression albeit short-lived 
(Figure 2.2.3). Additionally, studying genes in a tissue-specific microenvironment is 
possible by expressing transgenes under tissue-specific promoters (Figure 2.2.7). 
Finally, making use of the transposon Tol2, DNA sequences are randomly but stably 
incorporated in the zebrafish genome (Kawakami et al., 2004). 
 
1.2.3. Zebrafish as a model for human diseases 
With all these resources in hand, zebrafish are becoming an ever-relevant model to 
study human diseases. The initial focus of the zebrafish field was on developmental 
biology. However, the identification of a large number of mutant phenotypes 
resembling human disorders in two initial large genetic screens (Driever et al., 1996; 
Mullins et al., 1996) changed the way zebrafish was approached in research. 
Immediate attention was shifted towards the histological and genetic similarity 
between zebrafish and humans that share major genes and signalling pathways as 
well as tumour histopathology (Amatruda et al., 2002). Zebrafish models of human 
cancer include HRAS (Santoriello et al., 2010) and BRAF
V600E
 melanoma models 
(Patton et al., 2005) and KRAS rhabdomyosarcoma models (Langenau  et al., 2007). 
 
The conservation is not limited to neoplasia formation. Early embryogenesis, 
development and body axis formation are governed by molecular processes 
conserved across vertebrates. For example, neurulation and further neural crest cell 
migration and differentiation are integral to the proper formation of the heart, 
craniofacial structures, melanocytes and glial populations. The specific roles of 
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neural crest cell populations are discussed in further detail in Chapter 3 (Section 
3.1.8). 
 
Finally, zebrafish are increasingly being used in behavioural studies. A large number 
of tests have been developed to assess social aspects of zebrafish behaviour, 
including anxiety, social interaction (shoaling), fear, learning and memory (reviewed 
in Norton and Bally-Cuif, 2010). Such behavioural genetic studies focus on the 
relationship between genes or even specific mutations and a quantifiable manifested 
behavioural phenotype. Their main scopes are both to understand the behavioural 
aspect of human disorders as well as rapidly identify compounds that alleviate or 
ameliorate behavioural symptoms. A series of behavioural studies introducing a 
novel link between MAPK regulation and zebrafish behaviour is presented in 
Chapter 4. 
 
Taken together, it becomes evident that zebrafish offer a platform for highly 
controlled in vivo experimentation and for development of new techniques. In the 
scope of this project, the zebrafish system will be used aiming to advance 
comprehensive understanding of developmental processes and disease-promoting 





2. Chapter 2 - The Activity of CFC 
Alleles In Vivo 
 
“Somewhere, something incredible is waiting to be known”  
 - Carl Sagan 




2.1.1. Signalling down the MAPK cascade 
In the presence of extracellular signals transmembrane receptor tyrosine kinases 
dimerise resulting in their autophosphorylation. The receptor phosphorylation 
promotes the activation of the RAS-SOS-GRB2 complex, a step that initiates a 
cascade of serial downstream phosphorylation events (reviewed in Orton et al., 
2005). In more detail, in their active GTP-bound state, the human RAS proteins 
(HRAS, KRAS and NRAS) recruit the cytosolic RAF kinases  (BRAF and C-RAF) 
to the plasma membrane and activate them by binding to the RAS-RAF binding 
domain (reviewed in Wellbrock et al., 2004). Phosphorylated C-RAF and BRAF, in 
turn, stimulate MEK1 and MEK2. Finally, the activated MEK kinases phosphorylate 
ERK1 and ERK2.  Phospho-ERK1/2 (pERK1/2) further signal to several cytosolic 
pathways as well as translocating to the nucleus to phosphorylate transcription 
factors such as c-Myc, Ets-1 and Stat-3 (Figure 2.1.1).  
 
As pERK triggers multiple biochemical signals and has a key role in the cell cycle 
progression (reviewed in Kolch et al., 2005), it is vital that the output of the MAPK 
cascade is regulated by positive and negative feedback loops. This tight control is 
enforced by components of both the MAPK pathway itself and parallel pathways. 
For instance, to inhibit its over-expression, ERK negatively signals back to SOS-
GRB2 turning the pathway “off” (Kamioka et al., 2010). Additionally, downstream 
effectors of ERK affect the activation of individual MAPK pathway components. 
Dual specificity phosphatase (DUSP) proteins, achieve ERK1/2 de-phosphorylation 
(Jeffrey et al., 2007) with the cytoplasmic DUSP6, in particular, acting as a potent 
negative regulator of FGF/MAPK (Zhang et al., 2010). PAK tightly controls MEK 
activation by C-RAF and high pERK levels inhibit PAK to terminate the association 
(Eblen et al., 2004). pERK can also trigger a positive feedback loop by inactivating 
the RAF kinase inhibitor protein (RKIP) (Shin et al., 2009), a protein that prevents 
the BRAF-MEK complex formation (Yeung et al., 2000). 
 




Figure 2.1.1 The MAPK pathway 
 
Schematic illustration of the MAPK pathway and some of its regulatory feedback loops. The 
components of the pathway that are mutated in the RASopathies spectrum are highlighted in separate 
boxes. 
 
Control of MAPK signalling and specific expression of its components are crucial to 
ensure proper development and health. This becomes more evident when studying a 
number of different oncogenic and developmental diseases propagated by germ-line 
or somatic mutations of RAS/MAPK pathway genes (reviewed in Burkitt Wright and 
Kerr, 2010; Aoki et al., 2008; Bentires-Alj et al., 2006). To that end, further in vivo 
models would greatly benefit the understanding of how the RAS/MAPK pathway 
responds in cases of misregulation.  
 
2.1.2. The MAPK pathway in the onset of “RASopathies”  
Oncogenes are misregulated in cancer but it is not uncommon that, under normal 
conditions, they are essential for development and survival. The MAPK pathway has 
been the subject of extensive research for the past two decades due to the high 
mutation incidence of its components in human cancer. Recently, though, germ-line 
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mutations have been identified in genetic developmental syndromes (reviewed in 
Bentires-Alj et al., 2006).  
 
By virtue of the patients’ phenotypic overlap the medical genetic disorders of the 
MAPK pathway were collectively referred to as the neuro-cardio-facio-cutaneous 
(NCFC) syndromes (reviewed in Bentires-Alj et al., 2006). However, this term has 
been updated to “RASopathies” to reflect the genetic overlap between the disorders 
(reviewed in Tidyman and Rauen, 2009). The RASopathies spectrum includes the 
cardiofaciocutaneous syndrome (CFC), Costello syndrome (CS), Noonan syndrome 
(NS), LEOPARD syndrome (LS), Neurofibromatosis Type 1 (NF1) and Legius 
syndrome.  
 
Even though diagnosis of some patients is facilitated by the presence of characteristic 
features, symptom overlap and the progressiveness of the diseases renders 
discrimination between cases of NS, CS and CFC increasingly challenging. For 
example, children diagnosed with CS at birth present more CFC-like features as they 
grow older (Zenker et al., 2007). A CFC index was generated in the past decade to 
distinguish CFC patients (Kavamura et al., 2002) but diagnosis is frequently mostly 
based on molecular data of the patients. A precise map of specific genotype-to-
phenotype correlations is still being delineated but, to date, each disorder has been 
coupled with disease-causing genes (Table 2.1.1). CFC is driven by mutations in 
KRAS, BRAF, MEK1 and MEK2, CS by HRAS mutations, NS by SOS1, PTPN11, 
KRAS and CRAF mutations, NF1 by neurofibromin mutations, LEOPARD syndrome 
by PTPN11 and CRAF mutations and Legius syndrome by SPRED1 (Brems et al., 
2007; Zampino et al., 2007; Rodriguez-Viciana et al., 2006; Niihori et al., 2006; 
Aoki et al., 2005). A diagram highlighting the genes correlated with each syndrome 
is illustrated in Figure 2.1.1. Misdiagnosis is common but can be fundamental as 
with some syndromes there is a high risk of cancer development.  
 
2.1.2.1. Noonan Syndrome 
Noonan Syndrome (NS) (MIM ID #163950, #609942, #610733, #611553, #613224) 
is a genetic condition affecting between 1 in 1,000 and 1in 2,500 people (reviewed in 
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van der Burgt, 2007). NS was first described as a separate disorder in 1968 (Noonan, 
1968) and both its features and the underlying molecular genetics have since been 
closely examined. The majority of cases are caused by germ-line, missense gain-of-
function mutations in PTPN11 (Tartaglia et al, 2010) although gain-of-function 
mutations in SOS1 (Roberts et al, 2007; Tartaglia et al, 2007; Zenker et al, 2007; 
Ferrero et al, 2008), KRAS (Schubbert et al, 2006; Kratz et al, 2009), NRAS (Cristea 
et al, 2010) and CRAF (Pandit et al, 2007; Razzaque et al, 2007) have been more 
recently identified (Table 2.1.1).  
2.1.2.1.1. Clinical Symptoms and Cancer Predisposition 
The phenotypic spectrum of NS is variable leading to the belief that the condition is 
widely under-diagnosed. Interestingly, the severity of the symptoms is attenuated 
with time and patients can live an independent adult life. NS is best characterised by 
facial anomalies, congenital heart defects and short stature. Typical facial symptoms 
include eye hypertelorism, down-slanting eyelids, epicanthal folds and ocular ptosis 
(reviewed in Zenker et al., 2007), which can lead to poor vision. Moreover, low-set 
ears, flat nasal bridge, webbing of the neck and short curly hair are typical of NS. 
Cardiac abnormalities are almost universal, with pulmonary valve stenosis having 
the highest incidence, followed by atrial septal defects and hypertrophic 
cardiomyopathy (Croonen et al., 2008; Ferrero et al., 2008). Individuals usually fail 
to thrive, especially during their early ages, as they experience severe feeding 
difficulties (Shah et al., 1999). General muscle weakness (hypotonia) is prominent 
which may be a leading cause of speech delay and mild learning difficulties. Some 
males experience cryptorchidism and delayed puberty (Ferrero et al., 2008).  
 
NS is not correlated with increased cancer risk. Nevertheless, patients, often, develop 
multiple giant cell lesions of the jaw, most commonly the maxilla and the mandible, 
and other bone or cartilaginous tissues (Bertola et al., 2001; Tartaglia et al., 2010). 
More rarely, NS patients are diagnosed with juvenile myelomonocytic leukaemia 
(Bader-Meunier et al., 1997; Fukuda et al., 1997; Choong et al., 1999). 
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2.1.2.2. LEOPARD Syndrome 
LEOPARD Syndrome (LS) (MIM ID #151100, #611554) is an acronym describing 
the most common manifestations of the disorder (Gorlin et al., 1969): multiple 
Lentigines, Electrocardiographic conduction abnormalities, Ocular hypertelorism, 
Pulmonic stenosis, Abnormal genitalia, Retardation of growth, and sensorineural 
Deafness.  Lentigines are benign melanocyte hyperplasias that, unlike common 
moles (naevi), reside in a single layer below the epidermis. Onset of LS is driven by 
dominant loss-of function missense mutations in PTPN11 (Digillio et al., 2002) and 
C-RAF (Pandit et al., 2007). LS is a sporadic disorder with around 200 reported 
cases world-wide, but this is, likely, a mis-representation as many patients are 
undiagnosed due to lack of lentiginosis.  
 
2.1.2.2.1. Clinical Symptoms 
LS symptoms become evident in childhood and are progressive with time. Typical 
facial appearance in LS patients is characterised by hypertelorism, flattened nasal 
bridge and low set ears. Occasionally, patients present with eyelid ptosis, prominent 
lips and extra skin, which leads to neck webbing (Somerville and Bonham-Carter, 
1972). Cardiovascular anomalies affect 75% of the patients, who suffer from 
hypertrophic cardiomyopathy and pulmonary valve stenosis (Limongelli et al., 2007; 
Digillio et al., 2006; Sarkozy et al., 2004). Individuals with LS are developmentally 
delayed, experience late puberty and cryptorchidism, very commonly display 
thoracic abnormalities and can, less frequently, present with skeletal problems such 
as scoliosis, mandibular deformities and joint hyper-flexibility (Gorlin et al., 1990). 
Moreover, up to a quarter of LS patients are diagnosed with sensorineural deafness 
(Sarkozy et al., 2004), while a third experience mild learning difficulties (Digillio et 
al., 2006). 
 
The most characteristic features of LS are lentigines; flat, pigmented loci of 
melanocyte accumulation. Lentigines are normally correlated with old age and sun 
exposure. In LS patients however, they typically appear before 5 years of age, their 
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count increases with time and they occupy large areas of the face and upper body 
part. Additionally, congenital or late-development café-au-lait spots are observed, 
which appear darker than the ones on NF1 patients.  
 
Although cancer incidence is not high, a few LS patients have been diagnosed with 
malignant tumours such as myelodysplasia, acute myelogenous leukaemia 
neuroblastoma and melanoma (Merks et al., 2005; Shishima et al., 2007). 
 
2.1.2.3. Neurofibromatosis Type 1 
Neurofibromatosis (NF) is a medical term describing two different conditions; NF 
Type 1 and NF Type 2. Neurofibromatosis Type 1 (MIM ID #162200) is one of the 
most common genetic disorders in the UK, with one in 2,500 born infants being 
diagnosed with a driver mutation (Huson et al., 2008; reviewed in Williams et al., 
2009). It is caused by inherited or sporadic germ-line mutations of the NF1 gene.  
2.1.2.3.1. Clinical Symptoms 
Unlike other RASopathies, NF1 patients do not demonstrate severe facial or cardiac 
abnormalities, with the exception of relative macrocephaly (Clementi et al., 1999) 
and high blood pressure (Zinnamosca et al., 2010).  
 
NF1 symptoms develop in early ages and mostly affect the skin, without causing 
further complications. These features include an increased amount of freckling, 
commonly around the armpits and the groin, more than six café-au-lait spots and 
Lisch nodules, harmless brown pigmentation speckles in the iris of the eyes 
(McGaughran et al., 1999). The disease, however, takes its name from the early 
development of neurofibromas, benign tumours growing on or under the skin along 
nerves throughout the body. The neurofibromas can be soft or rigid in texture and, in 
most cases, cause no distress to the patient. Although their number or size can 
increase dramatically with age, neurofibromas generally remain non-cancerous 
(reviewed in Ferner et al., 2007; Williams et al., 2009). 
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2.1.2.3.2. NF1 tumours are associated with learning difficulties and 
malignancy 
NF1 is related with increased morbidity as sometimes neurofibromas can cause more 
prominent problems. Development of neurofibromas on the optic or the otic nerves 
can promote learning difficulties as a direct result of compromised vision and 
hearing. Moreover, neurofibromas on optic nerves can lead to the establishment of 
optic gliomas, benign growths, which could impair vision and require surgical 
attention (Daginakatte et al., 2007; Dasgupta et al., 2005). Nevertheless, optic 
gliomas can spontaneously regress leading to amelioration of vision (Parsa et al., 
2001). During adolescence or adulthood, some of the patients develop new malignant 
peripheral nerve sheath tumours (King et al., 2000) as well as leukaemia and brain 
tumours (reviewed in North, 2000). 
 
2.1.2.3.3. Neurofibromatosis-Noonan syndrome 
Neurofibromatosis-Noonan syndrome (NFNS) (MIM ID #601321) is a distinct 
condition from NF1 and NS and results in a combination of the clinical features 
manifested in the two syndromes. Although mutations in NF1 are the major driving 
force for the onset of this syndrome (De Luca et al., 2005), a few patients with 
concurrent mutations in NF1 and PTPN11 have been identified (Thiel et al., 2009; 
Bertola et al., 2005). NFNS symptoms can deviate slightly between patients, but 
generally include neurofibroma development, short stature, ptosis, learning 
disabilities, muscle hypotonia and, sometimes, atrial anomalies. 
 
2.1.2.3.4. Legius Syndrome 
Legius syndrome (MIM ID #611431) is a disorder only recently identified as a 
separate entity (Pasmant et al., 2009) as a result of heterozygous dominant mutations 
in SPRED1 (Brems et al., 2007; Pasmant et al., 2009). Correct diagnosis of this 
syndrome is important in genetic counselling as Legius syndrome symptoms are 
much milder and prognosis is better. Examined individuals have a normal facial 
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appearance, an increased count of café-au-lait spots and typical NF1 freckling. 
Additionally, patients lack neurofibromas and Lisch nodules but present with 
lipomas and learning disabilities.  
 
2.1.2.4. Costello Syndrome 
Costello syndrome (CS) (MIM ID 218040) was first described in 1977 (Costello, 
1977). Due to the phenotypic overlap between CS and cardiofaciocutaneous 
syndrome (CFC), a number of CFC patients had been mis-diagnosed in the past. 
However, currently CS onset is only thought to be triggered by de novo autosomal 
dominant mutations in a single gene, HRAS (Kerr et al., 2008; Aoki et al., 2005).  
 
2.1.2.4.1. Clinical Symptoms 
CS is characterised by distinctive craniofacial characteristics, cardiac and skin 
anomalies, as well as mental retardation. Typical facial features are coarse and 
include, flattened nasal bridge, epicanthal folds, full, prominent lips and a large 
mouth (reviewed in Hennekam, 2003). Cutaneous manifestations are distinctive and 
confirm CS diagnosis. CS patients’ hair appears to be curly and sparse and premature 
ageing or hair loss have been reported. Moreover, presentation of loose, redundant 
skin, mostly on the neck, as well as deep palmar and plantar creases is almost 
universal (reviewed in Hennekam, 2003). The skin itself is very soft, 
hyperpigmented with a high propensity to develop papillomata, benign, exophytic 
epithelial lesions. Papillomata are very common within this group and preferentially 
form around cavities of the body, usually, around the mouth, nares, ears and perianal 
region (reviewed in Costello et al., 1996).  
 
Frequently, CS promotes skeletal anomalies, most strikingly thoracic malformations, 
cyphoscholiosis and joint hyper-flexibility, which give CS patients a characteristic 
posture and short stature. Additionally, bad dental structure and osteoporosis are 
features of CS (White et al., 2005). Although, failure to thrive is characteristic in 
infants, due to exceptional feeding difficulties, normal body weight is gained later on 
in life. Despite the fact that overall development is delayed and that the majority 
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experience intellectual and learning deficits (Kawame et al., 2003), the patients’ 
sociable skills and friendliness are outstanding (Axelrad et al., 2004).  
 
2.1.2.4.2. Severe complications associated with CS 
Most CS patients exhibit severe cardiac abnormalities. Congenital pulmonary valve 
stenosis, cardiac hypertrophy and arrhythmia are the most frequently observed 
conditions and require tight medical attention (Lin et al., 2002). Moreover, CS 
patients have a high propensity of forming cancerous and non-cancerous tumours 
from very early on in life (Gripp et al., 2005; reviewed in Hennekam et al., 2003). 
The most common non-malignant tumours associated with this disorder are 
papillomas. Nevertheless, malignant lesions are frequent and develop very early in 
life. They include paediatric cancers such as rhabdomyosarcoma (cancer of muscle 
tissue) (Gripp et al., 2002; Feingold et al., 1999) and neuroblastoma (cancer of nerve 
cells) (Selcen et al., 2001; Kerr et al., 1998), as well as transitional cell carcinoma of 
the bladder (Gripp et al., 2000; Franceschini et al., 1999), a highly uncommon 
condition for young aged individuals. 
 
2.1.2.5. Cardiofaciocutaneous Syndrome 
The cardiofaciocutaneous syndrome (CFC) (MIM ID #115150, #190070, #164757, 
#176872, #601263) is one of the most severe disorders of the RASopathies spectrum. 
It was first characterised in 1986 by Reynolds and colleagues (Reynolds et al., 1986) 
on 8 patients of previously undefined congenital malformations. Approximately 200 
patients have been reported since and the precise prevalence of the disorder can only 
be estimated to not exceed 400 individuals worldwide. 
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2.1.2.5.1. Mutations in BRAF and MEK give rise to CFC syndrome 
Until recently, diagnosis was solely based on physical appearance and the presence 
of non-classical examples of patients (Kavamura et al., 2003; Kavamura et al., 2002) 
caused controversy on the diagnosis, rendering the CFC diagnostic index requisite 
(Kavamura et al., 2002). Nevertheless, ambiguous cases still cannot be readily 
resolved without molecular evidence. 
 
On the basis of the clinical features similarity, CFC was thought to be an extreme 
variant of NS. Half of the recorded cases of Noonan syndrome (NS) and the vast 
majority of the LEOPARD patients have missense mutations in PTPN11, the gene 
encoding for the protein tyrosine phosphatase SHP2 (Tartaglia and Gelb, 2005) 
However, after close screening of CFC patients, no PTPN11 mutations were found in 
any of the individuals (Musante et al., 2003; Ion et al., 2002) leading other groups to 
sequence different genes in the MAPK pathway.  
 
Niihori and colleagues sequenced the coding sequences of HRAS, KRAS and NRAS 
from 43 CFC patients only to find two mutations in KRAS that had not been 
previously identified in cancer (Niihori et al., 2006). Moreover, they identified eight 
mutations in BRAF. At the same time, Rauen and colleagues identified de novo 
germ-line mutations in BRAF, MEK1 and MEK2 (Rodriguez-Viciana et al., 2006). 
The eleven missense BRAF mutations were either clustered in the cysteine-rich 





), none of the mutations had been described in 
cancer patients. Two activating mutations of MEK1 were identified, one lying within 
the kinase (MEK1
Y130C
) domain and one outside (MEK1
F53S
). Finally, MEK2 




(Figure 2.1.2B).  Thus, 
the capacity to perform mutation analyses of RAS/MAPK pathway genes can be a 
useful tool in the prediction and correct diagnosis of the conditions. Understanding 
the activity of the key regulators of the developmental disorders can be enlightening 
in treatment design. 
 





Figure 2.1.2 Summary of allelic mutations of human BRAF, MEK1 and MEK2 
 
Primary structures of human BRAF (A), MEK1 and MEK2 (B) highlighting the mutations identified 
in CFC (light blue) and melanoma (black) patients, as well as engineered mutations (grey). Each 
numbered box illustrates a coding exon. Blue, green and red shading of the exons represent the Ras-
binding domain (A), cysteine-rich domains (A) and the protein kinase domains (A, B), respectively. 
Red arrows with double arrowheads represent mutations rendering the protein constitutively active 
and green arrows with double (A) and triple (B) arrowheads represent substitutions leading to a kinase 
dead protein. 
A Allelic substitutions illustrated above the linear BRAF sequence represent kinase-activating 
mutations (red arrows) and mutations conferring undetermined activity levels to the protein (dashed 
lines). Allelic substitutions positioned below the BRAF sequence represent kinase inactivating 
mutations (green arrows). 
B Kinase-activating (red arrows) and kinase-inactivating (green arrows) allelic substitutions are 
illustrated above the linear representations of MEK1 and MEK2.  
 
(Adapted from Rodriguez-Viciana et al., 2006) 
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2.1.2.5.2. Clinical features of cardiofaciocutaneous syndrome 
The sporadic occurrence of the disease causes a characteristic set of features that 
mainly affect heart formation (cardio-), facial structures (facio-), skin and hair tissues 
(cutaneous). The patients are usually of short stature and fail to thrive, as a direct 
result of oral feeding aversion. A range of mental retardation is observed, but in most 
cases it is mild (Schulz et al. 2008).  
 
The individuals have a distinguishing facial appearance, presenting with relative 
macrocephaly, significant hypertelorism and palpebral ptosis, a wide nasal bridge 
and low set ears with prominent helices (Kavamura et al., 2002). Dental 
malformations are also representative of this disease although they are not universal. 
 
Ectodermal anomalies are outstanding and have been crucial factors in the clinical 
diagnosis of CFC. The absence of eyebrows and eyelashes and distinctive dark, 
woolly curly hair are very common. More characteristically, the diverse skin 
anomalies of the patients include keratosis pilaris, hyperkeratosis mostly of the palms 
and soles of the feet, ichthyosis (scaly skin), eczema and ulerythema ophryogenes 
(Siegel et al., 2010).  
 
Severe heart defects are the most restrictive to the patients as cardiac complications 
lead to increased mortality in the first months of life (reviewed in Roberts et al., 
2006). Pulmonary valve stenosis, atrial and ventricular septal defects and 
hypertrophic cardiomyopathy present in most cases of CFC. 
 
Although BRAF, a gene very frequently mutated in human melanoma, is often the 
cause of CFC, skin cancer development has not been recorded in this group of 
patients. Intriguingly, however, more than 20% of affected individuals show an 
abnormally elevated count of melanocytic naevi, a number that steeply increases 
with age (Siegel et al., 2010). CFC patients are not in an increased risk of cancer, 
with only two reported patients with diagnosed acute lymphoblastic leukaemia 
(Makita et al., 2007; Van den Berg and Hennekam, 1999). 
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2.1.2.6. RASopathies target the same tissues but each pathway component has a 
unique role 
Close examination of the syndrome-driven symptoms reveals that disturbance of 
different components of the same pathway does not always translate to the same 
phenotypic outcome. Interestingly, however, all the diseases of the spectrum target 
the same tissues but affect them in different ways (Table 2.1.1). The multiple 
effectors of MAPK pathway components may account for the heterogeneity within 
the spectrum. Moreover, different genes might be particularly important in different 
tissues and their mutation might cause specific sensitivities to the patient. 
 
Although the mutations causing the various syndromes are being constantly 
delineated, the mechanism of action that promotes individual mutations to give rise 
to different phenotypes remains elusive. Kinase activity levels (e.g. impaired activity 
BRAF
G596V
 mutant versus high activity BRAF
Q257R
 mutant) are sometimes unrelated 
to the severity and extremity of the clinical symptoms in CFC, NS and LS 
(Rodriguez-Viciana et al., 2006; Aoki et al., 2005; Kontarides et al., 2005). Despite 
the rarity of the syndromes, the presumptive complexity underlying the MAPK 
pathway signalling has encouraged focused research on the components giving rise 
to the disorders. The fact alone that each syndrome presents different features 








  Syndrome 









 SOS1       
NF1       
PTPN11       
HRAS       
KRAS       
C-RAF       
B-RAF       
MEK1       






Large forehead       
Flat nasal bridge       
Relative 
macrocephaly 
      
Eyes 
 
Ptosis       
Down-slanting 
eyelids 
      
Epicanthal folds       
Ocular hypertelorism       
Affected vision    ()   
Ears 
Low-set ears       
Rotated ears       
Mouth 
Dental abnormalities       
Prominent lips       






 Pulmonary valve 
stenosis 
      
Hypertrophic 
cardiomyopathy 
      
Ventricular septal 
defects 
      
Tachycardia       
Arrhythmia       
Atrial septal defects       
Blood clotting/ 
bruising 
      
Increased blood 
pressure 







General Hypotonia       
Speech 
Deep/hoarse voice       
Speech difficulties       
GI tract/ 
Feeding 
Feeding difficulties       
Projectile vomiting       
Oral aversion       
Intestinal malrotation       
Gastro-oesophageal 
reflux 










Seizures       
Abnormal EEG       
Hydrocephalus       
Deafness (neural)    ()   
Learning/ 
Behaviour 




      
















Neck webbing       
Extra skin       
Thick skin       
Soft skin       
Premature skin 
ageing 
      
Cutaneous 
demonstrations 
Eczema       
Papillomata       
Neurofibromas       
Increased 
pigmentation 
      
Nevi       
Freckling       
Lentigines       
Café-au-lait spots       




      
Curly hair       
Sparse hair       















 General bone defects       
Short stature        
Thorax 
malformations 
      
Delayed bone 
development 
      
Osteoporosis/ 
Osteopenia 
      
Joint hyperflexibility       
Cyphoscholiosis       














      
Failure to thrive       
Growth hormone 
deficiency 
      
Genitalia 
Cryptorchidism       










 Rhabdomyosarcoma       
Neuroblastoma       
Early-onset 
transitional cell 
carcinoma of the 
bladder 
      
Optic glioma       
Myeloid dysplasia       
Leukaemia       
Melanoma       
Brain tumours       
 
Table 2.1.1 Phenotypic spectrum of the RASopathies 
Abbreviations: GI: Gastrointestinal, CNS: Central nervous system, EEG: Electroencephalogram 
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2.1.3. Zebrafish embryogenesis 
2.1.3.1. Gastrulation movements 
Malfunction of key signalling cascades such as the MAPK pathway often affects the 
progression of normal development. Study of early embryogenesis stages in 
zebrafish can elucidate the role of such cascades in early developmental processes. 
Gastrulation is the period of time in embryonic development during which the 
blastula precursors of the three germ layers, ectoderm, endoderm and mesoderm, are 
relocated to reach their final positions (reviewed in Solnica-Krezel, 2005). In 
zebrafish, it starts at about 4 hours postfertilisation (hpf) at the “high” stage (Kimmel 
et al., 1995) and lasts for almost 6 hours, until the “tail bud” stage (Kimmel et al., 
1995).  
 
Four major cell movements are required for its successful completion, each one of 
which confers a different effect on the shape of the embryo. Epiboly is the movement 
during which the dividing cells proliferate downwards towards the vegetal pole of 
the embryo, thus covering the surface of the yolk. It causes posterior migration of the 
cells, and embryo expansion (reviewed in Lepage and Bruce, 2010). Emboly or 
involution promotes inward folding of the dividing cell layer. This movement 
ensures that mesodermal and endodermal precursor cells fold at the blastopore to 
create the internal layers (Solnica-Krezel, 2006). Convergence movements narrow 
the dorsoventral axis of the embryo while extension causes dividing cells to move 
upwards elongating the anteroposterior axis (Figure 2.1.3). Proper control of all four 
cell migration movements is required for correct embryonic anteroposterior and 
dorsoventral axis patterning and normal further development. For instance, the cells 
at the axial mesoderm of the zebrafish embryo converge a little and extend a lot to 
achieve normal midline development. In summary, the gastrulation stage ensures that 
the ectoderm layer is in the surface of the embryo, the mesoderm becomes the 
middle layer and the endoderm is positioned internally (reviewed in Solnica-Krezel, 
2005). 
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Figure 2.1.3 Schematic representation of a gastrulating vertebrate embryo at 50% 
epiboly. 
  
The blue mesh top represents the dividing cells and the orange bottom represents the yolk. The 
different coloured arrows illustrate the four separate cell movements occurring during embryonic 
gastrulation. The time periods (hpf) and developmental stages of their activity are noted under each 
cell movement. 
(Yellow arrow: Extension; Red arrows: Convergence; Black arrows: Involution; Green arrow: 
Epiboly) 
 
2.1.3.2. Gastrulation defects in zebrafish embryogenesis 
Proper completion of gastrulation and cell movement orientation depend largely on 
the activity of the Mapk pathway.  Cellular proliferation is promoted by insulin-like 
growth factors via the Fgf/Mapk and PIP3 pathways (Pozios et al., 2001). After the 
mesodermal layer specification by nodal signalling, Fibroblast growth factor (Fgf) 
signalling maintains tissue patterning (reviewed in Schier and Talbot, 2005). Fgf 
signalling promotes dorsal and dorsolateral effects in a morphogen-like manner 
(Furthauer et al., 1997). This means that the mesodermal tissue furthest away from 
FGF expression will have a ventral fate, whereas precursor cells around areas of high 
FGF expression will give rise to more dorsal-like structures (Figure 2.1.4 A).  
 
 





Figure 2.1.4 Fgf8 presence dictates dorsoventral axis of the embryo 
 
A Fgf8 acts as a morphogen driving dorso-ventral axis orientation. Areas expressing high levels of 
FGF8 protein become more dorsalised, whereas no FGF expression triggers a ventralised fate. 
B Fgf8 mis-expression leads to an entirely dorsalised embryo. 
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Additionally, zebrafish provides a robust system to study phenotypes caused by 
Fgf/Mapk pathway misregulation in early gastrulation. Ectopic Fgf disorientates the 
fate of the dividing cells (Figure 2.1.4 B) leading to an elongated embryonic 
phenotype at the end of gastrulation (Furthauer et al., 2004). In detail, Fgf8 over-
expression promotes embryo dorsalisation due to Bmp downregulation. The opposite 
effect, embryo ventralisation, can be achieved by over-expression of the Mapk 
pathway phosphatase Mkp3 (Shinya et al., 2001), or the Mapk pathway inhibitor Sef 
(Furthauer et al., 2002). 
 
2.1.3.3. Expression profiling of MAPK components in zebrafish 
The function and early expression of MAPK pathway components are conserved 
between vertebrates. Therefore, expression data from large scale or focused studies 
give insight to spatiotemporal regulation and activity of the Mapk pathway genes in 
zebrafish. Mapk cascade gene products are maternally deposited and ubiquitously 
expressed until the end of gastrulation. However, after somitogenesis and by 2dpf 
membrane-bound components such as Fgfr1 (Rohner et al., 2009; Thisse and Thisse, 
2005), Nf1 (Padmanabhan et al., 2009 PNAS) and Ptpn11 (Razzaque  et al., 2007) as 
well as the cytosolic C-raf (Razzaque et al., 2007) and Erk1 (Krens et al., 2006; 
Thisse and Thisse, 2004) become specific to the head region. Membrane-bound Grb2 
and H-ras a are neuronally expressed (Thisse and Thisse, 2004), whereas K-ras (Liu 
et al., 2008), Braf and Mek2 expression (Thisse and Thisse, 2005) is thought to be 
ubiquitous throughout embryogenesis. Finally, Erk1 and Fgfr1 are prominently 
expressed in the pharyngeal arches (Thisse and Thisse, 2005). No expression profiles 
have been generated, to date, for sos1, mek1 and erk2.  
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2.1.4. Aims 
2.1.4.1. Establishing an in vivo bioassay to test activity of disease alleles 
BRAF and MEK germ-line mutations promote CFC in human patients. Using the 
simplicity of the developing zebrafish embryo, I aimed to determine if the same 
mutations affect early development in zebrafish. To that end, I over-expressed an 
array of human CFC, naevi and melanoma disease alleles in one-cell stage zebrafish 
and directly observed the early patterning and structure of the embryos. 
 
2.1.4.2. Drawing genotype-to-phenotype conclusions 
The different point mutations studied confer alternate kinase activity levels to the 
protein in vitro. In order to establish whether there is a genotype-to-phenotype 
correlation between protein activity levels and phenotypic severity I expressed a 
panel of BRAF and MEK allelic variants (kinase-activating, kinase-inactivating, 
kinase-dead) in wild-type zebrafish embryos and compared their phenotypes. 
 
2.1.4.3. Testing the oncogenic potential of BRAF CFC alleles 
Although somatic BRAF mutations are prevalent in premalignant melanocytic lesions 
(naevi) and melanoma, CFC patients harbouring germ-line BRAF mutations are not 
at increased risk of developing cancer. As sometimes CFC and neoplastic mutations 
overlap, I aimed to test the oncogenic potential of BRAF CFC alleles. For this study, 
I specifically expressed the different BRAF alleles in melanocytes of wild-type 
zebrafish and assessed their naevus-driving potential. 




The work presented in this chapter has been published and the relevant publication 
has been attached in Appendix II with permission from the journal. 
 
2.2.1. Similarity of human and zebrafish BRAF, MEK1 and MEK2 
The zebrafish genome has been fully sequenced and genomic resources are 
becoming more widely available. The ninth zebrafish genome assembly, Zv9, was 
made public from the Wellcome Trust Sanger Institute in Ensembl e60 in November 
2010. The final gene set contains 24,020 protein-coding genes and 38 pseudogenes. 
The majority of the sequencing results were based on clone data and the remaining 
gaps were filled using new RNA sequencing technology and aligned zebrafish 
cDNAs. 
 
The known zebrafish braf, mek1 and mek2 cDNA and amino acid (aa) sequences 
were aligned against the equivalent human sequences using the BLASTn and 
BLASTp programmes in the NCBI database, accordingly. The graphical illustrations 
were generated in R. 
 
Zebrafish and human cDNAs were similar. Zebrafish braf cDNA (2737bp) was 
longer than the human BRAF cDNA (2480bp) but shared 75% sequence identity. 
mek1 (2093bp) was 77% identical to MEK1 cDNA (2642bp) and the aligned cDNA 
sequence of mek2 (2787bp) was 79% identical to MEK2 (1734bp) (Figure 2.2.1). 
 
Braf is 817aa long as opposed to the shorter 766aa human BRAF. Upon alignment, 
636/763aa (84%) were identical and the overall sequence similarity was 87%. Mek1 
(395aa) and MEK1 (393aa) were identical in 348/393aa, with an overall sequence 
similarity of 95%. Finally, Mek2 (397aa) and MEK2 (400aa) shared 86% sequence 
identity and were 92% similar (Figure 2.2.1). 
 




Figure 2.2.1 Overlap between zebrafish and human BRAF, MEK1 and MEK2 
sequences 
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(Figure 2.2.1)  
Diagrams depicting identity between cDNA (Ai, Bi, Ci) and amino acid sequences (Aii, Bii, Cii) of 
BRAF (A), MEK1 (B) and MEK2 (C). The functional domains of each protein are shown above the 
alignments. 
Ai, Bi, Ci Sequence identity of human compared to zebrafish cDNA. Blue: identical; Red: mismatch; 
Grey: mismatch coding for the same amino acid. Aii, Bii, Cii  Amino acid identity between zebrafish 
and human proteins. Blue: identity; Red: mismatch; Grey: similarity in amino acid function. 
 
2.2.2. Mutations along the RAF-MAPK pathway are active in vivo 
The Fgf-Ras-Mapk pathway is of integral importance in early embryogenesis, as Fgf 
signalling levels govern the patterning of the dorso-ventral axis (Solnica-Krezel, 
2005). Ectopic expression of the normally stringently regulated Fgf proteins during 
gastrulation promotes dysfunctional convergence cell movements (Furthauer et al., 
1997, 2002, 2004). As epiboly, involution and extension movements are not affected 
by the loss of dorso-ventral orientation, activated FGF signalling results in embryo 
elongation (Furthauer et al., 2002).  
 
Based on the understanding of MAPK pathway importance in early development and 
the practical uses of having an established readout for gastrulation defects, I used the 
zebrafish system to test the in vivo significance of BRAF, MEK1 and MEK2 CFC 
alleles in a developmental context. 
 
2.2.2.1. BRAF CFC and melanoma alleles promote developmental abnormalities 
in zebrafish 
In order to determine whether human CFC and melanoma disease mutations have an 
effect on zebrafish development, mRNA from a small panel consisting of BRAF 
allelic variants were injected into one-cell stage zebrafish wild-type embryos. The 
mRNA was carrying the wild-type (WT) human BRAF protein, the most common 
melanoma mutation and highly kinase-activating BRAF
V600E
, the most common CFC 
and activating mutation BRAF
Q257R
 and the kinase-impaired melanoma and CFC 
mutation BRAF
G596V
. The injected individuals were closely monitored from early 
gastrulation.  
 





Figure 2.2.2 CFC and melanoma BRAF disease alleles are active in vivo 
 
A Embryos over-expressing BRAF disease alleles had specific developmental phenotypes that can be 











) were elongated at 10.5hpf 
when compared to the uninjected controls and the embryos expressing the wild-type BRAF protein. 
Mutations in BRAF promoted shortening of the antero-posterior axis, yolk extension defects and 
general developmental toxicity in 24 and 48hpf embryos.  
B Immunoblotting illustrating similar levels of BRAF mRNA expression in injected embryos. The 
mRNA constructs were myc-tagged and injected BRAF expression levels were detected by western 
blotting. -tubulin was used as a loading control. 
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Development of the embryos over-expressing BRAF mutations was compared to that 
of embryos injected with WT human BRAF mRNA as well as to the development of 
their untreated siblings. Whereas early cell movements were unaffected in all 
injected embryos, it became apparent by the end of gastrulation that both CFC and 
melanoma alleles were active in vivo (Figure 2.2.2A). At the tail-bud stage (10.5hpf) 
all embryos injected with BRAF mutant alleles were significantly elongated, 
similarly to embryos experiencing ectopic MAPK signalling (Furthauer et al., 2002).  
 
By 24hpf the body axis of the BRAF-expressing embryos was much shorter than the 
control larvae, with a characteristic loss of posterior structures and prominent cranial 
hypomorphism. Additionally, CFC and melanoma allele-expressing individuals 
presented with yolk extension defects. 
 
At 48hpf, the malformed embryos had not increased in size but were not 
developmentally delayed based on observations of heart development, blood 
circulation and normally acquired pigmentation.   
 
Most remarkably, over-expression of the wild-type BRAF protein did not cause any 
defects and embryos appeared indistinguishable from their un-injected siblings, 
suggesting that the injection process itself and the human mRNA levels were not 
toxic to zebrafish development. All BRAF proteins synthesised from the injected 
mRNA were myc-tagged and western blotting revealed that their expression levels 
were similar in all treatment groups (Figure 2.2.2 B). 
 
2.2.2.2. All zebrafish embryos expressing BRAF, MEK1 and MEK2 allelic 
variants exhibit the same elongation phenotype at the end of gastrulation 
Like in human melanoma, the BRAF-CFC mutations result in both kinase-activating 
and kinase-impaired activities, whereas all MEK CFC mutations are kinase active 
(Rodriguez-Viciana et al., 2008; Rodriguez-Viciana et al., 2006; K.A. Rauen, 
unpublished data). As irrespective of the kinase activity levels of the expressed 
protein all three BRAF allelic variants promoted the same phenotype in gastrulating 
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embryos, it was of interest to determine whether other available human and 
engineered mutations would have the same effect on zebrafish development. To that 
end, a library of more than thirty kinase-active and kinase-impaired BRAF, MEK1 
and MEK2 allelic variants (Rodriguez-Viciana et al., 2008; Rauen et al., 2006; 
Rodriguez-Viciana et al., 2006), including human CFC, melanoma and engineered 
mutations, was assessed for its in vivo activity (Table 2.2.1). Notably, kinase-
impaired mutations confer a lower activity to the kinase compared to the wild-type 
















Wild type Wild type N/A no (0/40) 
A246P Not determined CFC yes (31/57) 
Q257R Kinase-activating CFC yes (83/95) 
G464V Kinase-activating CFC yes (25/45) 
S467A Kinase-activating CFC yes (49/57) 
K483M Kinase dead CFC yes (34/44) 
K499E Kinase-activating CFC yes (23/44) 
G534R Kinase-activating CFC yes (33/38) 
N581D Not determined CFC yes (23/51) 
D594V Kinase-impaired Melanoma yes (43/56) 
G596V Kinase-impaired CFC/ Melanoma yes (86/104) 
T599E/S602D Constitutively active Engineered yes (36/73) 
V600E Kinase-activating Melanoma yes (68/84) 






Wild type Wild type N/A no (0/40) 
F53L Constitutively active Engineered yes (16/33) 
F53S Kinase-activating CFC yes (20/33) 
T55P Kinase-activating CFC yes (26/45) 
K97M Kinase dead Engineered yes (45/62) 
G128V Kinase-activating CFC yes (22/35) 
Y130C Kinase-activating CFC yes (30/45) 
S218D/S222D Constitutively active Engineered yes (45/55) 






Wild type Wild type N/A no (0/40) 
F57C Kinase-activating CFC yes (31/42) 
A62P Kinase-activating CFC yes (25/39) 
K101M Kinase dead Engineered yes (39/52) 
G132V Kinase-activating CFC yes (45/72) 
Y134C Kinase-activating CFC yes (30/54) 
S222D/S226D Constitutively active Engineered yes (33/49) 
K273R Kinase-activating CFC yes (42/63) 
 
Table 2.2.1 The panel of CFC, melanoma and engineered alleles used in this 
bioassay 
 





Figure 2.2.3 Testing the in vivo activity of BRAF, MEK1 and MEK2 constructs 
 
A-C All thirteen mutant forms of BRAF, including the BRAF
K483M
 kinase dead variant (A), seven 
MEK1 (B) and seven MEK2 mutant proteins (C) promoted embryonic elongation at 10.5hpf. Notably, 
over-expression of the wild-type proteins had no effect in embryonic development. 
Arrows next to the amino acid substitutions represent the activity level conferred to the kinase as a 
result of each mutation, compared to the wild-type protein. 
 
Thirty-one allelic variants were sub-cloned into destination vectors from their 
original plasmids, kindly sent by Dr. Katherine A. Rauen (UCSF) (refer to Chapter 
6; Materials and Methods). In order to test the elongation-promoting capacity, 
mRNA was in vitro transcribed from all vectors. One-cell stage wild-type zebrafish 
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embryos were injected with human mRNA from the library and were, subsequently, 
scored for their elongation status at 10.5hpf. To introduce a tighter control to the 
experiment and minimise the effects that individual embryos may have had on 
phenotypic outcomes, a minimum of two (and most commonly four) separate 
injection sets were performed on each embryo collection batch (i.e. injection of two 
or more mRNA samples in one embryo pool).  
 
Initially, BRAF CFC, melanoma and engineered alleles were assessed and allelic 
variants were found to promote embryo elongation at the tail bud stage irrespective 
of their activity levels (Figure 2.2.3A). Embryos expressing mutated forms of MEK1 
and MEK2 proteins they were, also, elongated at the same stage (Figure 2.2.3B, C). 














expressing individuals displayed an identical elongation phenotype. Importantly, 
none of the WT proteins triggered a phenotype. This suggested that, unlike their in 
vitro predicted activity, kinase-active and kinase-impaired alleles promote the same 
developmental outcome in vivo. In fact, western blotting of zebrafish embryonic 
lysates against pErk and total Erk protein confirmed that all BRAF and MEK alleles 
caused Erk activation (Figure 3.2.3). 
 
2.2.3. Over-expression of multiple disease alleles has an additive 
phenotypic effect in development 
SHP2 mutations identified in Noonan and LEOPARD syndrome patients also act by 
activating or in-activating downstream signalling. Additionally, generated shp2 
zebrafish mutants have both gain- and loss-of-function phenotypes (Jopling et al., 
2007). However, in our model all the mutations tested acted as gain-of-function in 
vivo, irrespective of their predicted in vitro activity.  
 
To elucidate the mode of action of activating and kinase-impaired mutations from 
our library, sub-optimal levels of combinations of CFC kinase-active, CFC kinase-
impaired and WT BRAF and MEK proteins were expressed in wild-type embryos.  





Figure 2.2.4 Over-expression of sub-optimal doses of two mutation variants has an 
additive effect in the embryonic elongation phenotype 
 
A Histogram supporting that BRAF kinase-active and kinase-impaired alleles promote additive effects 





) and kinase-impaired (BRAF
G596V
) CFC alleles or BRAF
WT
 mRNA. 
Co-expression of the wild-type protein with the CFC mutations did not alter the proportion of 
elongated embryos at 10.5hpf when compared to the embryos expressing the CFC alleles alone. Co-









 (p = 0.0003) as 
indicated by χ2 tests. 
B Histogram illustrating the additive effect promoted by co-expression of sub-optimal concentrations 
of MEK1 CFC (MEK1
Y130C
) and MEK2 CFC (MEK2
F57C





 caused a significant increase (p=0.0038) in the numbers of embryos with an elongated 




The numbers in the bars indicate the percentages of elongated embryos; n is the number of injected 
embryos in each set. 
 
The activating mutation BRAF
Q257R
 was co-expressed with the kinase-active 
BRAF
S467A
 and the kinase impaired BRAF
G596V
. The kinase-active MEK1
Y130C
 was 
co-expressed with the kinase-active MEK2
F57C
. As an internal control, each allelic 





accordingly. The percentage of elongated individuals in cohorts co-expressing two 
disease alleles was compared to that of embryos expressing a mutant allele and its 
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 promoted similar 
levels of embryo elongation as those in cohorts of embryos expressing the sub-
optimal level of the disease allele alone (Figure 2.2.4 A,B). These percentages 
ranged from 60.7% (BRAF
S467A
) to 72% (MEK1
Y130C
). In contrast, the combination 
of two kinase-activating alleles as well as one kinase-activating and one kinase-
inactivating allele promoted a highly significant increase (as indicated by chi-squared 













 87.3%). The proportion of 
these elongated embryos is directly comparable to the levels observed in optimally 
injected individuals. This suggests that all kinase activity level mutations act as gain-
of-function mutations during zebrafish development.   
 
2.2.4. Embryonic elongation starts around 7hpf 
The importance of early cell movements in correct axis patterning as well as the 
involvement of the FGF/MAPK cascade in this process have been highlighted in a 
number of embryonic zebrafish models (Furthauer et al., 2002, 2004). Moreover, 
convergence-extension defects have been recorded in zebrafish embryos lacking 
proper Shp-2 (Jopling et al., 2007) and Erk (Krens et al., 2008) signalling.  
 
To identify the point when embryo elongation first became apparent, the early 
development of a control un-injected embryo was directly compared to an embryo 
injected with the most common CFC mutation (BRAF
Q257R
) (Figure 2.2.5A). The 
closely monitored embryos were imaged every 20 minutes, from the beginning of 
gastrulation (4hpf) until the tail bud stage (10.5hpf). Early divisions and cell 
movements were identical between the two groups until 7hpf. After the 7.5hpf time-
point the appearance of the injected embryos started to deviate from the wild-type 
embryos, with the yolk becoming increasingly more elongated every hour. By 




Figure 2.2.5 Gastrulation cell movement defects cause the elongation phenotype 
 
A Time-course still images of developing embryos. The top panel shows the normal development of an uninjected control wild-type embryo. The lower panel 
illustrates the development of an embryo over-expressing BRAF
Q257R
, the most common CFC allele. The injected embryos were indistinguishable from the controls 
until 8.5hpf when their body axis started elongating and at 10.5hpf the embryos had the characteristic phenotype. By 24hpf the embryos were visibly shorter, lacking 
a significant part of their posterior structures, had an enlarged cardiac oedema and the yolk failed to extend properly. 
B Dlx3 and HggI in situ hybridisation staining revealed convergence-extension movement defects in all embryos expressing disease alleles, but not the wild-type 
proteins. The angle of Dlx3 expression (red dashed lines) relative to the embryo midline (horizontal blue line) was calculated for every embryo. Notably, embryos 
injected with BRAF
V600E
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2.2.5. Embryonic elongation originates from convergence-extension 
defects 
To determine whether the various BRAF and MEK mutations have a direct effect on 
convergence-extension movements, whole-mount in situ hybridisation (WISH) 
against specific convergence-extension markers was performed. Elongated embryos 
expressing a sub-panel of disease allelic variants were collected at the tail-bud stage, 
were processed and were hybridised with probes for Dlx3, expressed at the neuronal 
plate margin, and HggI, the hatching gland and anterior-posterior axis marker. 
 
The pattern of the embryos expressing the WT proteins was the same as that of the 
un-injected control embryos (Figure 2.2.5B). The angle of the Dlx3 pattern in 
reference to the embryo size and the HggI expression, however, was dramatically 
altered in all elongated embryos. Namely, the angle of Dlx3 relative to the horizontal 







 but narrower in MEK2
F57C
-embryos. Interestingly, Dlx3 expression 
was completely absent in BRAF
V600E
 embryos. HggI expression levels remained 
unaffected in all embryos. Taken together, these findings indicate that the disease 
alleles tested cause major disruptions in convergence cell movements.  
 
2.2.6. Interruption of BRAF signalling by c-raf knockdown does not 
prevent embryonic elongation 
BRAF mutant proteins in melanoma cell lines harbouring kinase-impaired BRAF 
mutations are thought to signal through C-RAF to activate downstream targets of the 
RAS-RAF-MAPK pathway (Wan et al., 2004). c-raf knockdown through injection of 
a specific translation block morpholino oliogonucleotide (MO) resulted in embryos 
that, by 3dpf, had a smaller head, close proximity of the otoliths, heart pericardium 
enlargement and minor atrioventricular valve malfunctions as well as yolk extension 
defects and curvature of the posterior structures (Appendix I-1), all in accordance 
with previously defined morphant phenotypes (Razzaque et al., 2007).  
 
 





Figure 2.2.6 C-raf morpholino does not rescue BRAF mRNA phenotype after co-
injection 
 











 mRNA and a control morpholino (MO). Embryos over-expressing 
mutated forms of the protein were elongated, unlike the BRAF
WT
-expressing samples. The lower 
panel shows that co-injection of the mRNA and a C-raf MO led to similar levels of embryo elongation 
as their paired controls. 
B Histogram showing the percentage of elongated embryos in each injection set (corresponding to 
injections in panel A). Grey bars represent embryos injected with the respective mRNA alone and the 
green bars represent embryos co-injected with mRNA and C-raf MO. The p values for each 
experimental set were calculated using the two-tailed Fisher’s exact t-test and were not considered to 
be statistically significant to the p<0.001 level. The BRAF
WT
 category was excluded from this 
calculation as no embryos were elongated. 
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To test whether C-raf is responsible for the downstream activation of MEK in the 











) were co-expressed 
with a C-raf translation block MO. Doubly injected embryos were tested for their 
elongation status at the tail bud stage and were compared to embryos expressing the 
disease alleles with a control fluorescein MO (Figure 2.2.6). Based on the two-tailed 
Fisher’s exact t-test, the levels of elongation incidence were not significantly altered 
in the presence of the C-raf MO to the p<0.001 level. The number of elongated 
embryos co-injected with BRAF
V600E
 and C-raf MO was reduced compared to the 
individuals expressing BRAF
V600E
 alone, but due to the low numbers and mortality 
of doubly injected embryos the reduction in elongation incidence was not considered 
C-raf MO-dependent.   
 
2.2.7. Oncogenic potential of CFC BRAF alleles 
As with many of the RASopathies, CFC is a progressive disorder with physical 
symptoms becoming more severe with time. Sometimes undiagnosed at birth, CFC 
patients acquire a vast range of disease manifestations as they get older. Although 
CFC syndrome is not traditionally correlated with high cancer risk, a number of 
patients present with an increased count of skin naevi, which could be viewed as 
benign lesions. The established bioassay described above clearly demonstrated the 
activity of transient expression of BRAF disease alleles during embryogenesis. To 
better understand the ability of CFC alleles to drive malignancy, stable and more 
permanent activity of BRAF allelic variants has to be tested in the context of an adult 
organism.  
 
To achieve that, I sub-cloned a sub-panel of BRAF variants under the melanocyte-
specific mitfa promoter in a way that the constructs were flanked by Tol2 transposon 
sequences.  Co-injection of wild-type embryos with a mix of the DNA plasmids and 
Tol2 transposase mRNA promoted random incorporation of the generated DNA in 
the fish genome. One-cell stage wild type (AB and TL) embryos were injected with  





Figure 2.2.7 Assessment of the oncogenic potential of BRAF disease allelic variants 
 
Illustration of fish expressing different human BRAF disease variants under the melanocyte-specific 
promoter, mitfa. Expression of mitfa-BRAF
V600E
 is sufficient to drive extensive ectopic 
pigmentation/naevi (B). The kinase-impaired mutant BRAF
G596V
 drove ectopic melanisation in vivo, 









 (D-G).  
Panel A shows control adult fish expressing mitfa-BRAF
WT
 on two different wild-type backgrounds. 
AB fish present with a striped pigmentation pattern (Ai and B) and TL Leopard have spots (Aii, C-G). 
Panels B-G illustrate the two sides of the same fish. The areas outlined by the dotted boxes are colour-
coded and magnified below each fish. Arrows after the amino acid substitutions indicate the kinase 
activity of the mutant protein compared to the WT BRAF. 


















. The embryos were grown into 
adulthood and were monitored regularly for abnormal pigmentation patterning 
(Figure 2.2.7). 
 
Fish expressing Mitfa-driven BRAF
WT
 developed as wild-type individuals and had 
no overt phenotype. From one and a half month of age, the fish expressing the most 
highly activating BRAF
V600E
 mutation under the mitfa promoter had obvious aberrant 
melanisation with multiple loci of naevi formation. By two months, the naevi had 
grown and the fish were covered in dark spots (Figure 2.2.7B). Most strikingly, 
BRAF
G596V
, a kinase-impairing mutation present in CFC and melanoma patients, was 
able to promote naevi formation (Figure 2.2.7C). This was the first incidence of an 
inactivating variant driving abnormal melanisation. This observation underpins the 
importance of studying a vast array of alleles irrespective of their predicted in vitro 
activity as even inactivating mutations can have, as in this case, a high oncogenic 
potential. Progression from a benign naevus to malignant melanoma requires 
acquisition of multiple driving somatic mutations. Therefore, it would be interesting 
to express BRAF
G596V
 alongside common melanoma mutations to assess the allele’s 
true oncogenicity. Fish injected with the rest of the constructs did not present with 
obvious naevi. However, the strict pigmentation pattern observed in the vast majority 
of wild-type adults was frequently disturbed (15-20%) in the injected individuals. 
 




 the oncogenic potential of CFC 
alleles was low. However, what became clear by monitoring the injected fish is that 
all phenotypes observed (naevi/ ectopic melanocytes/ disturbed pattering) were 
progressive (Figure 2.2.8). The fish expressing BRAF
G596V
 in their melanocytes 
initially demonstrated only a few ectopic melanised spots that later developed to 














A Left lateral view of a mitfa-BRAF
G596V
 fish over two months. Substantial ectopic pigmentation 
(naevi) (black arrowheads) was observed from two months (a) in fish with melanocyte-expressing 
BRAF
G596V
. By three months of age (b), the ectopic pigmentation pattern persisted (black arrowheads) 
but, also, new sites of nevi appeared (red arrowheads). At four months (c), the fish had acquired more 
new naevi (red arrowheads). 
B Right lateral view of the same fish at three (a) and four (b) months showing the appearance of new 
nevi (red arrowheads) that were not present earlier. 
 
Close-up images on the right highlight the progressive development of naevi. 




This work addressed the activity of CFC and other disease mutant alleles in a 
developing vertebrate organism. The mutations evaluated included 18 human CFC 
and three melanoma alleles all of which caused a similar developmental phenotype, 
irrespective of their predicted kinase activity. Wild-type zebrafish embryos were 
injected at the single cell stage either with human mRNA harbouring a disease allele, 
or with wild-type control mRNA and the phenotypes of the embryos were assessed 
ad the end of gastrulation (Figures 2.2.2, 2.2.3). Localised expression of Fgf/Mapk 
signalling is tightly controlled during normal development. This ensures proper 
shaping of the gastrulating embryos. As all kinase-active and –impaired variants 
triggered elongation, convergence-extension movements were monitored in disease 
allele-expressing individuals. All BRAF and MEK variants interfered with 
gastrulation movements in a comparable manner, suggesting a similar downstream 
mode of action. This observation could possibly explain why diverse mutations 
across different genes can lead to the same clinical symptoms in CFC syndrome.  
 
2.3.1. Wild-type levels of BRAF and MEK signalling are imperative for 
proper gastrulation 
BRAF allele substitution in CFC and melanoma naturally promotes both increased 
and decreased kinase activity to the protein by altering the physical accessibility to 
the kinase domain (Wan et al., 2004).  Unlike melanoma patients, BRAF mutations 
identified in CFC syndrome are not solely clustered around a specific domain. Both 
kinase-activating and –inactivating mutations have been identified in the kinase 
domain, the activation segment, the cysteine-rich domain of the conserved region 1 
(CR1) and the glycine loop in exon 11 (domains highlighted in Figures 2.1.2A, 
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While the mutations are distributed more widely than in melanoma, some mutations 
have overlapping functions. In particular, germ-line BRAF
G596V
 promotes CFC while 
somatic BRAF
G596V
, in the presence of a second mutation, can cause melanoma onset 
(Rodriguez-Viciana et al., 2006). The notion of mutations overlapping between 
syndromes is not novel. For instance, the same K-RAS allelic substitution has been 
identified both in a patient with CFC (Niihori et al., 2006) and Noonan syndrome 
(Schubbert  et al., 2006).  
 
Consistent with human clinical evidence, the current in vivo assay suggested that 
both increased and decreased activity BRAF, MEK1 and MEK2 CFC alleles disrupt 
the signalling of the MAPK cascade, promoting gastrulation defects. It became clear 
that disturbing normal MAPK signalling early in development had detrimental 
effects initially in the axis patterning and later in tissue formation. The dorsalisation 
of embryos at 10.5hpf was translated into severe shortening of the antero-posterior 
axis of the larvae at 24hpf (Figure 2.3.1).  
 
 The entire panel of allelic variants caused embryo elongation. The fact that over-
expression of the human wild-type proteins alone did not promote any morphological 
or molecular changes suggests, firstly, that the embryo elongation was not an artefact 
of the RNA injection of human mRNA and, secondly, that the embryos can cope in 
the presence of elevated amounts of a foreign protein without affecting the activity of 
the pathway or the progression of development.  In the framework of this assay, all 
the mutations were activating, irrespective of their in vitro or in silico predicted 
kinase activity. 
 
It was of interest to test whether early gastrulation movements were affected by the 
expression of disease alleles, as embryo dorsalisation results from Fgf-signalling 
disruption. HggI expression remained unaffected in all groups of embryos suggesting 
that convergence movements were not disrupted. Dlx3 expression, however, was 
widely modified in the embryos injected with the disease alleles, but not in those 
injected with the wild-type form of the human protein. Therefore, while convergence 
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carried on as normal, extension cell movements were enhanced, thus causing the 
elongated phenotype. The fact that convergence disruption is even greater than Shp2 
zebrafish mutants may indicate a different mode of action of Braf and Mek during 
gastrulation. 
 
2.3.2. Kinase-impaired mutants do not signal through C-raf to promote 
Mek activation 
Low activity BRAF mutants signal through C-RAF to activate the MEK and 
subsequently ERK in tumour cell lines (Dumaz et al., 2006; Garnett et al., 2005; 





 promoted embryo elongation. This suggests that they 
activated the pathway less optimally than the WT protein but sufficiently to affect 
gastrulation progression.  
 
To examine whether C-raf was, indeed, the mediator between impaired activity 
BRAF proteins and MEK1/2, kinase-inactivating BRAF variants were expressed in a 
C-raf knockdown background (Figure 2.2.6). The C-raf morpholino used was 
designed based on published data and morphant phenotypes were consistently 
reproduced (Razzaque et al., 2007). However, the reduction of endogenous C-raf 
levels did not prevent the elongated phenotype. This finding is in contrast with the 
previously speculated theory of BRAF-C-RAF dimerisation (Rushworth et al., 2006) 
and is suggestive of an alternative mode of pathway activation. In addition, a 
constitutively active C-RAF mutant (kind gift from Dr. Eric Holland, NY) failed to 
cause embryo dorsalisation (data not shown), suggesting that this bioassay is 











Figure 2.3.1 Schematic overview of in vivo activity of BRAF, MEK1 and MEK2 
mutant alleles 
 
Injection of one-cell stage wild-type embryos with a mRNA expressing mutant but not WT human 
BRAF, MEK1 and MEK2 proteins disrupted normal gastrulation movements and caused dorso-
ventral axis defects at 10hpf and significant shortening of the embryo by 24hpf. 
 




2.3.3. All CFC disease variants act as gain-of-function mutations in vivo 
It is not unusual for gain-of-function (gof) and loss-of-function (lof) mutations to 
advance similar clinical phenotype in different patients (Bentires-Alj et al., 2006; 
Keilhack et al., 2005). Conversely, gof and lof mutations of the same gene can lead 
to the onset of separate disorders. In the case of SHP2, germ-line gof mutations cause 
Noonan syndrome (NS) whereas lof mutations are found in LEOPARD syndrome 
(LS) (Stewart et al., 2010; reviewed in Edouard et al., 2007). Additionally, Shp-2 
knockdown as well as expression of NS and LS mutations give rise to comparable 
phenotypes both in zebrafish and Drosophila melanogaster models of the diseases 
(Oishi et al., 2009; Jopling et al., 2007; Oishi et al., 2006). There is presently no 
established correlation between kinase activity levels of MAPK components and 
symptom severity. Therefore, in vitro protein activity cannot be used as a reliable 
predictor of patient phenotype.  
 
Co-expression of sub-optimal levels of CFC BRAF and MEK disease alleles 
promoted an additive effect in terms of aberrant phenotype incidence (Figure 2.2.4). 
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Similarly, the presence of two mutations in the MAPK pathway can have an additive 
clinical outcome. For example, a severely affected NFNS patient had a de novo 
PTPN11 and an inherited NF1 mutation, and only one parent showed mild features 
of neurofibromatosis type I (Thiel et al., 2009).  Unlike NS and LS zebrafish models, 
where gof and lof mutations cancel each other out upon simultaneous expression 
(Jopling et al., 2007), concurrent presence of kinase-inactivating and kinase-
activating BRAF and MEK mutations significantly enhanced elongation frequency. 
These findings strongly support that all CFC allelic variants are activating the MAPK 
pathway and act as gof mutations in vivo.  
 
2.3.4. CFC alleles may have a low-penetrance oncogenic potential 
BRAF is often mutated in a range of cancer patients. Mutations arise in 
approximately 7% of all human cancers and, more strikingly, in 66% of malignant 
melanomas (Davies, 2002). The most frequent missense point mutation occurs at the 
valine 600 (V600) and the most common substitution, V600E, confers a 500-fold 
kinase activity increase to the protein (Wan et al., 2004). BRAF
V600E
 is found 
predominantly in pre-malignant naevi (Pollock et al. 2003), benign senescent lesions 
that normally would not progress to melanoma (Michaloglou et al., 2005; Bennet, 
2003). However, BRAF
V600E
 is present in more than 80% of primary and metastatic 
melanoma patients and its elevated oncogenic potential when specifically expressed 
in melanocytes, has, previously, been assessed (Patton and Zon, 2005; Patton et al., 
2005). 
 
Moreover, engineered MEK alleles promote transformation in cancer studies 
(Lemieux et al., 2009; Komatsu et al., 2006; Mansour et al., 1994). However CFC 
mutations in MEK1 and MEK2 were the first MEK mutations to be identified in a 
human disease. It is only very recently that activating MEK1 mutations were 
identified in ovarian cancer (Estep et al., 2007; Bian et al., 2004). 
 
Despite the germ-line mutations in BRAF and MEK, CFC patients are not thought to 
be at an increased risk for cancer. Nevertheless, their propensity to develop high 
Chapter 2 - Discussion 
51 
numbers (commonly over 100) (Tidyman and Rauen, 2010) of naevi poses the 
question whether CFC mutations possess increased oncogenicity. Having a 
previously established system to evaluate the potential of BRAF allelic variants to 
drive ectopic naevi formation, I tested the oncogenic effect of an array of CFC, 
melanoma and engineered BRAF mutations. 
 
For the first time, mosaic melanocyte expression of a kinase-inactivating mutation 
identified both in melanoma and CFC patients (BRAF
G596V
) was found to be 
sufficient to trigger extensive ectopic pigmentation (Figures 2.2.7, 2.2.8). Although 
no other variant was able to convincingly promote naevus formation, they all caused 
deviation from the standard defined pigmentation pattern. Most strikingly, new foci 
of pigment mis-patterning became apparent as the fish grew older. For instance, fish 
expressing BRAF
G596V
 under the mitfa promoter developed six new distinct areas of 
pigmentation in two months in previously normally patterned areas (Figure 2.2.8). 
The changing melanisation of CFC allele-expressing fish could be attributed to their 
ongoing development but could possibly be linked to the progressive nature of CFC 
syndrome. 
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2.3.5. Concluding remarks 
During this study I developed a robust bioassay that can be used as a tool to study the 
developmental effect of an allelic series. Using the embryonic phenotype at the end 
of gastrulation as the readout, the impact of the expression of multiple proteins can 
be easily accomplished and confirmed. Co-expressing different components of the 
same or different pathways can give insight into molecular and genetic interactions 
during gastrulation, within the physiological framework of a live developing 
organism.  
 
However, this assay does not mimic the actual genetics of CFC and a better 
understanding of the pathway regulation can help design more realistic ways of 
therapeutic targeting. Although creating an animal model that more closely 
represents the physiology of CFC is essential, it requires time. To genetically 
intercept the pathway more rapidly small molecule inhibitors can be beneficial in 
teasing apart the mechanism of action of MAPK components as well as in 
approaching the possibility of pharmaceutical intervention. 
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3.Chapter 3 - Pharmacological 
inhibition of the MAPK pathway in 
vivo 
“Cure sometimes, treat often, comfort always” 
 - Hippocrates 





3.1.1. The MAPK pathway as a target for drug development 
The role of oncogenic MAPK signalling in driving the initiation, progression and 
maintenance of cancer has made this pathway a priority target for drug development 
(reviewed in Pratilas and Solit, 2010). Aberrant upregulation of the pathway is noted 
in numerous neoplasias and confers enhanced survival, independent of growth factor 
binding, and metastatic ability. So far, the key components of the pathway (receptor 
tyrosine kinases, RAS, RAF and MEK) have been the molecular targets of chemical 
antagonists. Small molecules acting as potent inhibitors have already been identified, 
some of which are being successfully used in human clinical trials (Chapman and 
Miner, 2011; reviewed in Weickhardt et al., 2010; reviewed in Sebolt-Leopold, 
2008).  
 
The MAPK pathway endorses pro- and anti-apoptotic signals depending on the cell 
type and amongst other processes activated ERK1/2 controls regeneration, migration 
and cell shape changes (reviewed in Winter-Vann and Johnson, 2007). Thus, MAPK 
signalling and, by extension, its inhibitors are predicted to be primarily active in 
tissues undergoing regeneration or have rapid turnover rates. For example target 
tissues include the skin and the gastrointestinal tract. Moreover new advances 
delineate novel MAPK regulators through RNA interference library screening 
(Friedman et al., 2006). Therefore, with new knowledge at hand and focused study 
of already described endogenous inhibitors construction of new drugs for the 
pathway becomes more approachable. 
 
Development of new drugs specifically designed for the treatment of the 
RASopathies is mostly inhibited by the rarity of the disorders. However, recycling 
the use of already FDA-approved anti-cancer drugs or compounds in clinical trials 
provides a route to the possibility of RASopathies treatment (reviewed in Rauen et 
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al., 2011; reviewed in Sebolt-Leopold, 2008). Systemic therapy in young children 
can reduce the elevated output of the activated MAPK pathway thereby reducing the 
symptom severity of the patients. In the following section I will discuss the design of 
various inhibitors of the FGF/MAPK cascade developed to target cancerous lesions 
and highlight the compounds that could offer therapeutic potential for the 
RASopathies spectrum. 
 
3.1.2. Cell membrane receptor inhibition 
3.1.2.1. FGFR family in disease 
The mammalian fibroblast growth factor receptor (FGFR) family is highly conserved 
amongst vertebrates and consists of four members, while a fifth one has been 
recently characterised in humans (Sleeman et al., 2001). The receptors share 
sequence and structural similarity but perform distinct functions in different tissues 
(reviewed in McIntosh et al., 2000). Overall, FGFRs play a central role in 
development, angiogenesis and wound healing. Their aberrant expression leads to 
constitutive activation of the FGF/MAPK pathway and occurs through three 
mechanisms: point mutations, chromosomal translocations and gene amplifications.  
 
Most FGFR-related tumours arise due to gene amplifications. Over-expression of 
FGFR1-3 is a leading cause for the onset of rhabdomyosarcoma (FGFR1), breast 
(FGFR1, 2), ovarian (FGFR1), gastric (FGFR2) and bladder cancer (FGFR1, 3). 
Point mutations are most commonly associated with endometrial (FGFR2), bladder 
and cervical cancer (FGFR3). Translocations are identified in leukaemia (FGFR1), 
lymphoma (FGFR1) and myeloma (FGFR3) development (reviewed in Turner and 
Grose, 2010). 
 
FGFRs predominantly activate the RAS/MAPK pathway (Corson et al., 2003) both 
in physiological and tumourigenic conditions. Coupled with their great involvement 
in cancer progression the design of compounds that block their function has 
increased. 
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3.1.2.2. FGFR germ-line mutations  
Like the RASopathies, gain-of-function FGFR germ-line mutations promote the 
onset of a spectrum of genetic disorders (Lajeunie et al., 2006). All syndromes affect 
the embryonic development of branchial arches and as such result to similar clinical 
manifestations involving cartilage and bone malformations. The disorders include 
Crouzon syndrome (FGFR2, 3) (OMIM 123500)  (Reardon et al., 1994), Jackson-
Weiss syndrome (FGFR1, 2) (OMIM 123150) (Jabs et al., 1994), Pfeiffer syndrome 
(FGFR1, 2) (OMIM 101600) (Rutland et al., 1995) and Apert syndrome (FGFR2) 
(OMIM 101200) (Anderson et al., 1998; Moloney et al., 1996; Park et al., 1995; 
Wilkie et al., 1995).  
 
FGFR2 mutations are responsible for the onset of craniosynostosis (Kan et al., 
2002), the most important common feature between the syndromes. This condition 
causes infant skull sutures to fuse prematurely impeding proper cranial development. 
Similarly to the RASopathies, the branchial arches syndromes are progressive in 
severity due to bone growth with increasing age. Craniofacial and tooth formation is 
prominently disturbed and characteristic facial features include widely spaced eyes 
and low set ears. 
 
3.1.2.3. Somatic mutations are targeted with chemical compounds 
Many different FGFR alterations have been reported to be involved in cancer 
progression (reviewed in Turner and Grose, 2010). Carcinogenic FGFRs are mostly 
associated with bladder cancer, with almost half the reported cases harbouring an 
FGFR3 mutation (van Rhijn et al., 2002; Cappellen et al., 1999). Interestingly, most 
somatic mutations identified in patients with FGFR-induced tumours are the same as 
the germ-line mutations promoting thanatophoric dysplasia, a developmental 
disorder of the FGFR spectrum (van Rhijn et al., 2002). Overlap between the same 
variant causing melanoma in somatic mutations and CFC syndrome in germ-line 
mutations has been observed with the BRAF
G596V
 allele.  
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Inhibition of FGFRs has clinical significance especially in tumourigenic lesions with 
amplified FGFR expression, like breast and bladder cancer. Small molecule 
compounds have been generated to block the activated receptor tyrosine kinases in 
vitro and in vivo. However, the majority of the drugs are not FGFR-selective. Due to 
their structural similarity, most inhibitors target FGFRs, vascular endothelial growth 
factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs) at 
a similar dosage (reviewed in Hynes and Dey, 2010). An example of a broad-range 
anti-angiogenic drug is Dovitinib (Sarker et al., 2008) currently in clinical trials 
against solid tumours (Loriot et al., 2010). 
 
Affecting a large spectrum of kinases has been beneficial in impeding tumour 
progression in cancer patients but it is important to be able to selectively target a 
single protein. To this end, antibodies may become useful in inhibiting single FGFRs 
in cancer patients (Qing et al., 2009; Sun et al., 2007). Additionally, ligand traps are 
compounds that selectively inhibit the binding of different ligands to their respective 
receptor tyrosine kinases, thereby completely impeding mitogen-dependent 
activation of the molecular cascades downstream of the receptors. Such ligand traps 
have already entered clinical trials (ClinicalTrials.gov identifier: NCT01244438). 
 
3.1.2.4. FGFR-selective inhibitors 
SU5402 (Figures 3.1.1, 3.1.2) and PD173074 were identified through a chemical 
library screen for their ability to inhibit autophosphorylation of FGFR1 and 
phosphorylation of ERK1/2 in NIH 3T3 cells at low concentrations (Mohammadi et 
al., 1998; Mohammadi et al., 1997). Resolution of the crystal structure of the FGFR1 
kinase domain confirmed the ATP-competitive interaction of the compounds with 
the catalytic domain of the receptor (Figure 3.1.1). Importantly, both agents exhibit 
high specificity for FGFR1. They do not block the activation of epithelial growth 
factor receptors (EGFRs), PDGFRs or insulin receptors. However they can potently 
inhibit VEGFRs. The specificity to FGFR and VEGFR relies on the presence of an 
asparagine residue in the hinge region of the kinases. Binding to this particular amino 
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acid promotes structural changes stabilising the binding loop of the receptor 
(Mohammadi et al., 1997). 
 
 
Figure 3.1.1 Illustration of FGF receptor 1 (FGFR1) bound to the inhibitor SU-5402 
 
A Three-dimensional reconstruction of the surface of  FGFR1.  
B Schematic illustration of FGFR1 and SU-5402 in the binding pocket of the receptor. The secondary 
structures of FGFR1 are highlighted in magenta (α helices) and yellow (β sheets). The small molecule 
inhibitor is shown in a plain ball and stick style. Carbon, nitrogen and oxygen atoms are represented 
by grey, blue and red balls, respectively. 
 
Both images were generated using the Jmol version 12.0.18 application on RCSB Protein Data Bank 
(PDB reference 1FGI). 
 
 
SU5402 and PD173074 are soluble chemical agents selective for FGFR that are 
predominantly used in animal and in vitro work. Breast tumour cell lines with 
activating mutations or FGFR amplifications showed increased sensitivity to 
PD173074 treatment (Turner et al., 2010; Koziczak et al., 2004). Similarly, growth, 
survival and migration of non-small cell lung carcinoma lines were inhibited by 
SU5402 treatment (Fischer et al., 2008). Both SU5402 and PD173074 have been 
able to induce apoptosis in multiple myeloma cell lines (Grand et al., 2004) and 
mouse models (Paterson et al., 2004) as well as in bladder cancer tumour cell lines 
(Lamont et al., 2011) with activated and amplified FGFR1 and FGFR3. 
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Most features of the branchial arch syndromes are surgically corrected and patients 
are not treated with active FGFR inhibitors. However, treatment of a mouse model of  
Crouzon syndrome with an FGFR inhibitor (PD173074) promoted normal skull 
development (Perlyn et al., 2006). This is encouraging for the developmental 
syndromes field and suggests the possibility of pharmacological craniosynostosis 
patients treatment  
 
Small molecule inhibitors of other receptor tyrosine kinases are being used 
successfully either as second line of treatment (e.g. Gefitinib inhibiting EGFR in 
non-small cell lung carcinoma) or are in advanced clinical trials (e.g. bevacizumab 
targeting VEGFR in non-small cell lung carcinoma and renal cancer) (reviewed in 
van Meter and Kim, 2010, reviewed in Shao et al., 2010).  
 
3.1.3. RAS inhibition 
Increased activity of the cascade can also be triggered by mutations downstream of 
the tyrosine kinase receptors. RAS proteins, H-RAS, N-RAS and K-RAS, are 
frequently mutated in a variety of human cancers. Constitutive activation of RAS 
either as a result of a mutation or of continuous growth factor stimulation is 
imperative for tissue transformation and tumour growth. This is further supported by 
the fact that single correction of RAS-driven aberrant signalling reverses malignant 
transformations even in the presence of additional genetic mutations. For the past 
twenty years researchers have tried to prevent the activation of this component in the 
scope of anti-cancer drug development (reviewed in Krens et al., 2010; Saxena et al., 
2008; Konstantinopoulos et al., 2007; reviewed in Sebolt-Leopold and Herrera, 
2004). 
 
3.1.3.1. Mode of RAS inactivation 
The oncogenicity of RAS depends on activated RAS (Ras-GTP) binding to the inner 
cell membrane (Kohl et al., 1993; James et al., 1993). Attachment to the plasma 
membrane is ensured by post-translational modifications such as prenylation (Reuter 
Chapter 3 - Introduction 
60 
et al., 2000). This process entails the stable attachment of a farnesyl (15 carbon-) or 
geranylgeranyl (20 carbon-) group to the cysteines at the carboxyl end of the protein.  
 
RAS membrane association is promoted by the prenylation of a characteristic CAAX 
(Cysteine- Aliphatic amino acid- Aliphatic amino acid- any amino acid) motif at the 
carboxyl terminal of the kinase. Without this step, RAS is restricted to the cytoplasm 
and downstream activation of the pathway is impeded. Mutations of the protein 
anchoring site or introduction of inhibitors of the farnesyl transferase enzyme block 
RAS activation and, thus, MAPK pathway signalling.  
 
3.1.3.2. Development of post-translational modification inhibitors 
Farnesyl transferase inhibitors (FTIs) have been successful in preventing tumour 
progression in h-ras transgenic mice and mice xenografted with fibroblasts 
harbouring h-ras mutations (Liu et al., 1998). Some FTIs have been evaluated in 
clinical trials (Alsina et al., 2004; Cortes et al., 2003; Morgan et al., 2003). However, 
they have not shown high clinical efficiency and the response to the treatment was 
incomplete (Alsina et al., 2004). This may be accounted for by the fact that FTIs 
only inhibit farnesylation and the most commonly mutated K-RAS and N-RAS 
kinases undergo a different type of end modification, geranylgeranylation (Rowel et 
al., 1997; Whyte et al., 1997; Zhang et al., 1997).  
 
To that end, a new inhibitor was developed to target all three orthologues. 
Farnesylthiosalicylic acid (FTS), also known as salirasib, competitively occupies the 
RAS-docking sites on the cell membrane impeding RAS-GTP anchorage and 
promoting its degradation (reviewed in Gana-Weisz et al., 2002; Weisz et al., 1999; 
Haklai et al., 1998). FTS has been the most successful in uncoupling all RAS 
proteins from the cell membrane and promoting RAS-independent growth in vivo 
and in vitro (Jansen et al., 1999; Weisz et al., 1999). FTS inhibits tumour formation 
both in mice xenograft experiments (Zundelevich et al., 2007; Jansen et al., 1999; 
Weisz et al., 1999) and after direct oral administration (Haklai et al., 2008) most 
importantly without causing any toxicity to the animals.  
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Being the only active compound against K-RAS and N-RAS, coupled with the lack 
of adverse side effects at physiological doses (reviewed in Gana-Weisz et al., 2002)  
rendered FTS a good potential candidate for clinical trials. It has already been 
entered in phase I and II clinical trials against non-small cell lung carcinoma, lung 
adenocarcinoma and pancreatic cancer (Clinical trial identifier: NCT00531401; 
Tsimberidou et al., 2009; reviewed in Bustinza-Linares et al., 2010). 
 
Further obstruction of RAS post-translational modifications also seems promising. 
Inhibiting ICMT, the protein that methylates RAS after proteolytic cleavage of its 
CAAX motif, halts cellular transformation (Bergo et al., 2004) and potent inhibitors 
are being developed against it, like cysmethynil, (Winter-Vann et al., 2005). 
 
3.1.3.3. FTIs and FTS against RASopathies 
Neurofibromin 1 is encoded by the NF1 gene and acts as a Ras-GTP-ase activating 
protein. Its implication in the onset of Neurofibromatosis Type I (NF1) has been 
previously discussed (Chapter 2). The activity of NF1 exons 23-29 promotes RAS 
inactivation by hydrolysing the active GTP-bound RAS to the inactive GDP-bound 
protein (Ballester et al., 1990; Martin et al., 1990). Mutations leading to 
neurofibromin 1-depletion promote perpetual RAS activation and tumourogenicity.  
 
NF1 patients develop a plethora of tumours, which are accounted for by the cellular 
increase of RAS-GDP. Thus, administration of FTIs presented as a potential 
treatment for some NF1-related symptoms. Indeed, FTIs blocked the oncogenic 
growth of neurofibromin 1-deficient malignant cell lines (Mahgoub et al., 1999; Kim 
et al., 1997; Yan et al., 1995). Later studies further supported NF1 treatment through 
RAS inhibition as the more effective FTS inhibitor restored normal RAS-GTP levels, 
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3.1.4. RAF inhibition 
After the identification of BRAF as an oncogene and its frequent implication in 
multiple cancer types (Davies et al., 2002), community interest was shifted towards 
identifying therapeutic agents against RAF kinases. Although the members of the 
RAF family are structurally similar, their activity and expression patterns differ 
(Chapter 2). This together with the fact that Raf proteins are interacting both 
positively and negatively with a complicated network of downstream effectors, 
render the simultaneous inhibition of all three kinases more difficult.  
 
3.1.4.1. Inhibitors of C-RAF are not specific 
From all the small molecule inhibitors directed against RAF, only one has been 
entered in clinical trials. The C-RAF inhibitor BAY 43-9006 (Sorafenib) competes 
with ATP to bind to C-RAF and BRAF pockets (Lyons et al., 2001). It has been 
entered into Phase I, II and III trials (Wilhelm et al., 2006; Lee and McCubrey, 2003; 
reviewed in Bollag et al., 2003) with manageable side effects. The drug promoted 
gastrointestinal and cutaneous reactions (Hotte et al., 2002), common side effects to 
inhibitors of the MAPK pathway. 
  
However, pERK was only partially suppressed following sorafenib treatment and 
inhibition effectiveness depended on the tissue type examined (Clark et al., 2005; 
Strumberg et al., 2005). Moreover, the compound lacked in specificity (Wilhelm et 
al., 2004) and failed to induce a response in BRAF-specific tumours such as 
melanoma. This is likely to be the case as the small molecule binds to the inactive 
form of BRAF and the malignant protein may be less sensitive to inhibition (Wan et 
al., 2004). Kinase assays supported that sorafenib was preferentially selective for 
growth factor receptors like VEGFR2-3, PDGFR and KIT (Wilhelm et al., 2004) and 
not RAF. Despite the lack of MAPK inhibition, the compound had great success in 
prohibiting renal and hepatocellular carcinoma in clinical trials (Escudier et al., 
2009; Escudier et al., 2007; Strumberg et al., 2005).   
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3.1.4.2. Targeting specific BRAF mutant conformations 
BRAF mutations are most frequently identified in melanoma (Satyamoorthy et al., 
2000; Davies et al., 2002) but are also prevalent in colorectal (Yuen et al., 2002), 
ovarian (Singer et al., 2003) and thyroid cancer (Kimura et al., 2003). The majority 
of the mutations result in the substitution of the valine at the amino acid 600, which  
causes a structural change to the protein. BRAF
V600E
 mutations highly enhance the 
kinase activity by mimicking the active conformation of the activation loop of the 
protein (Wan et al., 2004).  
 
After the crystallisation of BRAF (Wan et al., 2004), second generation RAF 
inhibitors were developed. The structure of the most promising inhibitor PLX-4032 
was based on the conformation of BRAF
V600E
 thus exhibiting very high specificity 
for the mutant and not the wild type kinase (Tsai et al., 2008). In initial studies, 
melanoma cell lines treated with PLX-4032 were positively responsive to the 
inhibitor (Sala et al., 2008). The drug soon entered clinical trials against metastatic 
melanoma with great success in promoting non-toxic growth regression and 
inhibiting metastasis (reviewed in Wellbrock and Hurlstone, 2010). It is currently in 
Phase III trials.  
 
Despite the increased patient responsiveness, drug resistance with PLX-4032 was 
common and developed in as little as two months of treatment (Tuma, 2011). Two 
mechanisms of resistance have been characterised. In some patients, the cells 
compensated for the loss of BRAF activity by making use of parallel pathways 
(Johannessen et al., 2010). C-RAF and COT directly activated downstream MAPK 
signalling in a BRAF-independent manner.  Alternatively, secondary oncogenic 
mutations affecting the MAPK cascade arose to promote resistance (Nazarian et al., 
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3.1.5. MEK inhibition 
MEK kinases have a seminal role in the promotion of the MAPK pathway and the 
further transduction of proliferative or apoptotic signals. MEK1/2 have been 
described as oncogenes by virtue of the tumourigenic potential of their constitutively 
active forms in vitro (Hoshino et al., 1999; Cowley et al., 1994; Mansour et al., 
1994). It is possible to target both kinases simultaneously based on their highly 




Figure 3.1.2 Chemical structures of small molecule inhibitors 
 
Representations of the structures of small molecule inhibitors of the FGF/MAPK pathway. 
A The FGF receptor inhibitor SU5402  
B-E The MEK1/2 inhibitors UO126 (B), CI-1040 (C), Compound 1 (D) and PD032501 (E). The red 
dotted boxes are highlighting the  chemical differences between CI-1040 and Compound 1 and their 
derivative PD0325901 (bold). 






Figure 3.1.3 Illustrations of MEK1 and MEK2 
 
A, B Three-dimensional reconstructions of  MEK1 (A) and MEK2 (B) from different angles. The 
images on the right of each panel illustrate the same molecules rotated anti-clockwise, thus revealing 
the opening of the binding pocket (green asterisk). 
C Illustration of a MEK2 homodimer. For clarity purposes the hue of each MEK2 monomer is altered.  
D, E Simplified representations of the secondary structures of MEK1 (D) and MEK2 (E). Oriented at 
similar angles to each other the structural similarity of the proteins is apparent. The structures 
illustrated are α helices (magenta), β sheets (yellow) and the binding pocket (green asterisk). 
F PD0325901 bound to MEK1 
All images were generated using the Jmol version 12.0.18 application on RCSB Protein Data Bank 
(PDB references MEK1: 3EQG; 3EQG; MEK2: 1S9I). 
 
3.1.5.1. Partial success with the first MEK inhibitors  
With only two known effectors, ERK1 and ERK2, MEK1 and MEK2 were initially 
targeted with PD98059 (Dudley et al., 1995). The development of this small 
molecule inhibitor advanced the study and understanding of the MAPK pathway by 
the academic community. A more potent inhibitor, UO126 (Figure 3.1.2), was 
generated shortly after PD98059 (Ahn et al., 2001; Favata et al., 1998) but neither 
were administered during clinical trials due to their rapid turnover rate. 
 
The first drug to successfully block tumour growth in vivo was the non-ATP 
competitive inhibitor CI-1040 (Figure 3.1.2). Oral administration of CI-1040 
effectively impeded up to 80% of colon tumour growth in mice (Sebolt-Leopold et 
al., 1999). CI-1040 treatments of zebrafish embryos promoted defined 
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developmental phenotypes that resemble CFC syndrome defects (Grzmil et al., 
2007). Namely, heart development, body axis and craniofacial cartilage structures 
were vastly affected. 
  
After its initial success in animal models (Sebolt-Leopold et al., 1999) and its high 
specificity for MEK1/2 (Davies et al., 2000), CI-1040 entered Phase I and II clinical 
trials (Rinehart et al., 2004; Allen et al., 2003). The drug successfully inhibited ERK 
phosphorylation at doses well tolerated by patients, some of whom showed evidence 
of tumour regression. It has, however, been proposed that CI-1040 preferentially 
inhibits proliferation of thyroid tumours harbouring BRAF or RAS mutations (Liu et 
al., 2007). This is a possible explanation as to why the drug only halted tumour 
growth without being overtly successful in causing tumour regression in clinical 
trials. Additionally, as the compound was rapidly metabolised the trials were 
terminated.  
 
3.1.5.2. Second generation MEK inhibitors enter clinical trials 
The design of PD0325901 was based on CI-1040 and as such is biologically and 
structurally (Figure 3.1.2) very similar. PD0325901 is equally selective for MEK1 
and MEK2 as CI-1040 but is more potent in inhibiting MEK both in vitro and in vivo 
(reviewed in Sebolt-Leopold, 2008). The enhanced activity of the drug is attributed 
to its improved stability and increased solubility. This was achieved by optimising 
the compound’s core and modifying its side chain (Barrett et al., 2008). PD0325901 
treatment has been effective in a range of human tumours. It has been tested in 
clinical trials for patients with MAPK-activated solid tumours, breast cancer, colon 
cancer, melanoma and non-small cell lung carcinoma (Haura et al., 2010; LoRusso et 
al., 2010; clinical trial identifiers:  NCT00147550; NCT00174369). 
 
3.1.5.3. MEK inhibitors are highly selective  
MEK1/2 inhibition has proven to be the most highly selective one as the developed 
small molecule compounds failed to sufficiently inhibit a spectrum of other kinases 
(Davies et al., 2000). CI-1040 can only additionally inhibit MEK5 at a concentration 
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100 times higher than MEK1/2 (Mody et al., 2001). Blocking MEK with small 
molecules in vitro effectively inhibits the activity of mutant BRAF resulting in 
growth arrest and apoptosis (Solit et al., 2006). This suggests that the cancerous cells 
are addicted to BRAF, a notion referred to as oncogene addiction.  
 
Crystallisation of the kinase domain of MEK1 and MEK2 identified the presence of 
an inhibitor-binding domain, unique to MEK1/2 kinases (Ohren et al., 2004). This 
site is directly adjacent to the ATP-binding pocket. Resolution of the structure 
revealed that simultaneous binding of ATP and the inhibitor is possible. This 
association leads to conformational changes of the protein without suppressing its 
kinase activity. In detail, CI-1040 and PD0325901 binding disrupts the catalytic site 
of the protein by stabilising the naturally occurring inactive conformation of the 
activation loop and helix C. The possibility of the presence of analogous binding 
pockets in other kinases facilitates the design of new non-ATP competitive drugs 
(non-classical kinase inhibitors) (Tecle et al., 2008). 
 
3.1.5.4. MEK inhibitors and RASopathies 
The development of high specificity and efficacy MEK inhibitors offers therapeutic 
potential in the RASopathies field. Such drugs function by impeding the activation of 
ERK. As all germ-line mutations identified in this spectrum are mostly upstream of 
MEK and in the case of 25% of CFC patients are in MEK, halting the downstream 
output of the pathway has the potential of restoring physiological MAPK signalling 
levels. Indeed, pre-natal PD0325901 administration to a mouse model of Noonan 
syndrome (NS) with a homozygous SOS1 mutation reduced both lethality and the 
severity of the phenotypes (Chen et al. 2010). Additionally, post-natal MEK 
inhibition of a different NS mouse model harbouring C-RAF mutations overtly 
improved the NS features of the animal (Wu et al., 2011). Both studies are 
encouraging and support the benefits of reducing MAPK pathway activity by 
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Agent Class Target Clinical Trials 
















Sunitinib Multitarget agent 
PDGFR, VEGFR2, KIT, 
FLT3 
 
Bevacizumab Monoclonal antibody VEGFR  
Salirasab Farnesylation inhibitor KRAS, NRAS  






Sorafenib Multitarget agent 
PDGFR, VEGR2/3, 
KIT, FLT3, C-RAF, 
BRAF 
 
















Table 3.1.1 List of MAPK pathway inhibitors and their clinical trial status 
The drugs highlighted in bold were used in the present study 
 
 
Developmental disorders other than RASopathies can profit from the study of MEK 
inhibition.  FGFR syndromes, for instance, are phenotypically and molecularly 
similar to the RASopathies. An FGFR3 mosaic somatic mutation was recently 
identified promoting CFC reminiscing- skin softening, increased naevi count and 
mental impairment (Garcia-Vargas et al., 2008). Moreover, craniocystosis patients 
with activated FGFR signalling can evade FGFR drug resistance and benefit by 
MEK inhibition, as already demonstrated in a pre-clinical mouse model of Apert 
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3.1.6. Development of drug resistance 
Inhibitor resistance is a principal issue in cancer treatment and occurs with many 
widely used cancer drugs. Resistance is potentially conferred by many factors. One 
theory is that the cancerous cells produce more of the particular protein to 
compensate for the loss of its function in response to treatment-induced inactivation 
of a particular kinase (Gorre et al., 2001). Alternatively, following prolonged 
treatment, mutations can arise in the catalytic domain of the protein impeding 
optimal binding of the pharmacological agents (Kobayashi et al., 2005). Finally, 
activity of parallel pathways can account for resistance when no mutations have 
developed in the targeted kinase (Wang et al., 2005). 
 
3.1.6.1. Gene amplification 
FGFR1 amplification in breast cancer induces resistance to endocrine therapies 
(Turner et al., 2010). Moreover, to elucidate the mechanisms driving potential MEK 
inhibitor resistance a model of AXD6244-resistant colorectal cell lines was 
generated. In the pre-clinical model, resistance against MEK and BRAF inhibitors 
was achieved through amplification of the BRAF gene (Corcoran et al., 2010). 
 
3.1.6.2. Development of resistance as a result of secondary mutations 
The BCR-ABL fusion protein acquires resistance against the ATP-competitive 
imatinib (Gleevec) by developing a mutation at the threonine 315 in the kinase 
domain (Bishop, 2004). The mutation causes destabilisation of the activation loop 
and reduction in binding affinity to the drug (Gorre et al., 2001). An analogous 
mutation has been identified in the ATP-binding site of other receptor tyrosine 
kinases. The substitution of threonine 670 for an isoleucine impedes binding of 
imatinib to the cytokine receptor KIT (Tamborini et al., 2006).  Equivalent threonine 
substitutions at the binding pockets of EGFR (Kobayashi et al., 2005; Pao et al., 
2005) and PDGFR (Azam et al., 2008) are responsible for drug resistance. This 
mutation locus may be conserved in other tyrosine kinases, accounting for the 
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developed resistance against kinase-specific drugs. To avoid such resistance, HG-7-
85-01 was developed to inhibit mutant and wild-type forms of kinases irrespective of 
the mutational status of the essential threonine. This inhibitor targets BCR/ABL, 
PDGFR, KIT and Src kinases (Weisberg et al., 2010). 
 
3.1.6.3. Parallel components promote downstream activation 
Although inhibitors may be successful in blocking the function of their targets, the 
signalling route is frequently circumvented in neoplasias in order to promote 
oncogenic growth. Activating mutations of BRAF, such as BRAF
V600E
, promote 
cancer survival by enforcing continuous downstream signalling. Pharmacological 
inhibition of oncogenic BRAF
V600E
 has been successful but brief (Sala et al., 2008). 
A characterised way for persistent downstream signalling in cancerous tissues 
harbouring BRAF mutations that lose their sensitivity to the drugs is by the 
activation of C-RAF.  In inhibitor-resistant melanoma cells the levels of wild-type C-
RAF increase and the oncogene dependency is swapped between the two RAF 
kinases (Montagut et al., 2008). In a similar manner low kinase activity BRAF 
mutants heterodimerise with wild-type C-RAF to achieve further MEK and ERK 
activation (Garnett et al., 2005). 
 
Recently, a counter-intuitive form of resistance against BRAF inhibitors was 
described. Upon inhibition with PLX4032 and other RAF inhibitors, BRAF/MAPK 
signalling was blocked in cells with oncogenic BRAF but was enhanced in cells with 
wild-type BRAF (Poulikakos et al., 2010). All drugs used act by binding to the 
BRAF member (BRAF
V600E







) and inactivating it. This step, in turn, activates the other member (C-
RAF). Upstream signalling (RAS) is not activated in BRAF
V600E 
–dependent cells, 
hence reducing the concentration of activated C-RAF and the chances of 
transactivation of another dimer (C-RAF-C-RAF or C-RAF-B-RAF). As ERK 
phosphorylation depends entirely on RAS/RAF/MEK signalling, pERK levels were 
inhibited in a dose-dependent manner with increasing concentrations of the 
inhibitors. Conversely, free C-RAF heterodimers or homodimers were transactivated 
in treated cells with wild-type RAF, thus inducing ERK activation.  
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3.1.7. Overcoming drug resistance through combination therapy  
3.1.7.1. Targeting multiple components of the same pathway 
Developing anti-cancer drugs that promote tumour regression as single agents is a 
great challenge. Most malignancies arise due to or acquire multiple genetic mutations 
making it difficult for individual compounds to concurrently target all the defects. 
The use of two highly selective drugs that act on the same pathway constitutes a 
potential solution to the drug resistance problem. Acquisition of dual resistance 
would not be common, hence more studies are being focused on double targeting. 
This combinatorial approach has a low probability of generating an additive 
phenotype that is different to the one that either one of the agents would promote on 
their own.  
 
In the framework of the MAPK pathway, CI-1040 interacts synergistically with 17-
DMAG, an hsp90 inhibitor, to cause mitochondrial damage in leukaemia cells and 
reduction of the expression of the anti-apoptotic protein Bcl-xL (Nguyen et al., 2006). 
Additionally, targeting the VEGFR/mTOR pathway at different levels provides 
improved outcomes for the therapy of metastatic renal carcinoma.  
 
3.1.7.2. Dual inhibition of different pathways 
Another effective approach for clinical treatment is simultaneous targeting of all 
affected pathways. Tumours and cancer cell lines with activated survival-inducing 
FGF/MAPK signalling often present with aberrant levels of pro-apoptotic 
PI3K/AKT/mTOR signalling, leading to the complication of cell fate decision.  
 
It is uncommon for two mutations to exist within the same pathway. Indeed, N-RAS 
and BRAF mutations are mutually exclusive (Gorden et al., 2003; Davies et al., 
2002). Nevertheless, there is a high incidence of MAPK and phosphatidylinositol 3-
kinase (PI3K) pathway mutations in melanoma cases (Dankort et al., 2009; Stahl et 
al., 2003), suggesting co-operation between the two cascades. Activating BRAF 
Chapter 3 - Introduction 
72 
mutations coincide with loss of PTEN (a component of the PI3K pathway) much 
more frequently than independent PTEN mutations arise in lesions (Michailidou et 
al., 2009; Tsao et al., 2004; Tsao et al., 2003). Conversely, PI3K (Wee et al., 2009) 
and AKT (Gopal et al., 2010) over-activation confer resistance to MEK inhibition. 
This supports that malignant progression requires aberrant regulation of both 
pathways. Simultaneous suppression of components of both pathways ameliorates 
the effectiveness of the treatment (Meier et al., 2007; Bedogni et al., 2006; Smalley 
et al., 2006).  
 
mTOR is another serine-threonine kinase activated by extracellular stimuli and is 
frequently dysregulated in human cancer. Its inhibitor rapamycin (Sirolimus) has not 
had success in generating a response in melanoma clinical trials when administered 
alone (Margolin et al., 2005). However, mTOR inhibition combined with agents 
directed against the MAPK pathway prohibits tumour growth and invasion.  
Simultaneous treatment with sorafenib promotes sensitivity to BRAF inhibition and 
apoptosis (Niessner et al., 2011; Gedaly et al., 2010; Lasithiotakis et al., 2008).  
Moreover, co-treatment with PD0325901 promotes melanoma tumour regression in 
mice (Dankort et al., 2009). 
 
3.1.8. Neural crest cell populations are targeted during aberrant MAPK 
signalling 
It becomes evident through the study of FGFR congenital defects and the 
RASopathies that the phenotypes presented by the patients are closely related. The 
similarity of the craniofacial malformations is particularly indicative of a specific 
population of cells being affected by FGF/MAPK signalling modulation. 
Additionally, pharmacological targeting of the MAPK cascade is predominantly 
affecting cutaneous and gastrointestinal tract tissues, both arising from the neural 
crest cell (NCC) population. It can be hypothesised that the anomalies caused by 
chemical intervention can be the direct result of improper control of NCC 
maturation. If the genetic mutations and the small molecules targeting the cascade 
are indeed affecting the NCC it is important to understand their molecular 
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background. Comprehension of NCC generation, migration and differentiation can 
elucidate the mechanisms underlying the abnormal development and the acquired 
clinical manifestations promoted by dysregulated MAPK signalling.  
 
3.1.8.1. Neural crest cell migration 
Neural crest cells (NCCs) are an embryonic cell population that delaminates from the 
dorsal neural tube to give rise to melanocytes, smooth muscle, peripheral and enteric 
neurons, ganglia as well as craniofacial bone and cartilage (reviewed in Knecht and 
Bronner-Fraser, 2002).  
 
In gastrulating embryos, NCCs are confined at the neural plate border. This is the site 
of dlx3 expression (Kaji and Artinger, 2004), which was vastly affected by the 
expression of CFC disease alleles in developing zebrafish (Chapter 2; Figure 2.2.5). 
This confirms that at least the NCC orientation is altered upon aberrant MAPK 
signalling.  
 
Neurulation is the embryonic process that succeeds gastrulation. After its completion 
three separate progenitor cell layers, the ectoderm, the neural plate border and the 
neural plate fold within themselves at the plate border to generate the epidermis, the 
neural crest and the neural tube. At that point, the epithelial NCCs migrate from the 
dorsal neural tube to remote sites along the vertebrate embryo, giving rise to neural 
and non-neural cell types. During the migration process, NCCs undergo epithelial to 
mesenchymal transition (EMT) (reviewed in Trainor, 2005; reviewed in Chizhikov 
and Millen, 2004). The FGF/MAPK pathway is a key regulator of EMT and controls 
NC cell motility, polarity and survival (Szabo-Rogers et al., 2008; Abu-Issa et al., 
2002). Attracting signals drive NCC migration to peripheral locations promoting 
NCC differentiation into craniofacial, cardiac and skeletal NC tissues. 
 
3.1.8.2. Craniofacial neural crest  
FGF/MAPK signalling controls the anteroposterior and dorsoventral polarity as well 
as the left-right asymmetry of the cranial NCC (reviewed in Minoux and Rijli, 2010).  
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Craniofacial NCCs move ventrolaterally to give rise to the nasal skeleton, 
membranous skull bones and the pharyngeal arches (PAs). The seven PAs develop 
into the thyroid cartilages, otoliths, odontoblasts and jaw (Cordero et al., 2010; Chai 
et al., 2000; reviewed in Fagman and Nilsson, 2010; reviewed in Gross and Hanken, 
2008; reviewed in Knight and Schilling, 2006). In zebrafish, PAs additionally 
contribute to the formation of part of the gills. The craniofacial cartilage of 4dpf 
zebrafish  embryos is composed of seven pharyngeal arches: the Meckel’s cartilage 
(mandibular arch), the ceratohyal cartilage (hyoid arch), and the five branchial arches 
(Figure 3.2.10A).  
 
Maintenance of pharyngeal structures is ensured by a highly controlled network of 
pathways and genes, which include Slug, Snail, Sox10 and c-Myc. Importantly, 
cranial NCC specification and maintenance is induced by MAPK signalling 
(Nechiporuk et al., 2007; Crump et al., 2004).  FGFs are particularly essential in PA 
formation and development. Fgf3 and Fgf8 promote NCC survival and subsequent 
formation of PA3/4 (David et al., 2002) and PA1 (Creuzet et al., 2004), respectively, 
and the majority of their derived structures. This partly explains the scale of the 
impact of an FGFR3 germ-line mutation (White et al., 2005).  
 
3.1.8.3. Cardiac and trunk neural crest cells 
The trunk (skeletal) NCCs migrate either dorsolaterally towards the ectoderm to 
form melanocytes or ventrolaterally to the anterior part of the sclerotomes to form 
the dorsal root ganglia. These undergo further specification. Progenitors of the 
sympathetic ganglia, aortic nerves and adrenal medulla undergo ventral migration 
(Cheung et al., 2005). Alternatively, vagal and sacral NCCs differentiate into the 
parasympathetic ganglia, the glia of the enteric nervous system (reviewed in Burns et 
al., 2009). 
 
The cardiac NCCs are situated between the cranial and the skeletal NCCs. They 
populate the lower hindbrain and migrate via PAs 3,4 and 6 towards the heart 
(reviewed in Maschhoff and Baldwin, 2000). They develop into melanocytes, the 
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semilunar valves, the entirety of the muscle connective tissue of the heart arteries and 
also contribute to the neuron population of pharyngeal arches (Jain et al., 2011; 
reviewed in Aman and Piotrowski, 2009).  
 
In all vertebrates, the heart forms during somitogenesis when two primordia fuse to 
form a linear tube. The atrium and ventricle are formed when the primary tube loops 
asymmetrically along the left-right axis. Unlike higher vertebrates, the zebrafish 
heart retains the simplistic structure of two cardiac chambers and has a single blood 
vessel connected to the gill arches (Hu et al., 2000). Zebrafish NCCs originally 
occupy a broader region than the one normally seen in other animal models and 
contribute to the ventricle, the atrium, the atrioventricular junction and the bulbus 
arteriosus (the cardiac outflow tract) (Li et al., 2003; Sato and Yost, 2003). 
 
3.1.9. Aims 
Having established that CFC and melanoma alleles are active in early development, I 
aimed to test whether the phenotype promoted by aberrant MAPK signalling can be 
prevented by pathway inhibition. Making use of highly selective anti-cancer drugs 
currently used in clinical trials against FGFR and MEK, I treated embryos over-
expressing CFC and melanoma disease alleles. 





CFC syndrome patients exhibit symptoms that may alter or develop in severity with 
time. This progressive nature suggests the possibility that specific pharmacologic 
administration could prevent the onset of latent phenotypes. Targeted inhibition of 
the mutated genes’ signalling, either upstream or downstream of them, might be the 
key to develop new therapeutic agents and consider the possibility of chemical 
intervention to alleviate symptoms. The work in sections 3.2.1, 3.2.2.2, 3.2.3-3.2.5 
has been published and the relevant publication has been attached in Appendix II 
with permission from the journal. 
 
3.2.1. Fgf inhibition restores normal development in embryos expressing 
BRAF and MEK mutations 
As argued earlier, proper Fgf/Mapk signalling is indispensable for the completion of 
the four embryonic cell movements during gastrulation. Aberrant expression of Fgf 
has a prominent role both in zebrafish development and cancer. In the established 
bioassay embryos over-expressing active CFC and melanoma disease variants 
acquired identical phenotypes as individuals with ectopic Fgf (Furthauer et al, 2004) 
by the end of gastrulation. This suggested that mutations downstream of Fgf 
receptors (Fgfr) may feed back to activate the entire Mapk pathway and lead to 
similar in vivo outcomes to those observed in Fgf mutants. Moreover, it is plausible 
that endogenous activity of the Mapk pathway in conjunction with disease allele 
injections had an additive effect in promoting elongation. Thus, it was hypothesised 
that inhibiting endogenous Fgfr could suppress the abnormal gastrulation phenotype. 
 
Embryos expressing BRAF CFC, melanoma and engineered alleles (Figure 3.2.1A) 
as well as MEK1 and MEK2 CFC and engineered alleles (Figure 3.2.1B) were 
incubated in 0.5M SU-5402, an FGFR1 inhibitor, at the beginning of gastrulation 
(4hpf). The phenotype of embryos was assessed at 10.5hpf. The development of  all 






Figure 3.2.1 Treatment of BRAF, MEK1 and MEK2 variants with SU-5402.  
 
A The elongation promoted by BRAF variants was pharmacologically prevented by treating with 




B MEK1 and MEK2 disease allele-driven phenotypes were, also, prevented by SU-5402 treatment.  
C Western blotting of total zebrafish lysates for Erk and p-Erk protein shows that SU-5402 treatment 
caused reduction of Erk phosphorylation. α-tubulin was used as a loading control. 
 
individuals in all but one treatment groups was restored (Figure 3.2.1). The effect of 
the highly activating melanoma mutation BRAF
V600E
 was not fully rescued. This 
finding coupled with reduction of p-Erk readout supports the hypothesis that 
individual BRAF and MEK mutations affect total levels of Mapk signalling, as 
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illustrated by western blots of treated embryos (Figure 3.2.1.C). Inhibition of the 
pathway, even upstream of the mutations, can avert their pathological output. 
 
3.2.2. The MEK inhibitors CI-1040 and PD325901 disrupt the Mapk 
pathway 
 
3.2.2.1. PD325901 decreases the expression levels of Dusp6  
In order to determine whether the MEK inhibitor PD0325901 effectively prohibited 
Mapk activity in the developing embryo, I made use of the transgenic line dusp6-
GFP. DUSP6 is a downstream effector of ERK1 and ERK2 and its expression 
depends on active MAPK signalling (Section 2.1.1). The Dusp6 expression pattern in 
zebrafish is visualised via the GFP reporter driven by a 10Kb region upstream of the 
dusp6 gene (Molina et al., 2007). Using this system, I could optically ascertain 
whether inhibition of ERK phosphorylation coincided with a decrease in Dusp6 
levels. 
 
To examine whether the expression pattern of Dusp6 was altered, un-injected dusp6-
GFP embryos were treated with DMSO, 0.5M or 1.0M of PD0325901 at 4hpf and 
were imaged for 20 hours using a time-lapse set up (Figure 3.2.2). At the shield 
stage (30% epiboly) Dusp6 expression is localised at the shield and the margin 
(Molina et al., 2007) a dorsal embryonic tissue giving rise to the germ ring and the 
tail bud. In this study, the GFP signal was, first, detected in DMSO-treated embryos 
at 50-60% epiboly at the axial hypoblast (white arrowheads), which derives from the 
shield and develops into the axial mesoderm. The expression expanded vegetally as 
gastrulation progressed to have a diffuse, almost ubiquitous pattern but, also, occupy 
specific foci such as the tail bud (yellow arrowheads). By 24hpf high levels of Dusp6 
remained at the tail bud but were also detected at the midbrain-hindbrain boundary 
and the telencephalon (red arrowheads) (Figure 3.2.2A). Dusp6 patterning did not 
alter after PD0325901 addition but increasing concentrations of the MEK inhibitor 
resulted in a linear decrease and slight diffusion of the signal intensity (Figure 
3.2.2B,C). Thus, PD0325901 seems to be down-regulating p-ERK activity in vivo. 





Figure 3.2.2  Dusp6 expression appears to decrease in PD325901-treated embryos 
 
A Normal Dusp6 expression in developing dusp6-GFP transgenic zebrafish embryos treated with 
DMSO. The GFP signal was first detected in gastrulating embryos at 50-60% epiboly (white 
arrowhead). The expression area expanded towards the vegetal pole during epiboly (white arrowhead) 
and at the tail-bud stage the expression was more diffuse with higher expression levels at the tail bud 
(yellow arrowhead). By the next day (20 somites and 24hpf), high levels of Dusp6 were detected in 
the midbrain-hindbrain boundary and more posterior parts of the brain (red arrowheads) as well as the 
tail bud.  
B,C Expression localisation did not alter after PD0325901 addition. However, higher concentrations 
of the MEK inhibitor (C) appeared to cause a decrease in signal intensity.  
The brightfield images of the embryos are on the top row and their paired fluorescence images are 
















Figure 3.2.3 The specific MEK inhibitors CI-1040 and PD0325901 are active in 
zebrafish 
 
A Immunoblotting against p-Erk demonstrates the differences in Mapk pathway activity promoted by 
the different mutant proteins (left panel) and the effective inhibition of the pathway by CI-1040 
administration, as illustrated by the significant reduction in phospho-Erk readout (right panel). Total 
Erk levels remained unaffected.  
B,C Immunoblotting against p-Erk demonstrates that increasing concentrations of PD0325901 (B) 
and CI-1040 (C) significantly decreased the activity of the Ras-Mapk pathway, with total levels of 
Erk being unaffected.  
α-tubulin was used as a loading control. 
 
3.2.2.2. CI-1040 and PD325901 effectively inhibited Erk phosphorylation 
To molecularly confirm that MEK inhibitors were impeding Mapk signalling, CI-
1040 or its derivative PD0325901 were administered to 4hpf wild-type or embryos 
expressing disease alleles. Immunoblotting of entire embryonic tissues against p-Erk 
demonstrated that the pathway was effectively inhibited after addition of the small 
molecule inhibitors but not of DMSO (Figure 3.2.3). Total Erk levels remained 
unaffected. 
 





Figure 3.2.4 CI-1040 and PD0325901 prevent elongation phenotype in all BRAF- 
and MEK- expressing embryos 
 
A The elongated phenotype of the embryos over-expressing CFC, melanoma and engineered BRAF 
mutations was fully prevented after incubation of the injected embryos in 1µM CI-1040 from 4hpf 
(the beginning of gastrulation). CI-1040 addition did not affect normal embryonic development. 
B Elongation promoted by MEK1 and MEK2 disease allele mRNA at 10hpf was rescued in 100% of 
embryos treated with 1µM of the specific MEK inhibitors CI-1040 and PD0325901. Administration 
of the inhibitors alone did not affect normal development of the embryo at 10hpf. 
 
 
3.2.3. Incubation of disease allele-expressing embryos in specific MEK 
inhibitors prevents the elongation phenotype 
As suppression of Fgfr was able to partially prevent the gastrulation phenotype of 
BRAF and MEK-expressing embryos, I aimed to test the efficacy of selective MEK 
inhibitors in restoring normal development. As both available MEK inhibitors have 
been entered in clinical trials as chemotherapeutic agents against cancer (Haura et 
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al., 2010; Rinehart et al., 2004) they represent physiological agents that could be 
potentially administered to CFC patients. The effect on MEK inhibition has only 
been studied in the framework of kinase-activating mutations and supports that 
activating BRAF mutations confer an increased in vitro sensitivity to MEK inhibition 
(Solit et al., 2006). Similarly, all the CFC mutations identified to date have been 
activating and have been shown to be reactive to the UO126 MEK suppressor in 






















































Table 3.2.1 Responsiveness of CFC, melanoma and engineered alleles to 
FGF/MAPK inhibition 
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To assess the sensitivity of all the disease alleles available against two specific MEK 
small molecule inhibitors, embryos expressing BRAF, MEK1 and MEK2 variants 
were incubated after 4hpf in 0.5M CI-1040 or PD325901. Embryo elongation was 
recorded at 10.5hpf (Figure 3.2.4). 100% of the MEK inhibitor-treated embryos 
expressing wild-type, highly active or kinase impaired proteins were 
indistinguishable from the wild-type DMSO-treated embryos, whereas the elongation 
incidence in injected embryos incubated in DMSO was the same as previously 
observed. This suggested that inhibition of Mapk signalling downstream of the 
dysregulated gene is enough to restore normal development at 10.5hpf 
 
3.2.4. Identification of a treatment window with CI-1040 restores normal 
development beyond gastrulation 
The MEK suppressors were able to fully prevent elongation in embryos expressing 
both activating and kinase-impaired mutations. Nevertheless, prolonged drug 
administration has severe toxic side-effects, leading to body axis shortening, 
craniofacial and cardiac malformations, phenotypes similar to those displayed in 
CFC patients. Disease allele-expressing embryos incubated in MEK inhibitors 
appeared normal at 10.5hpf but suffered serious developmental anomalies by 24hpf 
linked to the previously published studies from our lab (Grzmil et al., 2007). 
 
In order to identify a time period of drug exposure sufficient to prevent defects 
without disrupting development, embryos expressing the most common CFC allele, 
BRAF
Q257R
, underwent 12 separate treatments. Each treatment was initiated at 
different developmental stages and varied in duration (Figure 3.2.5). Elongation at 
10.5hpf was avoided in 100% of embryos treated from 4hpf and the aberrant 
phenotype was restored in fewer embryos as the treatment initiation was moved to 
later time points (Figure 3.2.5B). Importantly, a treatment window between 4.5-
5.5hpf was able to restore normality both at 10.5 and at 24hpf. Interestingly, it was 
not the short length of the treatment that was sufficient to avert adverse development, 
as incubation in CI-1040 between 9.5 and 10.5hpf did not prevent elongation. 





Figure 3.2.5 Identification of a zebrafish-CFC treatment window 
  
A Treatments of embryos over-expressing the most common CFC variant BRAF
Q257R
 demonstrate 
that all CI-1040 treatments (A-F), but not the control DMSO treatment (G), prevented embryo 
elongation at 10.5 hpf. Only short treatments A and B restored normal development both at 10.5 and 
27.5 hpf, with other drug treatments (C–F) causing additional developmental defects at 27.5hpf.  
B Six additional CI-1040 treatments (A–F) and a control treatment (G) of BRAF
Q257R
 -expressing 
embryos showed that a specific developmental window between 4.5–5.5hpf is necessary for the 
prevention of zebrafish-CFC early phenotypes and sufficient to restore normal further development.  
The numbers at the lower right corner of each image indicate the percentage of the elongated embryos 
in each set  (n ≥ 30/experiment). Blue bars represent embryo medium and red bars represent CI-1040 
treatment. 
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3.2.5. Design of a systematic approach to identify the target tissues of 
PD325901 during zebrafish development 
Recycling the use of cancer drugs to alleviate symptoms of congenital developmental 
disorders, such as the RASopathies, would be beneficial in the research and progress 
of the treatment of such diseases (Wilkie, 2007). Albeit very informative of early 
gastrulation mechanisms, isolation of the treatment window necessary to prevent 
toxic side-effects is not a notion that can be easily extrapolated to human care, as in 
utero CFC patient treatment is not possible during the developmental window.  
 
To identify a dose that can be continuously administered with minimal toxicity, a 
deeper knowledge of the specific effects of MEK inhibitors in normal development is 
required. To that end, a detailed analysis was designed to determine the main tissue 
targets of PD032590 throughout normal zebrafish embryogenesis (Figure 3.2.6). 
Wild-type embryos were collected at six different developmental stages (4, 10, 24, 
30, 48, 72hpf) and were incubated in increasing concentrations of PD0325901 
(0.1M-1.0M). The embryos were monitored closely and were imaged daily.  
 
Activated MAPK signalling in developmental syndromes affects the proper 
formation of tissues delineated from neural crest cells, including melanocytes, 
cardiac, craniofacial and gastrointestinal tissues. The targets of PD0325901 in 
developing zebrafish (Grzmil et al., 2007) and many MAPK pathway inhibitors used 
in clinical trials largely overlap with neural crest cell-derived populations. Based on 
this knowledge the recordings were focused on the appearance of the body axis, 












Figure 3.2.6 Design of systematic study of the PD0325901 effects in zebrafish 
development 
 
Wild-type embryos were treated with the specific MEK inhibitor PD0325901 to identify the most 
affected tissues at different developmental stages. Zebrafish embryos were treated with increasing 
concentrations of PD0325901 (0.1-1.0µM) at six different developmental stages (4hpf, 10hpf, 24hpf, 
30hpf, 48hpf, 72hpf) until 96hpf. The embryos were monitored daily and were assessed for body axis, 
cardiac morphology and craniofacial structure phenotypes at 4dpf (96hpf). 
 
 
3.2.5.1. Universal cardiac disruption 
Administration of increasing PD0325901 dosage at 4, 10, 24, 30 and 48hpf lead to 
heart anomalies in most embryos by 4dpf (Figure 3.2.7). The phenotype included 
cardiac oedemas and bulbus arteriosus blockage restricting the blood in the heart 
chambers and not letting it enter the bloodstream. The severity of the phenotype was 
not concentration-dependent as even 0.1µM PD0325901 caused the above 
symptoms. The cardiovascular system of embryos incubated in the drug at 72hpf 
appeared unaffected at 4dpf, but the embryos displayed the described aberrant 
cardiac phenotype at 5dpf, after a 48-hour incubation (data not shown).  







Figure 3.2.7 PD0325901 affects cardiac function 
 
Lateral views of 4dpf embryos treated with increasing concentrations of PD325901. Addition of the 
inhibitor, even at low concentrations (0.1µM), blocked the cardiac valve and blood remained 
restricted in the heart chambers (A-T). Cardiac oedemas were frequently observed (A-H; J-P; R-T). 












Figure 3.2.8 Incubation in PD0325901 promotes body axis defects 
 
Treatment with PD0325901 from 4hpf promoted shortening of the antero-posterior axis of zebrafish 
embryos in a dose-dependent manner. Administration of the drug after the completion of gastrulation 
did not affect the size of the embryo. 
 
3.2.5.2. Body axis is disrupted when MEK is inhibited during gastrulation 
The body axis of 4dpf embryos treated with PD0325901 from 4hpf was shorter than 
that of their wild-type control siblings (Figure 3.2.8). Their A-P axis was shortened, 
with higher concentrations being more detrimental to body length. Individuals 
incubated in 0.1µM developed to normal size, whereas those incubated in 1.0µM 
PD0325901 were half as long. Administration of the inhibitor at later points in 
development had no effect on body axis formation. Thus, active MEK signalling 
ensures proper body axis patterning during gastrulation. 





Figure 3.2.9 PD0325901 treatments cause craniofacial structure deformities 
 
A Administration of increasing concentrations of the PD0325901 (0.1-1.0µM) from the beginning of 
gastrulation (4hpf) caused progressive malformation of Meckel’s cartilage (orange arrowheads) and 
ceratohyal cartilage (black arrowheads), as well as loss of pharyngeal arches (red arrowheads). 
B Comparison of craniofacial cartilage of 4 day old control embryos (DMSO) and embryos treated 
with 1µM PD0325901 added at different timepoints in development (4-72hpf). Meckel’s cartilage is 
highlighted by orange arrowheads and ceratohyal cartilage by black arrowheads. 
Top panels show ventral and lower panels show lateral views of the same specimen. 
 
3.2.5.3. Craniofacial disruption 
The jaw of zebrafish and all vertebrates derives from neural crest cells and activated 
MAPK signalling is required for proper specification of craniofacial components 
(Komisarczuk et al., 2008; Crump et al., 2004; Wilson and Tucker, 2004; Walshe 
and Mason, 2003). Incubation of embryos at different developmental stages in 
PD0325901 promoted a variety of jaw phenotypes, which were time-and dose-
dependent (Figures 3.2.9-3.2.11; Appendix I-2). 
 




Figure 3.2.10 Schematic illustration of zebrafish cartilage structures 
 
A Simplified illustration of the ventral view of a 4dpf wild-type zebrafish jaw structures. All seven 
pharyngeal arches are formed and are clearly distinguishable.  
B Ventral representation of 4dpf zebrafish pharyngeal arches of an embryo treated with a high 
concentration of a MEK inhibitor. All structures are malformed, the angles of Meckel’s and 
ceratohyal cartilage are distorted and, at concentrations higher than 0.8µM of the drugs, the 4th and 
5th branchial arches are missing. 
The seven pharyngeal arches represented are: Mandibular arch/ Meckel’s cartilage (light blue), hyoid 
arch/ ceratohyal cartilage (dark blue), 1st-5th branchial arches (green), fins (grey). 
 
Addition of the drug at 4hpf caused progressive loss of pharyngeal arch development 
as well as malformation of the Meckel’s (MC) and ceratohyal cartilages (CH) 
(Figure 3.2.9). A schematic comparison between the jaw cartilage structures of 4dpf 
control and PD0325901-treated embryos clearly illustrates the angle distortion of 
MC and CH and the abnormally developed or absent pharyngeal arches (Figure 
3.2.10). Embryos incubated in the drug at 10hpf were phenotypically similar to the 
ones treated from 4hpf, with the exception that they successfully formed all seven 
pharyngeal arches. 
 
Administration of the drug at 1dpf (24, 30hpf) affected the size and angle of MC and 
addition of PD0325901 at 2dpf (48hpf) caused CH development anomalies. Mek 
inhibition in older embryos did not promote an overt craniofacial defect. 




Figure 3.2.11 Effect of addition of increasing concentrations of PD325901 at different timepoints in development 
 
A Heat-map of tissue sensitivity to PD325901 treatment. Each panel shows tissue sensitivity after the addition of increasing concentrations of PD325901 (0.1-1.0µM) 
at a different timepoint. Sensitivity to PD0325901 treatment was translated into colour (Green: No effect; Light grey: Mild effect; Pink: Intermediate effect; Purple: 
Severe effect). Embryos treated with 0.2µM PD0325901 from 4hpf had a normal A-P axis but showed mild malformation of the tail tip (asterisk, *). The heart valve 
of embryos treated with 0.1µM PD0325901 from 48hpf  and with all ten concentrations of  PD0325901 from 72 hpf was blocked at 5dpf (double asterisk, **). 
Abbreviations: pa: Pharyngeal arches; MC: Meckel’s cartilage; Ch: Ceratohyal cartilage; ba: Branchial arches.  
B Increasing levels of PD325901 caused reduction in phospho-Erk levels. Immunoblotting shows phospho-Erk levels in embryos treated with increasing 
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3.2.6. Selection of a dosage that allows continuous exposure to 
PD0325901 with minimal side-effects 
 
3.2.6.1. Heat map summarises effects of PD0325901 
In order to visually review all the recorded phenotypes promoted by Mek inhibition a 
series of “heat map” panels were generated (Figure 3.2.11A). In summary, embryo 
body axis was only affected when Mek was inhibited in early gastrulation (panels a-
b). All treated embryos presented heart defects suggesting that this might be a toxic 
side-effect of the drug and not a developmental phenotype (panels a-e). Gastrulation 
was crucial to the development of the 5th branchial arch and the proper formation of 
the 3rd and 4th branchial arches (panels a-b).  
 
The 24-30hpf time period was mostly critical for the proper formation and arching of 
the MC (panels c-d), whereas only the development of the CH cartilage was 
interrupted by Mek inhibition during the second day postfertilisation (panel e). 
Addition of PD0325901 later than 3dpf had no developmental phenotype (panel f) as 
all structures had already formed. 
 
3.2.6.2. Continuous PD0325901 administration (0.2M) restores almost normal 
embryonic development 
After examination of the heat maps it became obvious that administration of low 
doses of PD0325901 from early gastrulation only distorted normal development at a 
minimal level. It was, therefore, possible that constant incubation of zebrafish 
embryos in low concentrations of the drug would not prominently interfere with 
development. I also hypothesised that permanent inhibition of Mek may compensate 









Figure 3.2.12 Continuous administration of PD0325901 restores normality 
 
Embryos over-expressing the most common CFC allele BRAF
Q257R
 incubated in DMSO (F-J) have a 
cell movement phenotype at 10hpf (G). From 1dpf (H) they had a shorter anteroposterior axis and by 
2dpf (I) the cardiac disruption was evident (black arrows; I,J). 
Embryos injected with the CFC allele and continuously incubated in 0.2µM PD0325901 (K-O) 
demonstrated mild elongation status at the end of gastrulation (L) but only a slight developmental 
delay at 1dpf (M). The body axis of the 2dpf embryos (N) was comparable to their wild type siblings 
and normal development was restored, with the exception of mild cardiac valve closure (red arrows; 
N,O). 
 
To test the above hypotheses, wild-type embryos were injected with the most 
common CFC disease allele, BRAF
Q257R
, and were continuously incubated in 0.2M 
PD0325901 from 4hpf (Figure 3.2.12). At 10hpf, PD0325901-treated embryos were 
less elongated compared to control embryos (panels B,L). At 24hpf the body axis of 
treated embryos (panel M) was almost identical to wild-type uninjected siblings 
(panel C) and significantly longer than BRAF
Q257R
 expressing individuals (panel H). 
By 48hpf, incubation in PD0325901 caused a mild cardiac valve closure without 
other prominent side-effects.  
 
Therefore, the drug counter-balanced the developmental effect of CFC allele mis-
expression, corrected the total levels of the initially aberrant Mapk signalling and 
was able to restore near-normal development and survival. 





Activation of the MAPK pathway leading to high levels of ERK phosphorylation is 
commonly described in human cancers and, recently, in the RASopathies syndromes. 
Mutated pathway components, such as RAF and RAS, constitute potential 
therapeutic targets for all patients. Better understanding of genotype-phenotype 
correlations with respect to cancer development and progression has advanced our 
ability to manufacture drugs that selectively target specific proteins (reviewed in 
Sebolt-Leopold and Herrera, 2004) and even specific mutations (Sala et al., 2008). 
Small molecule inhibitors have already been successfully used in clinical trials for 
the treatment of human neoplasias (Friday and Adjei, 2008). The presence or absence 
of gene mutations has become predictive of the tumour’s responsiveness to given 
inhibitors. For instance, EGFR and KRAS mutational status in non-small cell lung 
carcinoma patients can predict their sensitivity to EGFR receptor inhibitors (Pao et 
al., 2005; Paez et al., 2004). Similarly, KRAS and BRAF mutations are strongly 
correlated with response to MEK inhibition in lung and ovarian cancer (Nakayama et 
al., 2008; Pratilas et al., 2008). 
 
As MEK CFC mutations have been responsive to MEK and RAF inhibition in in 
vitro studies (Senawong et al., 2008), I wanted to examine the sensitivity of the CFC 
and melanoma variant spectrum to MEK and FGFR inhibitors in vivo. Pre-clinical 
testing of anti-cancer drug efficacy on zebrafish exhibiting CFC features would 
allow assessment of potential therapeutic agents. Here, I have been able to rescue the 
disease-driven gastrulation phenotype in embryos expressing CFC, melanoma and 
engineered alleles after administration of specific FGFR and MEK inhibitors. 
Importantly, I identified a treatment window sufficient to prevent any malformations 
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3.3.1. Small molecule inhibitors of the MAPK pathway prevent cell 
migration defects  
 
3.3.1.1. FGFR inhibitor restoration of total Mapk signalling levels and possible 
implication of C-raf  
A functional Fgf/Mapk pathway is essential for the completion of gastrulation while 
its over-activation promotes the described elongation phenotype. Treatment of 
embryos with activated Mapk signalling with the FGFR1 inhibitor SU5402 resulted 
in complete prevention of the elongation phenotype in almost all the cases. All 
mutations except BRAF
V600E
 were sensitive to Fgfr inhibition. One theory to explain 
the rescue is that blocking Fgfr reduced the levels of total endogenous Fgf/Mapk 
signalling (Figure 3.3.1). This highlights the importance of total Mapk activity in the 
progression of CFC syndrome.  
 
Another explanation for the phenotype prevention in kinase-inactivating BRAF 
mutants may be that in the absence of high concentrations of upstream receptor 
stimulation and Ras, endogenous C-raf is not activated and cannot further 
phosphorylate Mek and Erk (Dumaz et al., 2006; Wan et al., 2004). This would also 
explain why BRAF
V600E
-expressing embryos were not responding to treatment. The 
most common BRAF mutation is promoting near constitutive activation of the kinase 
in vitro (Wan et al., 2004) which is RAS-independent and sufficient to drive 
malignant and pre-malignant transformation in vivo (Patton et al., 2005; Pollock et 
al., 2003; Davies et al., 2002). Moreover, the levels of in vitro BRAF activity 
conferred by the substitutions Q257R and V600E are similar (Rodriguez-Viciana et 
al., 2006). However, the fact that the effect of all CFC and engineered alleles but not 
that of BRAF
V600E
 was rescued supports that the latter variant is more severe in vivo.   
 
C-RAF exhibits an inhibitory effect against oncogenic BRAF in cell line studies by 
forming heterodimer C-RAF-BRAF
V600E
 complexes (Karreth et al., 2009). The 
abundance of such heterodimers is decreased in human melanoma with activating 
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mutations and presumably in the current zebrafish bioassay, as all the disease alleles 
expressed are acting as gain-of-function mutations. Therefore, further restraint of C-
RAF activity has the capacity to induce BRAF signalling. This notion is further 
supported by the fact that C-raf suppression by the use of 17-DMAG, an HSP90 
inhibitor was unable to prevent the gastrulation phenotype (data not shown).  
 
3.3.1.2. Mek inhibition prevents gastrulation phenotype 
I further tested the activity of the highly selective and clinically efficient MEK 
inhibitors CI-1040 and PD0325901 in vivo. The effective blocking of Erk1/2 
phosphorylation in this zebrafish model was demonstrated both optically and 
molecularly and was supported by the decrease in Dusp6-GFP intensity (Figure 
3.2.2) and p-Erk levels of treated embryos (Figure 3.2.3). Activation of RTK-
independent signalling by activated BRAF or MEK increases the levels of effectors 
downstream of ERK, such as its negative regulator Dusp6 (Pratilas et al., 2009). 
Lower signal intensity in the treated dusp6-GFP embryos and reduced ERK 
phosphorylation confirms lower Mapk signalling output. Importantly, both 
compounds were able to prevent the developmental phenotype of the CFC and 
melanoma alleles. I demonstrated that the gastrulation defects were avoided in 100% 
of injected embryos by very low concentrations of either agent (Figure 3.2.4) and 
that treatment during a short developmental window (4-6hpf) was sufficient to 
prevent additional drug toxicity (Figure 3.2.5).  
  
3.3.2. Possibilities of PD0325901 use in developmental syndrome therapy 
The budget for drug design and the resources to carry out clinical trials are real 
obstacles in the way of generating novel compounds to target rare congenital 
disorders such as CFC (Wilkie, 2007). Making use of already available anti-cancer 
agents that block the activity of genes mutated in developmental syndromes renders 










Figure 3.3.1 Suggested mode of action of CFC-disease variants in combination with 
small molecule potential treatment 





Schematic representation of the zebrafish-based approach designed to examine the in vivo 
significance of BRAF and MEK CFC disease mutations.  
A Microinjection of BRAF or MEK CFC variant mRNA into the single-cell zebrafish embryo 
promoted an elongated zebrafish embryo at 10.5hpf that led to severe further development defects, 
including body axis malformation, and heart defects at 24hpf.  
B Treating CFC variant-over-expressing embryos with inhibitors of the FGF-MAPK signalling 
pathway (green) prevented aberrant development of the CFC-zebrafish embryos, possibly by restoring 
appropriate total levels of Mapk-signalling. 
 
In this zebrafish model the allelic spectrum affected very early processes in 
embryogenesis and the treatment window is limiting. Thus, similar temporally strict 
in utero drug administration is not possible in human patients. However, treatment 
after birth can alleviate the severity of the CFC features and possibly decelerate the 
advancement of the CFC evolving symptoms (reviewed in Tidyman and Rauen, 
2010). To mimic clinical treatment, I aimed to identify an optimal dose that can be 
continuously administered to CFC-zebrafish with minimal side effects. 
 
 
3.3.2.1. Methodical characterisation of PD0325901 revealed spatio-temporal 
targets 
In order to delineate the targets of a specific MEK inhibitor in disease, I first 
examined the tissues most affected by the activity of Mapk signalling during normal 
development of wild-type individuals. Close monitoring of treated embryos revealed 
that proper body axis patterning is defined very early in development, at the 
beginning of gastrulation (Figure 3.2.5, 3.2.8).  Blocked Mapk signalling does not 
affect body length past the first hours of embryogenesis (4-6hpf).  
 
On the contrary, incubation in all tested concentrations of PD0325901 for any period 
of time longer than 24 hours lead to semilunar valve blockage (Figure 3.2.7). This 
valve is responsible for blood outflow from the heart chambers and is a structure that 
originates from cardiac NCCs. It is, thus, possible that cardiac neural crest cell 
derivatives require continuous Mapk signalling to maintain their muscular functions. 
Alternatively, PD0325901 may chemically interfere with the lining of the heart 
promoting valve closure.  




Cranial NCC-derived pharyngeal arches were prominently affected by Mek 
inhibition. Treatment with the drug at 0dpf is imperative for the formation of the 
branchial arches 3-5. 1dpf embryos require active Mek for proper Meckel’s cartilage 
development and 2dpf for ceratohyal cartilage formation. This suggests that 
PD0325901 acts in a posterior-to-anterior direction. The most anteriorly-positioned 
cranial NCCs give rise to Meckel’s and ceratohyal cartilage (rhombomeres 2-5) and 
posterior cranial NCCs contribute to the branchial arches (Schilling and Kimmel, 
1994).  
 
Evidently active Mapk signalling is required in NCC-derived tissues but PD0325901 
only targets a sub-set of them. Whereas cardiac and craniofacial structures were 
disrupted, the pigmentation patterns and of embryos incubated in PD0325901 were 
unaffected. This is the opposite effect to the one observed in the colourless (cls) 
mutants (Dutton et al., 2001). In cls, sox-10 mutations lead to abnormal development 
of pigment cells, sympathetic and parasympathetic neurons but the pharyngeal arch 
formation is complete (Kelsh and Eisen, 2000). Therefore, I can conclude that tissues 
of the cranial and cardiac NCCs but not of trunk NCCs are sensitive to Mek 
inhibition. This hypothesis can be further validated in future studies by examining 


















Figure 3.3.2 Schematic overview of elongation phenotype prevention after Mek 
signalling inhibition. 
 
Injection of the most common CFC allele promoted embryo elongation at 10hpf and short body axis at 
24hpf (top blue panel). Treatment of injected embryos with 1µM PD0325901 (middle green panel) 
from 4hpf prevented the elongation, while a treatment-window (4-6hpf) was also sufficient to prevent 
further developmental defects. A continuous dose of PD0325901 (0.2µM) (lower light green panel) 











Chapter 3 - Discussion 
101 
3.3.2.2. Concluding remarks 
Mek inhibition efficiently restored both the cell migration phenotype in gastrulating 
embryos and the developmental anomalies propelled by CFC disease alleles further 
along in development. Most importantly, continuous treatment with 0.2µM 
PD0325901 from the beginning of gastrulation reversed the mutation-driven defects 
and was administered in a low enough dose to avoid drug toxicity (Figure 3.2.12, 
3.3.2). As discussed in Chapter 2, CFC allele-driven Mapk over-activation causes 
embryo elongation at the end of gastrulation and multiple tissue malformation at later 
stages. It was until now hypothesised that this early cell movement defect was 
directly linked to the additional future phenotypes. The PD0325901- treated CFC 
allele-expressing embryos were slightly elongated at 10hpf. The fact that they had 
not completely overcome the gastrulation defect at 10hpf but appeared almost 
normal at 24 and 48hpf suggests that the effect of the CFC alleles is evident beyond 
gastrulation and that their aberrant effect can be counter-balanced by low levels of 
Mek inhibition. 
 
The current work is becoming increasingly relevant to the treatment of 
developmental disorders of the FGF/MAPK spectrum and reinforces the notion of 












4.Chapter 4 - MAPK in Behaviour 
 
“Hide not your talents. They for use were made. What's a 
sundial in the shade?” - Benjamin Franklin





4.1.1. Signalling network between cAMP and MAPK pathways 
Multicellular organisms require the presence of both intercellular and intracellular 
signalling for proper development and function. This communication is achieved 
through the activity of various pathways. It is increasingly evident that different 
molecular cascades do not act in isolation but interact with each other at multiple 
levels within the pathway. This cross-talk controls the intensity, duration and 
localisation of the signalling outcome.  
 
The MAPK and cAMP pathways are near ubiquitously expressed. Experimental data 
supports that they are both important in development and survival and regulate 
similar processes but often function to achieve different outcomes. MAPK 
predominantly controls cell proliferation, growth and survival (reviewed in Zhang 
and Liu, 2002), whereas cAMP mostly mediates tissue-specific processes such as 
metabolism and memory formation (Li et al., 2011; reviewed in Houslay, 2010). 
Although the latter pathway inhibits growth in most tissues (Hewer et al., 2011; 
Weinberg et al., 2009; reviewed in Stork and Schmitt, 2002), this is not true in the 
thyroid and pituitary, for example, where cell growth is stimulated by cAMP 
(Chiappini et al., 2011; reviewed in Pertuit et al., 2009). However, in every case it is 
the interconnection between the two cascades that is thought to shape and elicit a 
specific cellular response. Rather than functioning independently in a linear manner, 











Figure 4.1.1 The cAMP pathway and its interactions with MAPK signalling 
 
A Schematic diagram illustrating the mechanism of cAMP activation and its major downstream 
targets. Small molecule cAMP elevators are shown in purple (Forskolin, Rolipram, IBMX). 
 
B Diagram showing common interactions between the cAMP and the MAPK pathways. lPDE4: long 
PDE4; sPDE4: short PDE4; ssPDE4: super short PDE4 
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The cross-talk between the RAS/MAPK and the cAMP/PKA pathways was first 
described almost twenty years ago when it was demonstrated that cAMP elevation 
differentially affected the activity of MAPK depending on the cell type studied 
(reviewed in Gertis et al., 2008). The complex communication between the two is yet 
to be fully delineated but recent studies have shed light in the understanding of the 
molecular connections between different cell types. The abundance of isoforms of 
different components of the pathways and the specificity of their intracellular 
localisation points towards the idea of compartmentalised signals within a cell or a 
tissue type (reviewed in Houslay et al., 2005). Such compartmentalisation and 
temporal control of a signalling outcome can be pivotal in cell fate determination and 
differentiation. Therefore, close examination of individual isoenzymes and 
components of the two pathways is important in the delineation of a tissue-specific 
signalling network. The following section will explore the various interconnection 
points between the MAPK and cAMP pathways (Figure 4.1.1B). Understanding the 
function of such a network would allow for better knowledge of cellular function in 
physiological conditions and improvement of therapeutic targeting in disease. 
 
4.1.2. PDE4 – a mediator between two pathways 
The phosphodiesterase (PDE) 4 family of enzymes consists of four genes, PDE4A, 
4B, 4C and 4D, and represents one of eleven PDE families that act by degrading 
cyclic nucleotides (reviewed in Beavo and Brunton, 2002). PDE4s catalyse the 
hydrolysis of the ubiquitous second messenger molecule cyclic adenosine 3’, 5’-
monophosphate (cAMP), thus regulating its intracellular concentration and 
downstream signalling (Lynch et al., 2006). Downstream effectors of cAMP include 
protein kinase A (PKA), exchange proteins activated by cAMP (EPACs) and cAMP-
gated ion channels (CNGCs) (reviewed in McCahill et al., 2008). There are more 
than 20 isoforms of PDE4s, each one with different and specific expression patterns, 
which assist in tissue and sub-cellular compartmentalisation of cAMP (reviewed in 
Houslay and Adams, 2003). The sheer number of different PDE isoforms, which 
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approximates 100, and the conservation of PDE orthologues across species underpin 
the importance of their function. 
 
4.1.2.1. PDE4s protein structure  
Each of the four different PDE4 genes is encoded by an average of 20 exons and 
alternative splicing gives rise to a plethora of isoforms of different length (Bolger et 
al., 1997). The isoforms can be categorised into four groups based on their 
composition; long, short, super-short and dead-short. Each one has a unique N-
terminal region, which determines the isoform sub-cellular localisation, and a highly 
conserved catalytic domain (reviewed in Houslay and Adams, 2003). Between these 
units long isoforms have two additional domains: the upstream conserved region 
(UCR) 1 and the UCR2. These modules have regulatory functions and further act as 
platforms for scaffolding proteins. Protein kinase A (PKA) phosphorylates UCR1 
thereby activating PDE4 long isoforms (reviewed in McCahill et al., 2008). Short 
isoforms lack UCR1 and super-short isoforms only possess a truncated UCR2 unit. 
Dead-short isoforms are catalytically inactive in terms of PDE activity as they are C- 
and N-terminally truncated but are highly conserved (Johnston et al., 2004). Their 
function remains elusive.  
 
The catalytic subunit of PDE4 proteins can adopt two binding states defined by its 
affinity to inhibitors, namely the High Affinity Rolipram Binding State (HARBS) 
and the Low Affinity Rolipram Binding State (LARBS). The reason for the existence 
of the different states is poorly understood but recent studies support that the 
conformational changes are driven by isoform dimerisation at the UCR1 and UCR2 
regions (Richter and Conti, 2001). LARBS PDE4 is mostly expressed in peripheral 
tissues and the brain (Zhao et al., 2003a) and is involved in inflammatory responses 
of peripheral sites (Souness et al., 1997). The HARBS form is prominent in the brain 
and is specifically important in the hippocampus, the cortex and the olfactory bulbs 
(Kaulen et al., 1989). Administration of antidepressant drugs increases the HARBS 
but not the LARBS levels (Zhao et al., 2003b). As a result the focus has shifted 
towards HABS PDE4s in antidepressant tests. 
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4.1.2.2. PDE4s are regulated by PKA and ERK 
The study of different PDE4 isoforms has revealed that alternatively spliced variants 
are dissimilarly regulated. UCR2 acts as an inherent constitutive inhibitor of PDE4s 
(Lim et al., 1999). Its effect can be reversed in long isoforms by PKA 
phosphorylation at UCR1 (MacKenzie et al., 2002), a domain completely absent in 
short and super-short isoforms. On the contrary, ERK can bind and phosphorylate the 
catalytic domain of all isoforms except that of PDE4A (Baillie et al., 2000). 
Interestingly, phosphorylation by ERK has varied effects on different isoforms, 
activating short isoforms but strongly and weakly inhibiting long and super short 
isoforms, respectively (MacKenzie et al., 2000). Nevertheless, this ERK-driven 
PDE4 inhibition is transient as the resulting localised cAMP elevation promotes a 
PKA increase and, hence, PDE4 activation. This system provides a negative 
feedback mechanism to control cAMP levels. Therefore, it is evident that PDE4s are 
acting as mediators between activated MAPK and cAMP signalling and the ratio of 
long to short PDE4 isoforms within a tissue plays a very important role in controlling 
signal dissemination (Figure 4.1.1B).  
 
4.1.2.3. PDE4 inhibitors for the treatment of human disease 
Due to their mediating function between two pathways, PDEs have been the target of 
drug development for decades with the most widely known compound being the 
PDE5 inhibitor Viagra (Soderlin et al., 1998; Boolel et al., 1996). However, PDE4s 
have the largest group of manufactured antagonists. A number of natural or 
chemically engineered inhibitors have been identified with anti-inflammatory, anti-
depressant and memory-enhancing abilities (reviewed in Jeon et al., 2005).  
 
Non-selective competitive PDE inhibitors include methylated xanthines such as 
IBMX, which compromise the function both of PDEs and adenosine receptors. 
Specific PDE4 inhibitors include Rolipram and its derivative catechol class, such as 
CDP840, Cilomilast and Piclamilast. The latter group have been used in the therapy 
of inflammatory and autoimmune (dermatitis, psoriasis, Crohn’s disease, rheumatoid 
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arthritis, cancer), cognitive (depression, Alzheimer’s disease) and pulmonary 
(chronic obstructive pulmonary disease (COPD), asthma) disorders (Zhang et al., 
2006, reviewed in Houslay et al., 2005). More recently, they were introduced in anti-
psychotic, learning and memory studies (Zhang et al., 2004; Zhang et al., 2000). The 
effect of PDE4 inhibitors can be phenocopied by cAMP agonists, such as Forskolin. 
This is a hydrophobic small molecule that increases cAMP levels by activating the 
enzyme adenylyl cyclase (reviewed in Insel and Ostrom, 2003).  
 
Rolipram is a first generation competitive PDE4 inhibitor extensively used in in vitro 
and in vivo studies as a tool to chemically elevate cAMP. It was initially identified as 
an anti-depressant (Zeller et al., 1984) and was also used for treatment of 
Parkinson’s disease (Parkes et al., 1984). The current wide use and success of 
Rolipram is partly due to its outstanding anti-inflammatory effects and the ability to 
penetrate the blood-brain barrier to target central nervous system (CNS) tissues 
(Nikulina et al., 2004). This is crucial in the management of brain cancer. PDE4A is 
a positive regulator of intracranial tumour growth and is over-expressed 
predominantly in a variety of brain tumours. Other PDE4 isoforms have been 
involved in a larger spectrum of neoplasias including glioblastoma (Yang et al., 
2007), colon carcinoma (McEwan et al., 2007), as well as lung and breast cancer 
(reviewed in Marko et al., 2000).  
 
4.1.2.4. Limitations of PDE4 inhibitors 
Rolipram was withdrawn as a result of its short treatment windows, but second 
generation PDE4 inhibitors, such as Roflumilast and Cilomilast, are currently in 
Phase III clinical trials (reviewed in McCahill et al., 2008). The therapeutic 
advantage of elevating cAMP levels is, however, limited by the prominent side 
effects of the drugs, nausea and emesis, thought to be caused by the concurrent 
inhibition of all PDE4s.  
 
The expression pattern of the different PDE4 genes is directly correlated with their 
role. Therefore, gene-specific inhibitors can maximise the focus and therapeutic 
success of the treatment. For example, PDE4B is mostly expressed in neutrophils and 
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monocytes. Thus, blocking its activity would have an anti-inflammatory effect in the 
treatment of asthma, psoriasis and chronic obstructive pulmonary disease.  
Conversely, PDE4D is a key component of central nervous system and cardiac 
signalling (reviewed in Houslay et al., 2005).  
 
4.1.3. Receptor kinase and cAMP/PKA interaction  
cAMP interacts with the epidermal growth factor receptor (EGFR) to achieve 
different end processes, depending on the cell lineage. Firstly, cAMP can target 
EGFR in a PKA-dependent manner. Over-expression of the regulatory unit of PKA 
alone in breast epithelial cells was able to constitutively activate the classical 
EGFR/RAS/MAPK pathway in the absence of a mitogen by directly binding and 
activating the receptor-bound protein Grb2 (Tortora et al., 1997). Secondly, 
increased muscle contraction in cardiomyocytes occurred when EGFR activated the 
cAMP/PKA pathway by stimulating adenylyl cyclase to generate cAMP (Sun et al., 
1995).  
 
4.1.4. Nf1 and cAMP/PKA interaction 
As previously discussed in Chapter 2 (Section 2.1.2.3), neurofibromin 1 germ-line 
mutations promote neurofibromatosis type I and secondary somatic mutations drive 
the onset of nerve sheath tumours as a result of RAS/MAPK pathway over-
activation. However, NF1 brain expression was recently linked to cAMP/PKA 
signalling (Brown et al., 2010). Interestingly, neurofibromin 1-depletion affects the 
growth and survival of central nervous system (CNS) (Hegedus et al., 2007) but not 
peripheral nervous system (PNS) neurons in a MAPK-independent manner (Brown 
et al., 2010). The cAMP elevator Forskolin and the PDE4 inhibitor Rolipram but not 
the MEK inhibitor PD0325901 were able to restore the morphology and survival rate 
of hippocampus and retinal ganglion Nf1
+/-
 cells. Additionally, Rolipram increased 
the survival rates in mice with optic gliomas (Brown et al., 2010) and xenografted 
glioblastoma cells (Goldhoff et al., 2008). In combination with temozolomide and 
radiation, the current first line treatment for gliomas, Rolipram endorsed tumour 
regression (Goldhoff et al., 2008). 
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4.1.5. cAMP mediates RAF activation 
 
4.1.5.1. cAMP inhibits C-RAF 
C-RAF activation requires specific phosphorylation events, membrane recruitment 
by RAS and binding to various proteins such as the prolyl isomerase PIN1 and the 
phosphatase PP2A (reviewed in Baccarini, 2005). High cAMP levels induce C-RAF 
inhibition in fibroblasts, fat cells and smooth muscle cells (reviewed in Houslay and 
Kolch, 2000). This occurs via a PKA-C-RAF interaction. PKA constitutively 
phosphorylates C-RAF enforcing an inactive conformation of the kinase and 
interfering with its RAS binding domain (Dumaz and Marais, 2003). This, in turn, 
does not allow the kinase to be recruited by Ras in the cell membrane and impedes 
downstream C-RAF/MEK/ERK activation. Moreover, PKA-independent activation 
of cytosolic RAP1, a RAS-related G protein, via cAMP/EPAC results in C-RAF 
sequestering 
 
4.1.5.2. cAMP activates BRAF 
Interestingly, cAMP promotes MAPK activity in some cell types, including 
neuronal, ovarian, melanoma and pituitary cells, as well as adipocytes (reviewed in 
Gerits et al., 2008). In these tissues ERK and cAMP collaborate to elicit a functional 
response such as precise regulation of long-tem potentiation and circadian gene 
expression. Increased levels of cAMP stimulate PKA which triggers the plasma 
membrane-localised Rap1 allowing the latter to bind and activate BRAF (Wang et 
al., 2006).  
 
The most well defined example of cross-talk between cAMP and MAPK pathways 
comes from the study of neuronal differentiation. This process requires long-term 
cAMP-mediated ERK activation (Yao et al., 1998). In this situation, extracellular 
stimulation of undifferentiated cells with the neuronal growth factor (NGF) triggers 
two separate events that affect MAPK signalling in a cAMP-regulated fashion. 
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Firstly, RAF/C-RAF are activated and promote ERK phosphorylation. However, C-
RAF is rapidly inhibited by PKA (Section 4.1.5.1) impeding further downstream 
signalling. Secondly, NGF stimulates the RAS-related G protein RAP1, which in 
turn binds and enhances BRAF signalling, thus promoting a prolonged period of 
ERK activation (Vossler et al., 1997). Extracellular stimulation by a non-neuronal 
mitogen, such as EGF, fails to activate RAP1, thus activating the MAPK pathway 
only transiently and not allowing cellular differentiation to proceed.  
 
4.1.6. MAPK and cAMP cross-talk at the ERK level 
The key role of ERK in regulating the activation of PDE4s has been previously 
introduced (Section 4.1.2) and essentially presents a platform for ERK to control 
cAMP signalling (Figure 4.1.1B). Additionally, ERK1/2 activation and stimulation 
of its downstream targets are important in the development and function of the 
central nervous system (CNS). cAMP has an inhibitory role towards ERK1/2 in non-
neuronal cells and activates ERK1/2 in neurons (Cavanaugh et al., 2001). Moreover, 
protein tyrosyl phosphatase (PTP) is a cytosolic negative regulator of ERK that acts 
by dephosphorylating active ERK and blocking its translocation to the nucleus. 
cAMP ultimately endorses the activated state of ERK1/2 by antagonising the 
function of PTP in a PKA-dependent manner (Saxena et al., 1999). Notably, it is this 
inter-connection between cAMP and ERK1/2 that determines neuronal specificity 
and the conservation of this connection is pivotal for neuronal survival and memory 
formation (Gerstner et al., 2009; Yao et al., 1998).  
 
4.1.7. Conclusions 
Different cell types exhibit different sensitivity to cAMP elevation after 
pharmacologic treatment and act differently in response to genetic inhibition or 
activation of cAMP. Drawing conclusions about cAMP interactions in a linear 
fashion is becoming increasingly complex. It is thus clear that cAMP 
compartmentalisation is regulating distinct downstream signalling networks in a 
tissue-specific manner.  
 




An important aspect of the RASopathies lies in the presence of behavioural 
anomalies of patients. Having established the therapeutic efficacy of MAPK pathway 
inhibitors against CFC disease alleles, I aimed to assess their potential in modifying 
behaviour. To accomplish that, I tested the effect of the MEK inhibitor PD0325901 
on the behaviour of 3dpf zebrafish embryos exhibiting a robust and reproducible 
Rolipram-induced, cAMP-mediated behavioural phenotype previously identified in 
our lab by Nicola Grant (MSc Thesis, 2010).  





4.2.1. Characterisation of the edge effect 
Small molecule inhibition of key molecular pathways can elicit behavioural 
outcomes. Previous work in our lab identified a highly reproducible behavioural 
phenotype demonstrated after effective endogenous pde4 inhibition (MSc thesis, 
Grant). Chemical blocking of pde4 with the small molecule inhibitor Rolipram 
promotes a specific phenotype in 3dpf zebrafish embryos referred to as the “edge 
effect”. This behaviour takes its name after the rapid positioning of the Rolipram-
treated embryos at the edge of their containers. Treated individuals space themselves 
around the Petri dish directly facing its edge (Figure 4.2.1A, B, D) actively 
swimming in the same spot to maintain their position. Upon agitation or physical 
stimulation embryos immediately swim against the current and seek an edge 
(Anastasaki et al., manuscript in preparation).  
 
Embryos exhibiting this “edge effect” phenotype were scored to quantify this 
behaviour for subsequent experiments. Only embryos perpendicularly facing the 
edge of the plate with their heads fully positioned within the outer ring (Figure 
4.2.1C, D) were scored as “edge effect”-positive. The inner edge of the outer ring 
(dashed lines) was defined as a circle concentric to the perimeter of the Petri dish 
with a smaller radius. The difference in radius length was equal to a third of a 3dpf 













Figure 4.2.1 Schematic diagram defining the “edge effect” 
 
A Illustration of the Rolipram-induced “edge effect”. The treated embryos space themselves around 
the Petri dish to directly face the edge of the container. Once they reach this position they only move 
upon physical stimulation. 
B Enhanced contrast brightfield image of live 3dpf embryos treated with 15μM Rolipram. 
C Strict selection of embryos displaying the edge effect phenotype. Embryos swimming in the inner 
ring of the Petri dish (behaviour D-ii) or in the proximity of the edge (outer ring, separated by the 
dashed circle) but not directly facing the edge of the plate (behaviours B, C) were not counted as 
“edge effect”-positive in subsequent experiments. Embryos facing the edge of the plate but not 
adhering to it (behaviour D-i) were, also, discarded from the counts. The only “edge effect”-positive 
embryos are the ones displaying behaviour A. 
D Brightfield image of embryo exhibiting the “edge effect” and magnification of its 
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4.2.2. Rolipram induces the “edge effect” 
Administration of 15µM Rolipram but not DMSO vehicle control to wild-type 
embryos promoted the “edge effect” (Figure 4.2.2). Statistical analysis comparing 
the behaviours exhibited by the two treatment groups revealed a significant 
difference in embryo positioning after Pde4 inhibition (p<0.0001). 
 
 
Figure 4.2.2 Rolipram promotes the “edge effect” 
 
A Enhanced contrast brightfield images showing the distribution of 3dpf embryos in their plates. 
Incubation of 31 wild-type embryos in 15μM Rolipram induced embryos to exhibit the “edge effect”. 
Their 31 DMSO-treated siblings were randomly distributed across the plate surface.  
 
B Highlighted position of embryos in the same brightfield images as in A. For clarity purposes the 
position of the embryos in subsequent figures will be highlighted by a coloured dot. Randomly 
positioned embryos will be illustrated by a green dot and “edge effect”-positive embryos will be 
illustrated by a red dot. The p value below the Rolipram-treated embryos was calculated using 











Figure 4.2.3 The “edge effect” is phenocopied by cAMP elevators 
 
The “edge effect” first identified after Rolipram addition was fully and partially phenocopied by the 
cAMP elevators Forskolin and IBMX, respectively. In each case the drugs promoted a statistically 
significant change of behaviour compared to the DMSO control embryos at the p<0.05 level. The p 
values were calculated using Fisher’s exact test with DMSO-treated embryos as the control. 
 
 
4.2.3. Forskolin and IBMX phenocopy Rolipram 
Rolipram-driven PDE4 inhibition promotes an increase in cAMP levels. To confirm 
that Rolipram-induced cAMP elevation was responsible for the “edge effect” the role 
of IBMX, an inhibitor of all PDEs, and Forskolin, an adenylyl cyclase activator 
(Figure 4.1.1), on zebrafish behaviour were investigated. I was able to reproduce 
previous findings (MSc thesis, Grant). Incubation of 3dpf embryos in 7.5µM 
Forskolin fully phenocopied Rolipram and a fraction of embryos treated with 15µM 
IBMX exhibited the “edge effect” (Figure 4.2.3). Treatment with all three cAMP 
elevators promoted a significantly different behaviour than the one observed in 
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DMSO control-treated embryos. This data confirms previous work and suggests that 
cAMP elevation is sufficient to influence zebrafish behaviour and enhance the “edge 
effect”. 
 
4.2.4. A role for MAPK in behaviour 
There is a strong link between cAMP activation, human learning and behavioural 
disease, such as depression (Li et al., 2011; Rutten et al., 2011). Recently, however, 
mutations along the Mapk pathway have been correlated with alterations in learning 
and behaviour in Drosophila melanogaster (Pagani et al., 2009). The cAMP and the 
MAPK pathways act in parallel and there has been evidence supporting cross-talk 
between the signalling cascades (reviewed in Gerits et al., 2008). Taken together this 
data suggests that Mapk activation may play a role in the endorsement of the “edge 
effect” phenotype. 
 
4.2.4.1. Rolipram treatment promotes Erk activation 
To test whether Mapk activity levels play a role in the establishment of the “edge 
effect” whole embryos exhibiting the “edge effect” were lysed and their pErk levels 
were assessed by western blotting. Immunoblotting revealed that increasing 
concentrations of Rolipram correlated with Erk activation in a dose-dependent 
manner (Figure 4.2.5), consistent with a mechanistic link between pErk elevation 
and the “edge effect”. 
 




Figure 4.2.4 PD0325901 rescues the “edge effect” 
 
Co-treatment of cAMP elevators Rolipram (f), Forskolin (g) and IBMX (h) with the MEK inhibitor PD0325901 rescued the “edge effect” phenotype observed with 
the single treatments (b, c, d, respectively). Panels a-d are identical to Figure 4.2.3 .The p values at the bottom right corner of every image were calculated using 


















Figure 4.2.5 The “edge effect” affects Erk activity 
 
A Immunoblotting of 10hpf wild-type zebrafish embryos treated for six hours with different 
combinations of drugs. Increasing doses of Rolipram promote increasing activation of Erk. 
Conversely, administration of the MEK inhibitor PD0325901 alone or in combination with a high 
dose of Rolipram (15μM) reduces the levels of pErk. 
B Simplified schematic illustration of mode of action of small molecule inhibitors of the MAPK and 
cAMP pathways. Addition of Rolipram increases intracellular cAMP, which in turn activates the 
Ras/Mapk pathway upstream of Mek. Addition of the specific MEK inhibitor PD0325901 blocks the 
cAMP-driven pErk elevation.  
 
4.2.4.2. MEK inhibition rescues the Rolipram-induced edge effect 
Previous screening of the Enzo Life Sciences Kinase Inhibitor Library revealed a 
suppressive role of a MEK inhibitor against the Rolipram-induced “edge effect” 
(MSc Thesis, Grant). Having established that pErk is a component associated with 
the behavioural phenotype and knowing that the “edge effect” was reversible after  
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Mapk disruption, I wanted to assess whether the specific MEK inhibitor PD0325901 
was behaviourally active. To this end, 3dpf embryos were initially treated with 
Rolipram, Forskolin and IBMX until the “edge effect” was established. The MEK 
inhibitor PD0325901 was subsequently added to a final dilution of 1µM (Chapter 
3), the plate was agitated and the position of the embryos was scored 15 minutes 
post-treatment. Mek inhibition rescued the “edge effect” phenotype in all treatment 
groups (Figure 4.2.4) and decreased the pErk levels (Figure 4.2.5). Thus, blocking 
the Mapk pathway at the Mek level was sufficient to restore normal behaviour. 
 
4.2.5. Study of genetic elevation of cAMP 
 
4.2.5.1.  PDE4D is highly conserved between humans and zebrafish 





 mutant fish. There are multiple PDE4D splice variants both in 
humans and zebrafish. The N- and C-regions of the coded transcript are species- and 
tissue-specific but the catalytic region of the protein is highly conserved amongst 
vertebrates. The high sequence identity (90.53%) between the human PDE4D-001 
and the zebrafish pde4d-001 (Figure 4.2.6C) further highlights the importance of the 




 mutant line was identified after a large-scale mutagenesis 
screen in the Sanger Institute. A single nonsense point mutation (A to T) at the 
beginning of the PDEase active site converts a lysine residue to a stop codon, 
therefore producing an incomplete catalytically inactive transcript (Figure 4.2.6A). 
Initial examination of the genetically mutant zebrafish embryos and adults (both 
heterozygous and homozygous) were anatomically and physically indistinguishable 
from wild-type individuals (data not shown). 
 




Figure 4.2.6 Homology between zebrafish and human PDE4D 
 
A Schematic representation of the zebrafish pde4d-001 gene. Each numbered box represents an exon. The catalytic domain and the mutation site of the PDE4D-/- 
mutant line are highlighted. 
B Schematic alignment of human (light and dark purple) and zebrafish (light and dark blue) PDE4D cDNA. Each box represents a single exon, the sequence of which 
is highly similar to that of the exon directly below it. 
C Sequence alignment between zebrafish and human PDE4D cDNA reveals 90.53% sequence identity (red lines). Blue lines represent sequence mis-matches. The 


















Figure 4.2.7 Schematic 
representation of the “edge 
effect” enrichment experiment on 
pde4d+/- intercross progeny 
 
The experiment aimed to isolate 3dpf 
embryos from a population consisting of 
wild-type, heterozygous and 
homozygous for the pde4d mutation 
individuals, which robustly exhibited the 
“edge effect”. Embryos from pde4d+/- 
intercross matings were placed in 
separate Petri dishes and were incubated 
in E3 embryo medium (Plate 1). The 
embryos were physically agitated by 
swirling the plate (red arrows) and 
following a set incubation time of 45 
minutes, embryos not demonstrating the 
“edge effect” were transferred into new 
plates (Plates 2-4). After their removal, 
the remaining embryos underwent two 
additional enrichment rounds. The 
number of remaining embryos in Plate 1 
was recorded for subsequent analysis. 





Figure 4.2.8 A portion of pde4d+/- intercross progeny display  the “edge effect” 
 
A 3dpf wild-type embryos before (left) and after (right) treatment with 15µM Rolipram were used as 
controls in the enrichment experiment. Untreated embryos position themselves randomly around the 
plate, whereas embryos incubated in Rolipram display the “edge effect”. 
B Serial enrichment of pde4d+/- intercross progeny for the “edge effect”. 53 “edge effect”-positive 
embryos were selected from the original population (n=114) at the first enrichment, 40 embryos at the 
second enrichment and 35 embryos at the third enrichment round. The pictures illustrated here were 
taken at the end of the 45minute incubation time. The proportion of “edge effect” positive individuals 
gradually significantly deviates from the wild-type untreated embryos and becomes more similar to 
that of Rolipram-treated wild-type individuals. The p values were calculated using Fisher’s exact test 
using the wild-type Rolipram-treated embryos as a control. Red values represent statistically 
significant deviation from the Rolipram-induced “edge effect” and black values a non-significant 
difference. 
The ratios at the bottom of every picture represent the number of “edge effect”-positive individuals 
over the total number of embryos within each group after the 45minute incubation time. 
 
4.2.5.2. The “edge effect” in pde4d+/-  and intercross progeny  
It was evident that a portion of the progeny of heterozygous mutant adult fish 
exhibited the “edge effect” (Figure 4.2.8). I carried out a phenotype enrichment 
experiment to establish whether the number of “edge effect”-positive individuals 
could be enhanced from the pool derived from an intercross of pde4d heterozygous 
fish (Figure 4.2.7). The expected outcome of the cross was that one in four offspring 
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would be wild-type, one in two heterozygous and one in four homozygous mutant. 
Despite original planning to genotype the individuals exhibiting the “edge effect” 
after the third enrichment, the experiment was carried out blind to pde4d mutation 
status. This was due to time limitations and the lack of a fully functioning assay to 
genotype single embryos and as a result the individuals were assessed solely on their 
“edge effect” behaviour. The frequency of the “edge effect” exhibition at each 
enrichment stage was compared to that of wild-type control individuals and that of 
wild-type Rolipram-treated embryos.  
 
The positional behaviour of pde4d
+/-
 progeny deviated significantly (p<0.0001) from 
that of wild-type control embryos even before the first enrichment for “edge effect”-
exhibiting individuals. After each enrichment round, the behaviour of the “edge 
effect”-enriched pde4d
+/-
 progeny increasingly deviated from that of wild-type 
untreated controls and progressively resembled that of the Rolipram-treated wild-
type embryos (Figure 4.2.8). This data suggests that loss of pde4d activity influences 
the positional behaviour of zebrafish embryos. The behaviour of embryos removed at 
each enrichment round for not exhibiting the “edge effect” was not significantly 
different from the wild-type controls (data not shown). 
 
4.2.5.3. Complete pde4d loss promotes the “edge effect”  
The behaviour of 3dpf homozygous pde4d
-/-
 mutants was analysed to determine if 
complete genetic loss of pde4d is sufficient to promote the “edge effect”. The 
position of DMSO-treated pde4d
/-
 embryos was significantly different than that of 
DMSO-treated wild-type individuals (p<0.0001). Interestingly, the behaviour of 
pde4d
-/-
 embryos was indistinguishable from that of the Rolipram-treated wild-type 
embryos (Figure 4.2.9). Thus, genetic ablation of a single pde4 gene can 











Figure 4.2.9 Genetic loss of pde4d promotes the “edge effect” phenotype in 3dpf 
embryos 
  
A Comparison of the positioning of wild-type (wt) DMSO or Rolipram-treated and pde4d-/- DMSO-
treated 3dpf embryos. Wt control embryos were randomly positioned unlike “edge effect”-exhibiting 
Rolipram-treated and pde4d-/- control-treated embryos. The p values were significant at the p<0.05 
level and were calculated using Fisher’s exact test with wt DMSO-treated embryos as the control.  
B Comparison of positional behaviour between the different genotypes and treatments. Using Fisher’s 
exact test, the difference of the positional behaviours was calculated to be significant between wt 
DMSO- and Rolipram-treated embryos and wt DMSO- and pde4d-/- DMSO-treated embryos (* 
p<0.0001). There was no significant difference between the behaviours of wt Rolipram-treated and 
pde4d-/- DMSO-treated individuals at the p<0.05 level (p=0.4816). (n numbers of embryos are written 









4.2.6. Mek inhibition in pde4d mutants does not rescue the “edge effect” 
phenotype 
After having rescued the Rolipram-induced phenotype in wild-type embryos with 
PD0325901, I wanted to establish the potential of the MEK inhibitor to prevent the 
“edge effect” in pde4d
-/- 
3dpf embryos. Wild-type or pde4d
-/-
 embryos were 
administered with Rolipram (15M), PD0325901 (1M) or with Rolipram (15M) 
plus PD0325901 (1M)  (Figure 4.2.10). Rolipram single treatment induced similar 
effects irrespective of the genetic background of the fish. PD0325901 alone had no 
effect in the natural positioning of the wild-type embryos. Similarly, co-treatment 
with Rolipram and PD0325901 was not able to reverse the “edge effect” in the 
mutant embryos (Figure 4.2.10A). 
 
Western blotting was performed on treated wild-type and pde4d
-/-
 embryos to 
molecularly analyse the effects of all the small molecules on individuals of different 
genotypes (Figure 4.2.10C). Comparison of Mapk activity between embryos of 
different genetic backgrounds revealed elevated pErk levels in pde4d
-/-
 mutants, thus 
supporting previous data correlating pde4 inhibition and Erk activation (Figure 
4.2.5A). Additionally, PD0325901 addition reduced Erk activation in all treatment 


















Figure 4.2.10 MEK inhibition does not rescue the pde4d-/- “edge effect” 
 
A Wild-type (wt) (a-d) and pde4d-/- (e-h) 3dpf embryos were treated either with Rolipram or 
PD0325901 alone or with a combination of both.  Neither single (f, g) nor dual treatment (h) had an 
effect on the behaviour of pde4d-/- embryos. p values were calculated using Fisher’s exact test with 
wt DMSO-treated embryos as controls (red values: significant at the p<0.05 level; black values: not 
significant at the p<0.05 level). 
B Histogram illustrating the proportions of embryos displaying each phenotype. The letters below the 
bars correspond to the treatment conditions in A. (n numbers inside bars; green: random positioning; 
red: “edge effect”)  
C Whole embryos from A were used to compare their Mapk activity levels. DMSO-treated pde4d-/- 
embryos exhibited increased pErk levels compared to the wt controls. Treatment with PD0325901 
alone or in combination with Rolipram revealed highly reduced pErk levels confirming the activity of 
the drug. Erk1/2 was used as a loading control. 





The results presented in this chapter are based on previous work in our lab that 
defined a specific zebrafish behavioural phenotype (“edge effect”) and identified the 
pathway responsible. Here, I established a novel regulative role for the MAPK 
pathway in behaviour. I was able to replicate the phenocopy of the “edge effect” by 
cAMP elevators, rescue the phenotype after Mek inhibition and provide evidence for 
a direct effect of pErk on behaviour.  
 
The cross-talk between cAMP and MAPK pathways and feedback signals linking the 
two cascades dictate behavioural outcomes in zebrafish swimming and positioning. 
Increased cAMP levels reproducibly promoted the defined “edge effect” (Figure 
4.2.1), a phenotype that can be reversed after Mek inhibition. Genetic loss of one of 
the four pde4 genes, pde4d, phenocopied the “edge effect” but blocking ERK 
activation failed to stably impede the positional behaviour of the zebrafish larvae. 
This study addresses the first attempt to unravel the molecular mechanism 
underlying the behavioural onset. 
 
4.3.1. MAPK and behaviour 
The link between the activation of the MAPK pathway and cognition has been long 
studied and has mostly focused on the areas of depression and memory. Triggered by 
the circadian clock, MAPK activation endogenously oscillates every 24h in the 
hippocampus (Eckel-Mahan et al., 2008) and peaks of cAMP and MAPK signalling 
induce expression of new genes, promoting long-term memory formation (Lyons et 
al., 2006). More recently, Noonan syndrome (NS) gain-of-function mutations of the 
Ptpn11 orthologue in D. melanogaster were found to drive alterations in Mapk 
signalling. This prolongs the resting intervals between the repeated training sessions 
impairing long-term memory formation (Pagani et al., 2009).  
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Importantly, RASopathies patients exhibit a range of behavioural phenotypes. Study 
of the adaptive behaviour of CFC and NS patients, although varied, shows some 
evidence for genotype-to-phenotype correlation (Pierpont et al., 2010). For example, 
all CFC patients present with cognitive impairment whereas a third of NS patients 
did so. Moreover, BRAF, MEK1 and MEK2 mutations are correlated with more 
impaired adaptive behaviour than PTPN11 mutations. 
 
Zebrafish provide a good model organism to study and measure behavioural patterns 
and have been previously used to dissect general behaviour (Guo et al., 2004), sleep 
patterns (Cahill et al., 2002), drug addiction (Ninkovic et al., 2006) and learning 
(Best et al., 2008). Although specific aspects of behavioural phenotypes of the 
RASopathies spectrum cannot be readily assessed in our system, I aimed to establish 
whether MAPK output modulation had an effect on zebrafish behaviour at all. To 
assess the extent to which the MEK inhibitor that rescued the developmental 
phenotype promoted by CFC mutations (Chapter 3) could also affect zebrafish 
behaviour, I tested the behavioural effect of PD0325901 on 3dpf zebrafish larvae 
triggered to exhibit the previously characterised “edge effect”.  
 
4.3.2. The “edge effect” is reminiscent of murine depression 
Administration of the three cAMP elevators Rolipram, Forskolin and IBMX to wild-
type fish resulted in the same phenotype (Figure 4.2.3), suggesting that increased 
cAMP levels alone can promote the defined behaviour. The behaviour was not 
attributed to general drug administration as zebrafish are DMSO-tolerant (Goldsmith 
et al., 2004) and other drugs including the MEK inhibitor PD0325901 and lithium 
chloride had no observable effect (Anastasaki et al., manuscript in preparation). The 
lower phenotype induction of IBMX compared to the other two small molecules may 
be explained by the non-specific nature of the former, which also acts as an 
adenosine receptor inhibitor.  
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The treated embryos positioned themselves perpendicularly to the edge of their 
container facing outwards, actively resuming their positioning upon agitation (MSc 
Thesis, Grant). This phenotype was previously characterised as the “edge effect”. 
This behaviour is reminiscent of thigmotaxis, which is the act of avoiding movement 
in open spaces and staying close to the wall. Thigmotaxis is commonly observed in 
mouse models of anxiety and depression (Miller et al., 2010) where the animals are 
characterised by seeking a darker environment and longer periods of inactivity 
compared to wild-type individuals. Similarly, in light conditions “edge effect”-
exhibiting zebrafish are not being entirely inactive as they dynamically maintain 
their positioning. However, they are not explorative of their environment in the light 
and appear static in the absence of agitation. Preliminary data supports the possibility 
that the “edge effect” is effectively a stronger than normal shade-seeking strategy, as 
embryos in total darkness are positioned randomly within their arena (Anastasaki et 
al., manuscript in preparation). Taken together, these suggest that steep cAMP 
increase may stress the treated zebrafish in the light and promote an anxiety-like, 
shade-seeking behaviour. 
 
4.3.3. cAMP elevation correlates with pErk increase 
Activation of the MAPK pathway and prolonged stress are key factors to depression 
onset (reviewed in Krishnan and Nestler, 2008; Hayley et al., 2005). Stress swim 
tests on mice have demonstrated a stress-driven prominent increase in the 
phosphorylation level of Mek1/2 in all brain regions paralleled by a slight increase in 
activated Erk1/2 (Shen et al., 2004). Similarly, pharmacologic or genetic increase of 
cAMP in zebrafish induced a stress-like response (“edge effect”) and an increase in 
pErk1/2. Increasing concentrations of Rolipram promoted higher levels of pErk 
(Figure 4.2.5A). This suggests that Erk1/2 phosphorylation is cAMP-dependent in 
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4.3.4. Mek inhibition rescues the “edge effect” 
Physiological negative regulation of Erk in mice induces a depression-like behaviour 
(Duric et al., 2010). The dominance of the effect is such that MEK inhibitors mask 
the behavioural outcome of antidepressants after co-treatment with the two agents 
(Duman et al., 2007). Conversely to murine studies though, administration of 
PD0325901 alone had no effect on larval behaviour and mobility (Figure 4.2.4). 
 
However, blocking the MAPK cascade can promote therapeutic effects in models of 
depression and stress. For example, antipsychotic agents, such as clozapine, 
selectively activate the MEK/ERK pathway and inhibition of the MAPK signalling 
upstream and downstream of RAF reverses the behavioural outcome of the drug 
(Browning et al., 2005). Conversely, the level of Mapk activation is inherently 
doubled in the amygdala of depressed-like rats demonstrating long periods of 
immobility. In that case, pharmacological inhibition of Mek1/2 can restore normal 
phosphorylation and mobility levels (Huang and Lin, 2006). In accordance to these 
findings, the MEK inhibitor PD0325901 was able to counter-act the immobility 
(light-avoidance) effect of Rolipram, Forskolin and IBMX in wild-type larvae 
(Figure 4.2.4). 
 
4.3.5. pde4d-/- mutants exhibit the “edge effect” but respond differently to 
wild-type larvae to MAPK inhibition 
Pde4d knockout mice exhibit increased cerebral cAMP levels and reduced 
depression (Zhang et al., 2002). In light conditions, pde4d
-/-
 zebrafish larvae 
phenocopied the effect of Rolipram. Progressive loss of pde4d copies correlated with 
an increase of “edge effect”-positive embryos. Moreover, pde4d loss caused an 
increase in pErk levels, similar to immobilised rats (Huang and Lin, 2006). Although 
the possibility of an antidepressant-like effect in pde4d
-/-
 adult fish is still being 
assessed, study of zebrafish embryos points towards the opposite direction. This 
could be partly explained by the fact that in this study the activity of zebrafish was 
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only observed during light conditions and close examination of the phenotypes 




 embryos with the MEK inhibitor failed to reproduce the level 
of rescue observed in wild type larvae. The reason MEK inhibition was not as 
effective as in wild-type individuals in preventing the “edge effect” possibly lies in 
the fact that genetic loss of a pde4 gene disturbs cAMP regulation more robustly. It is 
possible that global elevation of cAMP, and respectively pERK, triggers the 
activation of another signalling cascade, unaccounted for in this study.  
 
The increase in cAMP is, also, molecularly portrayed in the pErk elevation of the 
Rolipram-treated pde4d
-/-
 embryos compared to that of the WT embryos. PD0325901 
is potently inhibiting ERK phosphorylation at the administered dose, indicating that 
the drug was acting effectively and that the “edge effect” observed in pde4d
-/- 
embryos was, at least partially, MAPK-independent. It became apparent that in this 
system the behavioural outcome and molecular readout were not always correlated 
and that the cross-talk between cAMP and MAPK pathways in the establishment of 
the “edge effect” is not simplistic or linear. 




The theory that cAMP feeds back to BRAF in order to activate MAPK does not fully 
explain the lack of the phenotype rescue in pde4d mutants by PD0325901. Based on 
my results, I can conclude that pErk levels alone are not the optimal readout to 
explain embryonic behaviour. Firstly, Mek inhibition (reducing pErk levels) rescued 
the “edge effect” (increased pErk levels) in wild-type larvae but not in pde4d
-/-
 
mutants (increased pErk levels). There is a clear mechanistic difference between 
wild-type and mutant individuals that can possibly be explained by the constantly 
high levels of cAMP in pde4d
-/-
 embryos. In support of this, continuous incubation of 
wild type fish in Rolipram (constant increased levels of cAMP) recapitulates the 
edge effect. However, this phenotype cannot be rescued by the MEK inhibitor, 
similarly to the pde4d-/- mutants (data not shown).  
 
The chemical intervention of the cAMP molecular cascade and the genetic ablation 
of a pathway component (pde4d) give rise to the same phenotype but presumably 
promote the same measurable end effect through distinct processes. The pde4d
-/-
 
system is somehow compensating for the permanently higher cAMP signalling 
output in a non Mapk-related way. Although pde4d loss is paralleled by an increase 
in pErk and confirming the interaction between the two cascades, blocking the Mapk 
pathway seizes to have an effect on pde4-/- embryo behaviour. This suggests that the 
cAMP-dependent molecular trigger of the “edge effect” phenotype lies either 
downstream of Erk or in an parallel signalling pathway. 
 
Preliminary results from adult pde4d-/- zebrafish studies suggest that the adult 
mutant phenotype is rescued by PD0325901, unlike the embryonic behaviour. This 
finding could suggest that two separate effects of the cAMP elevation are being 
observed. One effect could be causing motor neuron deficiency impeding the fish 
from swimming properly, an effect that could be partly overcome in adults as they 
had more time to develop new tissue. Indeed, pde4-/- embryos and adults swim less 
than their wild-type siblings (Pia Lundegaard, personal communication). The second 
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effect could be the exaggeration of the natural shade-seeking behaviour of larval 
zebrafish.  Thus, one effect is light-dependent and the other swimming-dependent.  
 
The network of interactions between the two signalling cascades is not complete 
leading to a lack of tools available to understand their precise function in behaviour 
development. Determination of cAMP and pMek1/2 levels can help elucidate the 
complexity of cAMP and Mapk interactions in this system. However, it is necessary 
to address the possible effect of a third pathway. The existence of a role for Mapk 
signalling in zebrafish behaviour is certain but the mechanism of its action is yet to 




5.Chapter 5 - Concluding Remarks 
“One never notices what has been done; one can only see what 
remains to be done” - Marie Curie 
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5.1. Contribution to the field 
 
This project introduced a robust platform to study the genetic onset of the 
RASopathies, explore molecular interactors of the disease-causing genes as well as 
test potential patient treatments.  The main results of the project cluster around three 
major areas: developmental genetics, chemical genetics and behavioural genetics. 
 
5.1.1. Established zebrafish bioassay 
Firstly, the zebrafish model provided a thorough system to establish my bioassay. Its 
unique advantage is that it allowed me to closely examine both the effect of 
individual mutations as well as to test a vast array of them (Figure 2.2.3). Each 
embryo can be followed throughout embryogenesis and every developmental aspect 
can be monitored and measured. That way, one can understand different 
developmental processes during normal pathology.  
 
The optical transparency of the embryos and the molecular tools available rendered it 
easy to dissect the direct developmental effect of individual mutations. For instance, 
human BRAF
V600E
 mRNA over-expression not only caused prominent embryo 
dorsalisation by the end of gastrulation, like all other BRAF CFC and melanoma 
mutations, but also at high concentrations completely impeded the formation of eyes 
(Figure 2.2.2). Moreover, the abundance of embryos and the capacity to easily over-
express mutant mRNA allows to rapidly test the effect of tens (31 in this study) but 
potentially hundreds of mutations in development. 
 
5.1.2. All mutations act as gain-of-function 
Secondly, this study established that all CFC mutations are acting as gain-of-function 
in vivo irrespective of their predicted in vitro activity. This finding is in accordance 
with results from Drosophila studies, where all SHP-2 mutations also act as gain-of-
function (Oishi et al., 2009). The fact that all the tested CFC mutations had the same 
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effect can explain the phenotypic similarity between CFC and, indeed, RASopathies 
patients.  
 
Not only did kinase-impaired mutations promote the same gastrulation phenotype in 
embryos as kinase-activating ones did, but also stable mosaic expression of the 
kinase-inactivating CFC allele BRAF
G596V
 in zebrafish adults drove naevi formation. 
Ectopic melanisation requires a breach of the tightly controlled mechanism 
specifying pigmentation patterns and has only been observed in cases of highly 
activating oncogenes (such as BRAF
V600E
). This result underpins the oncogenic 
potential possessed by all CFC mutations and, importantly, reinforces the notion that 
in vitro activity levels of proteins are not representative measures of their in vivo 
output.   
 
5.1.3. Recycling of cancer drugs to treat developmental disorders 
Thirdly, I ascertained that drugs established in other fields of treatment can be 
recycled to target the same pathways in different disorders. The RASopathies 
spectrum has a low prevalence and represents a very small target market. Hence, the 
potentially small financial benefit has not made the RASopathies a primary 
investment target for pharmaceutical companies. Nevertheless, administration of 
anti-cancer agents for the treatment of developmental defects in the present bioassay 
has been successful. I tested one FGFR and two MEK inhibitors, all of which were 
able to fully prevent elongation in zebrafish embryos expressing disease alleles 
(Figures 3.2.1, 3.2.4). 
 
Recycling anti-cancer drugs that target the MAPK pathway or its peripheral 
regulators presents a real possibility for RASopathies treatment. This is further 
supported by the fact that a number of drugs have been developed, which act 
specifically on known MAPK components, have established side effects and 
evaluated potency. However, the caveat of this approach is that children are 
organisms that are still undergoing development. As such, complete blockage of a 
key signalling pathway such as MAPK can be detrimental to their physiology. 
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Indeed, blocking more than 50% of the MAPK pathway output drives prominent 
craniofacial malformations in developing zebrafish (Figures 3.2.9-3.2.11). To 
overcome this problem, the MAPK inhibition levels need to be fine-tuned in order to 
simultaneously block the activity of the pathway efficiently enough to avoid the CFC 
allele-driven aberrant signalling as well as retain enough MAPK output for normal 
development and tissue formation.  
 
To this end, I performed an initial systematic study primarily to understand the 
spatiotemporal requirements for active MAPK signalling in normal development. I 
looked at the specific molecular and developmental effects of the MEK inhibitor 
PD0325901 and established that increasing concentrations of the small molecule can 
turn the pathway off in a linear manner (evident both after dusp6-GFP transgenic line 
treatment Figure 3.2.2 and after western blotting Figure 3.2.11). The titration series 
also allowed clear distinction between phenotypes of optimal and sub-optimal drug 
treatments.  
 
Most importantly, after identifying a sub-optimal concentration that minimally 
affected development (0.2µM), I was able to alleviate the symptoms of embryos 
over-expressing the most common CFC allele BRAF
Q257R
 after continuous sub-
optimal PD0325901 treatment (Figure 3.2.12). The finding that a constant low dose 
of a MEK inhibitor can counter-act all the developmental defects promoted by CFC 
alleles restoring near-normality as the organism matures without greatly affecting 
development is integral to the potential treatment of the syndrome. The results 
presented here could represent the first step towards the consideration of CFC 
syndrome treatment with an appropriate dosage of a MEK inhibitor. 
 
 
5.1.4. Targeting the cAMP pathway to modulate MAPK signalling  
Lastly, this body of work identified a novel involvement of the Mapk pathway in 
zebrafish behaviour and introduced cAMP modulation as a possible avenue to target 
the MAPK pathway. The robust zebrafish “edge effect” phenotype promoted by 
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elevated cAMP signalling was molecularly translated to an increase in Mapk 
activation and inhibition of Mek was able to fully reverse the effect. The behaviour 
itself was suggestive of sudden anxiety or possible shade-seeking but future work 
will characterise this further.  
 
Intriguingly, the already non-linear image of cAMP and Mapk signalling interactions 
became more complex. Both the difficulty in fully understanding the network cross-
talk between the two cascades as well as the dissimilar phenotypes demonstrated by 
different PDE4D genetic mutants across species urge further studies of the cAMP-
driven behaviour. Preliminary data supports that light conditions have a significant 
effect in the positioning and motility of zebrafish experiencing increased cAMP 
levels. Future work will focus on examining detailed behavioural and molecular 
alterations in adult and embryonic genetic mutants in variable environments. 
 
Modifying cAMP levels is a very new treatment approach for paediatric disease 
therapy. It was not until recently that cAMP was considered a potential target, mostly 
because it is expressed in a variety of tissues and plays major roles in very distinct 
processes. It was feared that blocking or enhancing the activation of cAMP could 
have multiple side-effects due to the involvement of a great number of downstream 
signalling pathways, some of which are probably unknown. Additionally, cascade 
cross-talks are very tissue-specific, complex and, most importantly, not delineated. 
As discussed above, complete ablation of a signalling cascade can have profound 
unwanted side effects and, in the case of cAMP, predominantly in neuronal tissues. 
Topical application of drugs presents a possibility for tumour treatment. However, 
local injection of a drug to a developing organism such as a child is not a realistic 
option. Thus, combinations of sub- optimal dosages of drugs that target upstream or 
downstream effectors of the disease-driving genes can be helpful. 
 
Drug combination can work in two ways. First, drug resistance can be avoided, as 
low doses of drugs acting on the same or parallel pathways can have a moderate 
effect on their targets without completely inhibiting their action. Secondly, altering 
signalling in the “periphery” of the target pathway can have beneficial results. It is 
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clear that molecular pathways are not acting in a simplistic manner as originally 
described. Complex inter-connections and feedback mechanisms that are not yet 
established are the medium via which mutations in one pathway can cause alterations 
in signalling output of another. Blocking components peripheral to the key driving 
factors can moderate the intensity of the key signalling output and restore levels of 
signalling that an organism can cope with. 
 
The relationship between the MAPK and cAMP pathways has been discussed in 
detail in Chapter 4.1. In the framework of the RASopathies though, dual targeting of 
MAPK and cAMP pathways has the potential to be beneficial in terms of 
memory/learning, social behaviour/anxiety and circadian rhythms/sleeping patterns. 
However, the exact behavioural phenotypes of RASopathies patients are not yet fully 
characterised. Additionally, one of the intrinsic problems with examining behaviour 
is trying to dissect the underlying mechanism. A stable adult model of the syndromes 
would help both with establishing behavioural phenotypes and with identifying 
molecular drivers of mutant behaviour. 
 
5.2. Future directions 
 
5.2.1. Establishing a genotype-to-phenotype relationship 
At this stage, a precise genotype-to-phenotype correlation has not been established in 
CFC patients, with the exception of BRAF mutations that are thought to mostly 
involve skin malformation. However, KRAS-driven phenotypes are difficult to 
categorise but are generally associated with extreme severity of symptoms. A 
possible explanation for this is that unlike BRAF and MEK that have limited 
molecular targets, KRAS signals to more effector proteins leading to a larger set of 
symptoms that are harder to define. It is plausible that the higher a gene is in a 
signalling cascade, the broader the spectrum of its effects molecularly and 
phenotypically. Future studies based on my bioassay coupled with close examination 
of individual tissues can elucidate the role of Kras in zebrafish development.  
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Study of their effect in early development revealed that expression of a collection of 
CFC, melanoma and engineered BRAF and MEK alleles caused a severe gastrulation 
phenotype in zebrafish. Having determined that the phenotypic effect was 
mechanistically promoted by convergence movement defects, future studies can 
explore the molecular targets of the allelic variants. Performing a microarray analysis 
could clarify the molecular effects of each individual mutation in KRAS, BRAF, 
MEK1 and MEK2. This approach would highlight genes or pathways affected by 
individual mutations. Preliminary studies on zebrafish over-expressing a small panel 
of BRAF, MEK1 and MEK2 CFC alleles already show distinct regulation of 
downstream effectors depending. More extensive analysis can identify both common 
downstream effectors and differentially regulated targets of KRAS, BRAF, MEK1 
and MEK2.  
 
5.2.2. Generation of an adult model of CFC syndrome 







 mutations would be an ideal system to fully study and comprehend the 
mode of action of CFC disease alleles. A stable zebrafish line would have the 
advantage of endogenously expressing the mutant proteins throughout development 
at physiological levels similarly to human CFC patients. The CFC zebrafish could be 
assessed genetically, physically, histopathologically, molecularly and in terms of 
behaviour at different stages of their development, a study that could shed light in 
unexplored aspects of the disorder. Most importantly, CFC zebrafish would offer a 
model to assess the effectiveness of individual or combinations of drugs on 










6.1. List of Abbreviations 
6.1.1. Reagents 
Acrylamide/ Bis Solution :  N, N’ –methylene- bisacrylamide for electrophoresis 
APS : Ammonium persulfate for electrophoresis, 98% 
BSA : Bovine serum albumen 
ddH2O : Distilled deionised water  
DMSO : Dimethyl Sulfoxide 
E3 : Embryo growth medium 
EDTA : Ethylenediaminetetraacetic acid 
EtOH :  Ethanol 
H2O2 : Hydrogen peroxide 
HCl : Hydrochloric acid 
IBMX : 3-Isobutyl-1-Methylxanthine 
KCl : Potassium chloride 
KOH : Potassium hydroxide 
LB Broth : Lysogeny Broth; Luria-Bertani medium 
MeOH : Methanol 
NaCl : Sodium chloride 
NaF : Sodium fluoride 
NaOH : Sodium hydroxide 
NP40 : Tergitol-type NP-40, which is nonyl phenoxypolyethoxylethanol 
PBS : Phosphate Buffered Saline 
PBST : Phosphate Buffered Saline with Tween 20 
PFA : Paraformldehyde 
RIPA Buffer : Radioimmunoprecipitation assay buffer 
SDS : Sodium Dodecyl Sulphate 
SSC : Sodium chloride: Sodium Citrate Buffer 
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SU 5402 : 2-[(1,2-Dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-1H-pyrrole-
3-propanoic acid 
TBE : Tris/Borate/EDTA; Tris, Boric acid, EDTA 
TBS : Tris Buffered Saline 
TBST : Tris Buffered Saline with Tween 20 
Tris Base : tris(hydroxymethyl)aminomethane 
Tris- HCl: tris(hydroxymethyl)aminomethane hydrochloride 
tRNA : Purified Torulla yeast RNA 
6.1.2. Genes 
BRAF : Raf-1 murine leukaemia viral oncogene homolog B1 
cAMP : Cyclic Adenosine Monophosphate 
CRAF; RAF-1 : Raf-1 murine leukaemia viral oncogene homolog 1 
DLX3 : Distal-less homeobox 3 
ERK 1; MAPK1 : mitogen-activated protein kinase 1 
ERK2; MAPK2 : mitogen-activated protein kinase 2 
FGF : Fibroblast Growth Factor 
HGG1 :  Hatching Gland 1; aka Cathepsin L, 1 
MAPK : mitogen-activated protein kinase 
MEK1; MAP2K1 : mitogen-activated protein kinase-kinase 1 
MEK2 ; MAP2K2 : mitogen-activated protein kinase-kinase 2 
MITF : Micropthalmia-associated Transcription Factor 
p53 : Tumour protein 53 
PDE4 : Phosphodiesterase 4 
pERK1 : phospho-mitogen-activated protein kinase 1 
pERK2 : phospho-mitogen-activated protein kinase 2 
pMEK1 ; phospho-mitogen-activated protein kinase-kinase 1 
pMEK2 : phospho-mitogen-activated protein kinase-kinase 2 
PDE4 : phosphodiesterase 4 





Dpf : days postfertilisation 
Hpf : hours postfertilisation 
ISH : In situ hybridisation 
SDS-PAGE : Sodium Dodecyl Sulphate- Polyacrylamide Gel Electrophoresis 
WB : Western Blotting 
6.1.4. Units of measurement 
L: litre 
ml : millilitre 
µl : microlitre 
M : molar 
mM : millimolar 
µM : micromolar 
ng/µl : nanograms per microlitre 
g/ml : microgram per millilitre 
mg/ml : milligrams per millilitre 
m : meter 
cm : centimetre 
mm : millimter 
m : micrometer 
bp : Base pairs 
kb : Kilobases 
Mb : Megabases 
g : gram 
mg: milligram 
g : microgram 
ng : nanogram 
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pg : picogram 
pH : power of hydrogen  
ºC : degrees Celcius 
rpm : revolutions per minute 
V: Volts 
mA: milliamperes 
Dpi: Dots per inch 
 
6.1.5. Zebrafish Strains 
WT : Wild-type 
AB : Strain A crossed to Strain B 





 : Phosphodiesterase 4 heterozygous/homozygous mutants 
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6.2. General Use Buffers - Recipes 
 
PBS (pH 7.4) (1L) 
NaCl 8 g 
KCl 0.2 g 
Na2HPO4 1.44 g 
KH2PO4 0.24 g 
ddH2O up to 1L 
Autoclave to sterilise 
 
TBS 10x Stock Solution (1L) 
NaCl 87.66 g 
Tris Base 12.11 g 
ddH2O 800 ml 
Adjust pH to 8.0 
Fill up to 1L with ddH2O  
 
1M Tris Buffer (1 L) 
Tris Base 121.1 g 
ddH2O 800 ml 
Adjust pH accordingly to 6.8; 7; 8.8 with 10M HCl 
Fill up to 1L with ddH2O and autoclave to sterilise. 
 
0.5M EDTA (pH 8.0) (1L) 
Na2EDTA 186.1 g 
ddH2O 500 ml 
Adjust pH to 8.0 with 10M NaOH.  
Fill up to 1L with ddH2O and autoclave to sterilise. 
 
TBE 10x Stock Solution (1L) 
Tris Base 108 g 
Boric Acid 55 g 
0.5M EDTA (pH 8.0) 40 ml 




E3 Embryo Medium 60x Stock Solution (1L) 
NaCl 17.2 g 
KCl 0.76 g 
CaCl2•2H2O 2.9 g 
MgSO4•7H2O 4.9 g 
ddH2O up to 1L 
 
E3 Embryo Medium 1x Solution (6L) 
60x E3 Stock Solution 100 ml 
ddH2O 5.9 L 
Methyl Blue 2 drops 
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6.3. Zebrafish Husbandry 
Detailed zebrafish husbandry techniques can be found at The zebrafish book. A guide 
for the laboratory use of zebrafish (Danio rerio) (Westerfield, M., 2000) and 
Zebrafish  (Nusslein-Volhard and Dahm, 2002). 
6.3.1. General Zebrafish Care and Line Maintenance 
Embryos up to 5dpf were routinely maintained in 90mm diameter Petri dishes 
(Sterilin) filled with E3 embryo medium. Chemically treated embryos were, unless 
otherwise stated, incubated in tissue culture-treated, gamma-sterilised, RNase and 
DNase-free 6-well (Technoplastics Products) plates in a total volume of 10ml of E3 
enriched with the appropriate small molecule. All embryos were grown in a 28.5ºC 
incubator. The media were refreshed daily and the plates were monitored at least 
once per day to record phenotypes and discard of dead embryos.  
 
5dpf embryos were put in a flowing current aquatic system in a density of 
approximately 30 embryos per 2L tank. Juvenile fish (14dpf-1 month old) were 
transferred to tanks of larger volumes in order to ensure proper growth of the 
animals. Adult fish (older than 3 months) were either kept in the same tanks or were 
transferred in larger capacity tanks, depending on the fish density, to promote better 
mating.  
 
6.3.2. Zebrafish Feeding 
All the fish in the aquatic system were fed three times a day during weekdays and 
twice during the weekend. Their diet was age dependent and followed the scheme 
below: 
 
Larvae (5dpf – 14dpf)  
Dry food:  Half a spatula-full of a mixture made up by equal parts of ZM000 and 




Juveniles (14dpf – 1 month old) 
Dry food: 1 pinch of ground granular food constituted of equal parts of ZM200, ZM 
small granular, Zeiger adult diet and Hikari tropical micropellets (2 feeds) 
Approximately 2ml of freshly harvested brine shrimp solution (2 feeds) 
 
Adults (>1 month old) 
Dry food: 1 pinch of ground granular food constituted of equal parts of ZM200, ZM 
small granular, Zeiger adult diet and Hikari tropical micropellets (2 feeds) 
Approximately 2ml of freshly harvested brine shrimp solution (2 feeds) 
 
6.3.3. Embryo Collection and Bleaching 
Embryos that were to be raised past 5dpf in the aquarium had to be bleached, in 
order to minimise introduction of infection to the system.  
 
Bleaching Solution (500ml) 
10-15% Sodium hypochlorite (Sigma) 180 µl 
ddH2O 500 ml 
 
Up to 200 embryos were transferred into a plastic sieve that was serially submerged 
in five separate trays containing different solutions in the following order. Care was 
taken to avoid embryos overflowing out of the sieve. 
 
Tray 1 - Bleaching solution 5 mins 
Tray 2 - ddH2O 5 mins 
Tray 3 - Bleaching solution 5 mins 
Tray 4 - ddH2O 5 mins 
Tray 5 - E3 Embryo medium 5 mins 
 
After the last step, the embryos were transferred in a new 90mm Petri dish (Sterilin) 




6.3.4. Anaesthesia and Schedule I 
To image embryos or adults, zebrafish had to be anaesthetised temporarily in tricaine 
(3-amino benzoic acid ethyl ester; ethyl 3-aminobenzoate) (Sigma-Aldrich).  
 
Tricaine Anaesthetic Solution (100ml) 
Tricaine powder 400 mg 
ddH2O 97.9 ml 
1M Tris (pH 9.0) 2.1 ml 
 
500µl of tricaine anaesthetic solution was added in 30ml of embryo media to 
anaesthetise embryos in 90mm Petri dishes almost immediately. Adult zebrafish 
were transferred, one at a time, in a tank containing 4.2ml of tricaine solution and 
95.8ml of fresh aquatic system water until fully anaesthetised. The duration of this 
step depended on the size of the fish and ranged from 1 to 5 minutes. The fish 




6.4. Embryo Micro-injection 
6.4.1. Pulling Needles 
The needles used for injections were pulled using a P-97 Flaming/Brown 
Micropipette Puller (Sutter Instrument, Novato CA, USA). That was accomplished 
by heating up the middle section of 1mm outer diameter, 0.8mm inner diameter, 
10cm long single glass capillaries without filament (Intrafil) and then pulling the two 
ends of the capillary to opposite directions to create two needles. The ends of the two 
needles were automatically sealed as a result of the high temperature and the thin 
nature of the capillaries.  
 
6.4.2. DNA and RNA Solutions for Injections 
All DNA and RNA solutions prepared for injections were dissolved in ddH2O. 
Routinely, DNA solutions were injected at 100ng/µl to avoid toxic side-effects. As 
RNA abundance tolerated by embryos varies depending on the nature of the protein 
encoded for, the optimal end concentration used for BRAF, MEK1 and MEK2 
capped mRNA was 35ng/µl and the sub-optimal concentration was 15ng/µl 
 
6.4.3. Adjusting Needle Size and Position 
2-5µl of each construct to be injected was loaded to the end of the sealed needle 
using Microloader pipette tips (Eppendorf, UK). A P/N standard straight holder 
(Intracel, Herts, UK) adjusted onto a micromanipulator (Narishige International 
Limited, London, UK), held the capillaries in place. The position of the 
micromanipulator could be manually modified as its movement could be finely and 
precisely controlled in three planes. The needle holder was connected to a nitrogen-
powered Picospritzer III microinjector (Intracel) by a polyethylene tube and allowed 




Individual needle tips were broken steeply creating a non-blunt end using forceps, 
just prior to injection. The liquid automatically migrated to the end of the needle 
after the tip was broken due to capillary action. The amount of glass that was broken 
off the tip of the needle was estimated empirically, so that the capillary could 
penetrate the embryonic chorion without bending. The droplet size, however, was 
calculated to be 1nl by calculating the diameter of the droplet using a graticule, 
converting this to volume and adjusting the pressure and the duration of the injection 
(usually ranging from 5-15msec) until the desired volume was achieved.  
 
6.4.4. Injecting the Embryos 
Single-cell stage embryos were collected from mating tanks and transferred in clean 
Petri dishes in fresh E3 medium. Using a clean wide-tip 2ml graduated pastette a 
single file of embryos was positioned along the outer edge of a clean histology slide, 
which was, in turn, wedged within a 90mm Petri dish (as shown in the figure below). 
The injector was conjugated to a Nikon SMZ 1000 stereomicroscope illuminated 
from below, which allowed optimal alignment of the embryos and the needle and 
clear visualisation of the injection process. Most of the embryo medium around the 
embryos was removed in order to stop embryos from shifting positions during the 
injection process, with a few drops of liquid left surrounding them to prevent drying 
out. The embryos were manoeuvred either with forceps or with the needle itself so 








Microinjection of embryos 
 
The microscope was focused on the embryo to be injected and the needle was driven, in a single 
move, through the chorion directly into the cytoplasm of the cell. Using the foot switch the solution 
was visibly injected and the needle was swiftly retracted from the embryo. The dish was moved 
manually upwards in order to inject the next embryo in line and the procedure was repeated for all of 
the embryos in that set. All embryos were only injected once. It is important to note that the same 
needle was used between experimental and control injection sets, when possible, to ensure the injected 
volume was identical. 
 
6.4.5. Post-Injection Care 
Injected embryos were sensitive to post-injection infections and as such were 
routinely checked 3-4 hours after their injection to clean up their media and discard 
severely deformed or dead samples. This procedure promoted healthy development 
and well-being of the all individuals in the plate. 
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6.5. Drug Treatments 
6.5.1. MEK Inhibition 
Two specific MEK1/2 inhibitors were used throughout the course of this project. 
CI1040 (previously referred to as PD184352) was provided by Richard Marais (ICR, 
London, UK) and PD0325901 was purchased from Dundee University.  
 
1mg of CI-1040 (molecular weight: 478.67) was dissolved in 208.91µl of DMSO 
(Sigma-Aldrich) to achieve a final molarity of a 10mM stock solution. The solution 
was aliquoted and stored at -80ºC for up to one year. Once an aliquot was thawed it 
was not re-frozen, as it affected the activity of the small molecule. CI-1040 was used 
only for mRNA-promoted elongation prevention experiments (Chapter 3). It was 
used at a final molarity of 0.5M or 1.0M in 10ml E3. The drug was administered 
once to injected and uninjected embryos at 4hpf. The embryos were incubated in the 
small molecule for a maximum of 4.5 days, at which point the larvae were killed in 
an overdose of anaesthetic tricaine, following the Schedule I for the Animals 
Scientific Procedures of the Home Office/ Animal Procedures Committee (see 
above).  
 
1mg of PD0325901 (molecular weight: 482.2) was dissolved in 207.38µl of DMSO 
to achieve a final molarity of a 10mM stock solution. The stock was aliquoted and 
stored stably at -20ºC for up to 2 years. Freezing an aliquot after thawing the solution 
was avoided but did not have an overt effect on the activity of the compound.  
 
For the elongation prevention experiments, 10ml of PD0325901 were administered 
once at 0.5M and 1.0M at different stages during gastrulation: 4.5hpf, 5.5hpf, 
6.5hpf, 7.5hpf, 8.5hpf, 9.5hpf and 10.5hpf (Chapter 3). The mRNA-injected 
embryos were incubated in the drug until 24hpf. For the systematic study of the 
effects of MEK inhibition during normal development, 10ml of PD0325901 were 
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prepared fresh and were refreshed daily at the following molarities: 0.1M, 0.2M, 
0.3M, 0.4M, 0.5M, 0.6M, 0.7M, 0.8M, 0.9M and 1.0M. For the 
behavioural studies (Chapter 4), PD0325901 was administered in combination with 
other drugs according to Table 6.1. A total volume of 10ml was prepared for 
embryos treated at 4hpf and of 30ml for 3dpf embryos. 
 
6.5.2. FGFR Inhibition 
1mg of the FGFR inhibitor SU5402 (Tocris-Bioscience) powder (molecular weight: 
296.32) was dissolved in 33.75µl of DMSO to achieve a final molarity of a 100mM 
stock solution. The stock solution was aliquoted in 50µl tubes protected from light 
and stored at  -20ºC for up to 2 years. Embryos injected with BRAF, MEK1 and 
MEK2 capped mRNA used for rescue experiments (Chapter 3) were treated with 
10ml of freshly prepared 0.5M SU5402 in E3.  
 
 
 cAMP elevator MAPK inhibitor Time of Addition 
Rolipram + 
PD0325901 
15M 1M 4hpf; 3dpf 
Forskolin + 
PD0325901 
7.5M 1M 3dpf 
Forskolin + 
PD0325901 
7.5M 2M 3dpf 
Forskolin + 
PD0325901 
15M 1M 4hpf; 3dpf 
IBMX + 
PD325901 
15M 1M 4hpf; 3dpf 
 
Table 6.1 Final molarities of drugs used for dual treatments. 
 
6.5.3. Rolipram Treatment 
10mg of Rolipram (Tocris Bioscience) powder (molecular weight: 275.35) were 
diluted in 363.17µl DMSO to achieve a final molarity of a 100mM stock solution. 
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The stock was aliquoted and stored at -20ºC for 3-6 months. 4hpf embryos were 
treated in 10ml Rolipram or Rolipram+PD0325901 (Table 6.1) in a 6-well plate for 
six hours before being collected for Western blot analysis. 10hpf and 3dpf embryos 
were treated in 30ml Rolipram or Rolipram+PD032590 in a 90mm plate for up to 
10hpf before being imaged and collected for Western blot analysis. 
 
6.5.4. Forskolin Treatment 
10mg of Forskolin (Tocris Bioscience) powder (molecular weight: 410.51) were 
diluted in 487.2µl of DMSO to achieve a final molarity of a 50mM stock solution. 
The solution was aliquoted and stored at -20ºC for 6 months. 4hpf embryos were 
treated in 10ml Forskolin or Forskolin+PD0325901 in 6-well plates and 3dpf 
embryos were treated in 30ml Forskolin or Forskolin+PD0325901 in 90mm Petri 
dishes (Table 6.1).  
 
6.5.5. IBMX Treatment 
50mg of IBMX (Tocris Bioscience) powder (molecular weight: 222.24) were diluted 
in 4.49ml DMSO to achieve a final molarity of a 50mM stock solution. The stock 
was aliquoted and stored at -20ºC for 6 months. 4hpf embryos were treated in 10ml 
IBMX or IBMX+PD0325901 in a 6-well plate. 3dpf embryos were treated in 30ml 





6.6. Immunoblotting - Recipes 
6.6.1. Protein Extraction 
 
RIPA Buffer (10 ml) 
ddH2O 9.250 ml 
2M Tris-HCl pH 7.5 250 µl 
5M NaCl 300 µl 
1% NP40 (Sigma Aldrich) 100 µl 
10% SDS 100 µl 
Sodium deoxycholate 50mg 
 
10% SDS (1L) 
SDS 100 g 
ddH2O 1 L 
Heat to 68ºC 
Adjust pH to 6.6 
 
Lysis Buffer (1 ml) 
RIPA Buffer 925 µl 
NaF 10 µl 
Beta-glycosyl phosphate 25 µl 
25x Phosphatase inhibitors mix (Roche) 40 µl 
 
6.6.2. Preparing the SDS Gels 
 
1M Tris pH8.8 (500 ml) 
Tris base 60.55 g 
ddH2O 400 ml 
Adjust pH to 8.8 with 10M HCl 
Make up to 500ml with ddH2O 
 
0.5M Tris pH6.8 (200 ml) 
Tris base 12.1 g 
ddH2O 150 ml 
Adjust the pH to 6.8 with 10M HCl 




25% APS (1 ml) 
APS 0.25 g 
ddH2O 1 ml 
Store at 4ºC and use within 3 weeks 
 
8% SDS Resolving Gel (10 ml) 
ddH2O  3.47 ml 
1M Tris pH 8.8 3.73 ml 
30% Acrylamide/ Bis (BioRad) 2.7 ml 
10% SDS 100 µl 
TEMED (Sigma Aldrich) 10 µl 
25% APS 40 µl 
 
SDS Stacking Gel (4 ml) 
ddH2O  2.8 ml 
0.5M Tris pH 6.8 500 µl 
30% Acrylamide/ Bis (BioRad) 670 µl 
10% SDS 40 µl 
TEMED (Sigma Aldrich) 10 µl 




3x Sample Buffer (Cell Signaling)  
3x Sample Buffer 100 µl 
30x DTT 10 µl 
 
6.6.4. Running the Gel 
 
SDS Running Buffer 10x stock solution (1L) 
Glycine 144 g  
Tris Base 36.3 g  
SDS 10 g 




6.6.5. Transferring the Proteins 
 
Transfer Buffer 10x stock solution (1L) 
Glycine 144 g 
Tris Base 29 g 
 
1x Transfer Buffer (1L) 
10x Transfer Buffer stock solution 100 ml 
100% MeOH 100 ml 
ddH2O 800 ml 
 
6.6.6. Post-transfer Procedures 
 
1x TBS with Tween20/ TBST (1L) 
10xTBS stock solution 100 ml 
Tween 20  500 µl 
ddH2O 900 ml 
 
0.5% Ponceau Solution (100 ml) 
Ponceau S (Sigma Aldrich) 0.5 g 
Glacial acetic acid 1 ml 
ddH2O 99 ml 
 
Blocking Solution (100 ml) 
Dried milk 2 g (2%) or 0.2 g (0.2%) 
1xTBST 100 ml 
 
Stripping Buffer (1L) 
Glycine 15 g 
SDS 1 g 
Tween 20 10 ml 
ddH2O 800 ml 
Adjust pH to 2.2 




6.7. Immunoblotting - Methodology 
6.7.1. Protein Extraction from Embryos for SDS-PAGE Analysis 
6.7.1.1. Collection and storage of samples  
Ten embryos were hand-dechorionated at the appropriate developmental stage. 
Embryos younger than 24hpf were placed in 1.7ml sterile microcentrifuge tubes in 
minimal liquid medium. Embryos older than 24hpf were placed in 2ml sterile ribbed 
skirted tubes in minimal medium. All samples were snap frozen in a dry ice/ MeOH 
mix and were stored at -80ºC.  
 
6.7.1.2. Embryo Lysis 
For samples of embryos younger than 24hpf, 40µl of lysis buffer was added in each 
tube and the embryos were homogenised by pipetting repetitively up and down.  
For samples of embryos older than 24hpf, 40µl of lysis buffer and approximately 50 
acid-washed glass beads were added in each skirted tube. The samples were 
ribolysed for 6 seconds at a 6.5 speed in a ribolyser. Following a 15-minute 
incubation on ice, the samples were centrifuged at maximum speed for 15 minutes at 
4ºC on an Eppendorf 5415R table-top centrifuge.  The supernatant was transferred on 
a clean sterile 1.7ml microcentrifuge tube. The protein content of the samples was 
measured by calculating the A380 absorbance of the samples, normalised to the lysis 
buffer using a NanoDrop 2000 spectrophotometer. 
 
6.7.1.3. Embryo Denaturation 
Respective amounts of Sample Buffer (made freshly following manufacturer’s 
instructions) were added in each sample according to their protein content to achieve 
a total volume of 50µl. Each sample was denatured at 95ºC for 5 minutes and loaded 




6.7.2. Performing Western Blots of Zebrafish Embryos 
6.7.2.1. Making the Gel 
0.75mm SDS polyacrylamide gels were prepared following the above recipes. Three 
quarters of the glass plates (BioRad) were, initially, filled with approximately 4ml of 
the resolving gel mix. In order to accelerate the polymerisation process and ensure 
that no bubbles formed at the top of the gel, after pouring the resolving gel between 
the plates, 1ml of isopropanol was added on top. When the gel polymerised the 
isopropanol was poured off and filter paper was used to drain any remnants of it. At 
that time, approximately 1.5ml of the stacking gel mix was poured on top of the 
resolving gel and a 15-well comb was immediately placed between the plates. 
 
6.7.2.2. Running the Gel 
The gel tank was placed in a bigger tank filled with ice to lower the temperature of 
the running buffer and promote proper running of the high lipid content samples. The 
gel was run in a 1xSDS Running Buffer at 80V until the samples reached the bottom 
of the stacking gel. The voltage was increased to 120V until the samples ran out of 
the gel.   
 
6.7.2.3. Wet Protein Transfer 
The gels containing the protein extracts were placed in a wet-transfer assembly 
cassette (Bio-Rad) containing a Hybond-C nitrocellulose membrane.  All 
components of the cassette were pre-soaked in 1x Transfer buffer. An ice tray was 
placed in the transfer tank to lower the temperature of the buffer. The transfer was 
performed at a constant current of 400mA for 1 hour at room temperature.  To ensure 
full transfer and visually monitor protein abundance, the membranes were stained 
with 0.5% Ponceau solution for 5 minutes at room temperature, with mild agitation. 





Following successful transfer, each membrane was incubated in approximately 25ml 
of 2% milk in TBST (blocking solution) for 30 minutes at room temperature with 
mild agitation. 
 
6.7.2.5. Primary antibody incubation 
Each membrane was incubated in a heat-sealed plastic sleeve, in approximately 5ml 
of primary antibody dissolved in 2% Blocking solution, overnight at 4ºC, with mild 
agitation. The table lists all the antibodies used and their respective working 
dilutions. 
 
Antibody Animal Source Dilution 
Company/ Product 
Code 
Phospho- ERK 1/2 (E10) 
Mouse 
(monoclonal) 
1:2000 Cell Signaling / 9106 
ERK 1/2 Rabbit (Polyclonal) 1:1000 Cell Signaling / 9102 
Phospho- MEK 1/2 
Rabbit 
(monoclonal) 
1:1000 Cell Signaling / 2338 








1:5000 Cell Signaling / 2128 





Biotechnology /   
sc-23948 
 
Table 6.2 List of antibodies used for immunoblotting 
 
6.7.2.6. Primary antibody washes 
After disposing of the antibody, the membranes were washed with 0.2% blocking 
solution for 2 minutes at room temperature, with mild agitation.  They were, 
subsequently, washed three times in 1xTBST, each time for 5 minutes at room 




6.7.2.7. Secondary antibody incubation 
The respective secondary antibodies were prepared in 1:2000 dilution in 2% 
Blocking solution. Each membrane was incubated in approximately 5ml of 
secondary antibody solution for 45 minutes to1 hour at room temperature, with mild 
agitation. 
 
6.7.2.8. Secondary antibody washes 
The membranes were washed 4 times for 5 minutes in TBST at room temperature, 
with mild agitation.  
 
6.7.2.9. Exposure and development of the membranes 
The membranes were briefly air-dried and the protein-side of the membranes was 
incubated with 1ml of ECL Plus (GE Healthcare) for 5 minutes at room temperature, 
following manufacturer’s instructions. The membranes were, next, sealed with clear 
cling film and directly exposed on x-ray film in a developing cassette for varying 
lengths of time, depending on the signal intensity.  The x-ray films were developed 
and the films were scanned using an HP ScanJet 4300C scanner at 600dpi. 
 
6.7.2.10. Stripping the membranes 
To incubate already used membranes in a new antibody, eliminate the signal from 
the first antibody, the membranes were mildly stripped in 1x Stripping buffer for 10 
minutes at room temperature. The buffer was discarded and the membranes were 
incubated for further 10 minutes in fresh buffer at room temperature. The membranes 
were, then, washed twice in PBST for 10 minutes at room temperature and twice in 
TBST for 5 minutes at room temperature.  At that point, the membranes were 
blocked in 2% blocking solution for 30 minutes at room temperature and primary 




6.8. Wholemount in situ hybridisation – Recipes 
 
6.8.1. Day 1 ISH Recipes 
 
20x SSC (1 L) 
NaCl 175.3 g 
Sodium Citrate 88.2 g 
ddH2O 800 ml 
Adjust the pH to 7.0 and fill up to 1L with ddH2O. 
 
Hybridisation Buffer (+)/ Hyb (+) (100 ml) 
Formamide 50 ml 
20x SSC 25 ml 
tRNA 50 mg 
Heparin 50 mg 
1M Citric Acid 920 µl 
Tween 20 500 µl 
ddH2O 22.5 ml 
pH to 6.0 
 
6.8.2. Day 2 ISH Recipes  
 
Hybridisation Buffer (-)/ Hyb (-) (100 ml) 
Formamide 50 ml 
20x SSC 25 ml 
1M Citric Acid 920 µl 
Tween 20 500 µl 
ddH2O 22.5 ml 




2x SSC (1L) 
20x SSC 100 ml 
ddH2O 900 ml 
 
0.2xSSC (1L) 
2x SSC 100 ml 
ddH2O 900 ml 
 
6.8.3. Hyb (-) ; SSC Wash Buffers 
75% Hyb (-) : 25 % SSC (50 ml) 
Hyb (-) 37.5 ml 
2x SSC 12.5 ml 
 
50% Hyb (-) : 50% SSC (50 ml) 
Hyb (-) 25 ml 
2x SSC 25 ml 
 
25% Hyb (-) : 75% SSC (50 ml) 
Hyb (-) 12.5 ml 
2x SSC 37.5 ml 
 
6.8.4. Maleic Acid Wash Buffers 
Maleic Acid Buffer (MAB) (500ml) 
Maleic acid 8.31 g 
NaCl 4.38 g 
ddH2O 400ml 
Adjust pH to 7.5 with NaOH pellets. Fill up to 500 ml with ddH2O. 
 
MAB with Tween (MABT) (500 ml) 
MAB 500 ml 




6.8.5. SSC ; MAB Wash Buffers 
75% SSC: 25% MAB (50 ml) 
0.2x SSC 37.5 ml 
MABT 12.5 ml 
 
50% SSC: 50% MAB (50 ml) 
0.2x SSC 25 ml 
MABT 25 ml 
 
25% SSC: 75% MAB (50 ml) 
0.2xSSC 12.5 ml 
MABT 25 ml 
 
6.8.6. Blocking and Antibody Staining 
MAB Block (100 ml) 
MAB 100 ml 
Roche Blocking Reagent 2g 
Dissolve at 85ºC for 30 minutes 
 
Antibody in MAB+ Block 1:5000 dilution (50 ml) 
Anti-DIG AP Antiserum
* 
 10 µl 
MAB with Block 50 ml 
* 
Anti-Digoxigenin Alkaline Phosphatase Sheep Antiserum (Roche) 
 
6.8.7. Day 3 ISH Recipes 
Staining Buffer (150 ml) 
1M Tris-HCl (pH 9.5) 15 ml 
0.5M MgCl2 15 ml 
5M NaCl 3 ml 
20% Tween 20 750 µl 
ddH2O up to 150 ml 
 
Stop Solution/ EDTA in PBST (100 ml) 
0.5M EDTA 4 ml 
PBST 96 ml 
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6.9. Wholemount in Situ Hybridisation - Methodology 
6.9.1. Day 0  
6.9.1.1. Embryo preparation 
Embryos were collected at the appropriate stage and were moved in a 2ml sterile 
microcentrifuge tube in minimal solution. They were immediately fixed in fresh 4% 
paraformaldehyde in PBS overnight at 4ºC with mild agitation. The samples were not 
left in PFA for longer than 20 hours.  
The next day, PFA was discarded and fixed embryos that had not hatched from their 
chorions,  were hand-dechorionated in PBST buffer in a new Petri dish.  
The samples were, subsequently placed in new microcentrifuge tubes and were 
serially dehydrated in PBST:Methanol solutions in the following order: 
 
5 minutes 75% PBST; 25% MeOH 
5 minutes 50% PBST; 50% MeOH 
5 minutes 25% PBST; 75% MeOH 
5 minutes 100% MeOH 
 
All steps were carried out at room temperature on a rocker for mild agitation, to 
avoid embryos sticking together. The embryos were stored in fresh 100% MeOH and 
were stored for a minimum of 24 hours at -20ºC. 
 
6.9.1.2. Riboprobe production 
 
Plasmid recovery 





 Miniprep/ Maxiprep Kit following manufacturer's 
instructions. Following plasmid purification, the DNA was eluted in 30µl of RNase-
free ddH2O. Each insert was constituted of a 900bp fragment of the gene of interest. 
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That short stretch of DNA was selected as having a unique enough sequence to be 
specific to its respective gene.  
 
Template linearisation 
The plasmids were linearised for 2 hours at 37ºC, in a 30µl reaction, using the 
appropriate restriction enzyme, according to the table below. Plasmids cut at the 5' 
end of the inserts served as DNA templates for antisense RNA probe transcription. 
Respectively, plasmids digested at the 3' end of the gene fragment were used to 
produce control sense riboprobes. 
 
Template  Endonuclease  Direction of probe Transcriptional promoter 
HggI BamHI antisense T7 
Dlx3 SalI antisense  T7 
 
Table 6.3 Transcription of hggI and dlx3 riboprobes 
 
Digestion reaction (30 µl) 
Plasmid DNA 4ug 
10x Enzyme buffer 3 µl 
Enzyme 1 µl 
ddH2O to 30 µl 
 
Ethanol precipitation of the digest 
Linear plasmid DNA was purified by ethanol precipitation. One tenth of the total 
volume of the restriction reaction (3µl) of 3M Sodium Acetate and twice the total 
volume of the restriction reaction (60µl) of 100% EtOH were added in the reaction. 
The 93µl mix was left at room temperature for 15 minutes. The mix was, then, 
centrifuged at maximum speed (13,2000 rpm) for 10 minutes at 4ºC. The supernatant 
was discarded and the DNA pellet was washed with 1ml of 70% EtOH. The mix was 
centrifuged at maximum speed for 5 minutes at 4ºC. The supernatant was, once, 
again, discarded and the pellet was air-dried for a few minutes. The DNA was re-




In vitro RNA transcription 
A total of 20µl transcription reaction was assembled on ice in RNase-free conditions. 
The transcription reaction was incubated at 37ºC for a minimum of 2 hours. 
 
Transcription reaction (20 µl) 
Linear purified DNA 10 µl 
10x Transcription Buffer (Roche)
*
 2 µl 
0.1M DTT 2 µl 
ddH2O 2 µl 
DIG UTP mix (Roche) 2 µl 
RNase inhibitor (Roche) 1 µl 
RNA Polymerase (Roche)
*
 1 µl 
 
*
 The appropriate RNA polymerase enzymes and their respective transcription 
buffers were used according to Table 6.3.  
 
Stopping the transcription reaction 
1µl of DNase (Roche) was added in the reaction and was incubated at 37ºC for 15 
minutes to digest the un-transcribed DNA template. 1µl of 0.5M EDTA was added to 
effectively halt the enzyme activity. 
 
RNA precipitation 
1.4µl of 7.5M LiCl2 and 100µl of 100% EtOH were added in the reaction and were 
mixed in by inverting the tube a few times gently. RNA was precipitated for a 
minimum of 30 minutes at -20ºC or overnight at -80ºC. The samples were, then, 
centrifuged at maximum speed at 4ºC for 40 minutes. The supernatant was carefully 
removed and the remaining RNA pellet was washed with 70% EtOH. The samples 
were centrifuged, again, at maximum speed at 4ºC for 10 minutes. The supernatant 
was discarded carefully and the RNA pellet was briefly air-dried before being re-
suspended in a mix of 25µl Hyb (+) and 25µl formamide at a total volume of 50µl. 






The concentration of the eluted probes was quantified using a NanoDrop 
spectrophotometer, normalised to the absorption of 1:1 Hyb (+):Formamide mix, and 
was recorded for future reference. 
 
6.9.2. Day 1 
 
This protocol is a slightly modified version of the wholemount in situ hybridisation 
protocol by Thisse and Thisse (Thisse and Thisse, 2008).  
 
The stored embryos were transferred in RNase-free in situ baskets that allowed easy 
transfer of the embryos between different wells with no loss of samples. The 
procedure was set up at room temperature, in a 24-well plate, with each well 




Initially, the samples were serially re-hydrated in PBST:MeOH  solutions for 5 
minutes  in each of 75% MeOH; 25% PBST, 50% MeOH; 50% PBST and 25% 
MeOH; 75% PBST.  
 
6.9.2.2. Washes 
The embryos were then washed three times, for 5 minutes each, in PBST.  
 
6.9.2.3. Digestion 
1µl of the 20mg/ml stock of Proteinase K solution was diluted in 2ml of PBST to 
achieve a final concentration of 10ug/ml Proteinase K. The embryos were digested in 




Embryonic Stage Duration of Proteinase K  Digestion 
Blastula- end of gastrulation stage 30 sec 
1-14 Somite stage 1 min 
14-22 Somite stage 5 min 
1 dpf embryos 15 min 
2-3 dpf embryos 30 min 
 
Table 6.4 Proteinase K treatment duration 
 
6.9.2.4. Fixing 
The samples were fixed, again, for 20 minutes in 4% PFA and were washed four 
times in PBST, for 5 minutes each time. 
 
6.9.2.5. Pre-hybridisation 
The samples were transferred out of the baskets into sterile RNase-free tubes and 
were incubated in 1ml of Hyb (+) solution in a 70ºC water-bath for a minimum of 2 
hours.  
If necessary, the samples were stably stored at -20ºC in pre-hybridisation solution for 
a few days. 
 
6.9.2.6. Hybridisation 
The Hyb (+) buffer was discarded and the samples were incubated in 200µl of Probe: 
Hyb (+) mix, in the following optimised dilutions, at 70ºC overnight.  
 
Hyb (+) and riboprobes (200 µl) 
HggI probe 1 µl (100 ng) 
Dlx3 probe 3 µl (200 ng) 




6.9.3. Day 2 
The hybridised embryos were transferred in fresh RNase-free baskets and placed in 
specialised ISH trays that kept the baskets in place during the agitation of the motile 
stage of the ISH machine. The following steps were followed in the automated 
Biolane HTI ISH machine. 50 ml of each solution was used for each step. The steps 
and timings were as follows. 
 
Solution Temperature Duration Repetitions 
Stringency Washes 
100% Hyb (-) 65ºC 10 min 1x 
75% Hyb (-); 25% SSC 65ºC 10 min 1x 
50% Hyb (-); 50% SSC 65ºC 10 min 1x 
25% Hyb (-); 75% SSC 65ºC 10 min 1x 
2x SSC 65ºC 10 min 1x 
0.2x SSC 65ºC 15 min 4x 
75% SSC; 25% MABT 24ºC 10 min 1x 
50% SSC; 50% MABT 24ºC 10 min 1x 
25% SSC; 75% MABT 24ºC 10 min 1x 
MABT 24ºC 15 min 1x 
    
Blocking and antibody incubation 
MAB Block 24ºC 1 h 1x 
Anti-DIG Antibody 4ºC 12 h/ overnight 1x 
 
6.9.4. Day 3 
6.9.4.1. Washes 
Following antibody absorption, the embryos were thoroughly washed and incubated 
in staining buffer as follows. 
 
Solution Temperature Duration Repetitions 
Washes 
MABT 24ºC 15 min 8x 
Staining 





The embryos were transferred out of their tray in a 24-well ISH developing plate 
where they were incubated in 500µl of BM Purple staining solution (Roche) at room 
temperature, in the dark to avoid over-exposure, with mild agitation. The embryos 
were monitored at frequent intervals using a dissecting microscope and the optimal 
exposure time for the used probes was set to 45 minutes. 
 
6.9.4.3. Stopping Signal Development  
Once the desired signal intensity was reached, the embryos were washed three times, 
for 15 minutes each, in Stop solution at room temperature. As the embryos were 
younger than 24hpf, they were transferred in low pH PBST (pH 3.0) for 5 minutes at 
room temperature.  
 
6.9.4.4. Storage 
The embryos were transferred out of their baskets into six well plates, all of the 
PBST was removed and the samples were mounted in 100% glycerol. The embryos 
were stably stored in glycerol in the dark (in a dark box) at 4ºC for months. At this 
point, the embryos were readily imaged, illuminated from above using a Nikon SMZ 
1500 stereomicroscope conjugated with a Nikon coolpix camera and were edited 
using Adobe Photoshop
®





6.10. General DNA Techniques 
6.10.1. Bacterial DNA transformation 
In order to maintain bacterial stocks containing plasmids of interest, chemically 
competent DH5α and TOP10
®
 (Invitrogen) Escherichia coli (E. coli) were 
transformed with circular plasmid DNA.  
 
Routinely, 1-2µl of plasmid DNA was incubated in 50µl of E. coli on ice for a 
minimum of 30 minutes, in sterile 1.7ml screw-top tubes, avoiding excessive 
pipetting and disturbance of the cells. The bacteria were, then, heat-shocked at 42ºC 
for 20 seconds to promote DNA uptake and were transferred back on ice for a further 
2 minutes. 250µl of pre-warmed to 37ºC, autoclaved LB broth was added in each 
tube and each sample was transferred in a 37ºC shaker were they were allowed to 
grow for 2 hours whilst horizontally being shaken at 270rpm. During this time, LB-
Agar plates with selective antibiotics were being warmed in a 37ºC incubator. At the 
end of the 2h shaking time, the samples were centrifuged for 10 minutes at 9,000 
rpm. 150µl of the supernatant were discarded and the pellet was re-suspended in the 
rest of the 150µl solution by pipetting up and down gently.  This step concentrates 
the bacterial culture.  
 
The next steps were performed within a 30cm radius of a burning blue flame of a 
Bunsen burner to avoid contamination of the samples. Two selective plates were 
used for each bacterial culture. 20µl and 100µl of the re-suspended culture were 
aseptically plated on the pre-warmed plates containing the appropriate selective 
antibiotic, corresponding to the antibiotic resistance that the plasmid confers to the 




LB Broth  (1L) 
Bacto-tryptone 10 g 
Yeast extract 5 g 
NaCl 10 g 
ddH2O 800 µl 
Adjust pH to 7.5 with NaOH 
Fill up to 1 L with ddH2O and sterilise by autoclaving 
 
LB- Agar  (1L) 
Bacto-tryptone 10 g 
Yeast extract 5 g 
NaCl 10 g 
ddH2O 800 µl 
Adjust pH to 7.5 with NaOH 
 
Agar 15 g 
Melt agar in microwave 
Fill up to 1L with ddH2O and sterilise by autoclaving 
 
Single colonies were picked from the plates with autoclaved cocktail sticks and were 
incubated in 5ml of LB enriched with the equivalent antibiotic at 37ºC overnight in a 
shaker rotating at 250rpm. This bacterial culture was further used for bacterial stock 
production or plasmid purification, as described below. 
 
Antibiotic concentrations used in LB Broth and LB Agar plates 
Ampicillin 100 µg/ml 
Chloramphenicol 25 µg/ml 
Kanamycin 50 µg/ml 
 
6.10.2. Plasmid DNA isolation 
The 5ml bacterial cultures were directly used as a starter culture to perform a 
miniprep if low quantities of DNA were required or a maxiprep if larger amounts of 
DNA were of essence, according to manufacturer's instructions (QIAprep
®
 Spin 




6.10.3. Bacterial stock preparation 
500µl of the 5ml overnight bacterial culture solution was transferred in a new sterile 
microcentrifuge tube. 500µl of sterile 80% glycerol was added in the tube and the 
solution was mixed. The samples were stably stored for long-term purposes at -80ºC. 
 
6.10.4. DNA concentration quantification 
The optical density of DNA was measured using a NanoDrop
®
 2000 
spectrophotometer, which calculated the sample absorbance at 260nm (A260). The 
purity of the DNA was determined by calculating the A260/A280 ratio, which should 
be between 1.8 and 2.0. Values smaller than 1.8 indicated protein contamination, 
whereas values larger than 2.0 suggested RNA contamination. 
 
DNA Endonuclease Digestion 
Plasmid DNA 5 µg 
10x Endonuclease Buffer 5 µl 
Endonuclease 1 µl 
ddH2O up to 50 µl 
 
The ddH2O and DNA were added first and the endonuclease was added last. If the 
restriction enzyme required BSA addition for optimal activity, 0.5µl of 100x BSA 
were added to the mix. In the case of double digestions, 0.5µl of each enzyme were 
added to minimise the glycerol concentration of the end reaction. 
 




 PCR Purification Kit 
Manufacturer’s instructions for the above kit (using a table-top centrifuge) were 
followed to clean-up DNA restriction reactions using purification columns. In the 






 Microcon YM-30 purification columns 
 The reaction was topped up with the appropriate amount of ddH2O to make up a 
total volume of 500µl and the entire mix was transferred in the Microcon tubes with 
the column inserts. The samples were centrifuged for 12 minutes at 10,000rpm. 
When the centrifugation had ended, 10 µl were added directly on the membrane of 
the column and the column was immediately turned upside down and placed in a 
new sterile collection tube. The samples were centrifuged at maximum speed (14,500 
rpm) for 1 minute and the purified DNA concentration was recorded using a 
NanoDrop spectrophotometer, normalised to ddH2O.  
 
6.10.6. Sub-cloning Using the GATEWAY® System  
 
Single-Site LR Reaction 
According to manufacturer's instructions (Invitrogen) the LR
®
 reaction was 
performed in a total volume of 10µl as follows: 
 
Entry clone 50-150ng 1-7 µl 
Destination vector 1 µl 
TE Buffer pH 8.0 up to 8 µl 
 
LR Clonase II enzyme 2 µl  
 
The reaction was incubated at room temperature overnight. To stop the enzymatic 
activity 1µl of proteinase K was added and the mix was incubated at 37ºC for 10 
minutes. 1µl of the reaction was, subsequently, transformed into chemically 





Construct Name Backbone Vector Antibiotic Resistance Host Cells 
BRAF WT** pENTR3C Kanamycin DH5α 
BRAF A246P** pENTR3C Kanamycin DH5α 
BRAF Q257R** pENTR3C Kanamycin DH5α 
BRAF G464V** pENTR3C Kanamycin DH5α 
BRAF S467A** pENTR3C Kanamycin DH5α 
BRAF K483M** pENTR3C Kanamycin TOP10 
BRAF K499E** pENTR3C Kanamycin DH5α 
BRAF G534R** pENTR3C Kanamycin DH5α 
BRAF N581D** pENTR3C Kanamycin DH5α 
BRAF D594V** pENTR3C Kanamycin DH5α 
BRAF G596V** pENTR3C Kanamycin DH5α 
BRAF T599E/S602D** pENTR3C Kanamycin DH5α 
BRAF V600E** pENTR3C Kanamycin DH5α 
BRAF D638E** pENTR3C Kanamycin DH5α 
MEK1 WT** pENTR3C Kanamycin DH5α 
MEK1 F53S** pENTR3C Kanamycin DH5α 
MEK1 F53L** pENTR3C Kanamycin DH5α 
MEK1T55P** pENTR3C Kanamycin DH5α 
MEK1 K97M** pENTR3C Kanamycin DH5α 
MEK1 G128V** pENTR3C Kanamycin DH5α 
MEK1 Y130C** pENTR3C Kanamycin DH5α 
MEK1 S218D/S222D** pENTR3C Kanamycin DH5α 
MEK1 constitutively active** pENTR3C Kanamycin TOP10 
MEK2 WT** pENTR3C Kanamycin DH5α 
MEK2 F57C** pENTR3C Kanamycin DH5α 
MEK2 A62P** pENTR3C Kanamycin DH5α 
MEK2 K101M** pENTR3C Kanamycin DH5α 
MEK2 G132V** pENTR3C Kanamycin DH5α 
MEK2 Y134C** pENTR3C Kanamycin DH5α 
MEK2 S222D/S226D** pENTR3C Kanamycin DH5α 
MEK2 K273R** pENTR3C Kanamycin DH5α 
HRAS WT** pENTR3C Kanamycin DH5α 
HRAS G12V** pENTR3C Kanamycin DH5α 
HRAS G12S** pENTR3C Kanamycin TOP10 
HRAS G12A** pENTR3C Kanamycin TOP10 
HRAS G12V** pENTR3C Kanamycin TOP10 
HRAS G13C** pENTR3C Kanamycin DH5α 
HRAS G13D** pENTR3C Kanamycin DH5α 
HRAS Q22K** pENTR3C Kanamycin DH5α 
HRAS Q61L** pENTR3C Kanamycin TOP10 
HRAS E63K** pENTR3C Kanamycin TOP10 
HRAS K117R** pENTR3C Kanamycin TOP10 
HRAS A146T** pENTR3C Kanamycin TOP10 
 
**




Construct Name Backbone Vector Antibiotic Resistance Host Cells 
BRAF WT pDEST17 Ampicillin TOP10 
BRAF A246P pDEST17 Ampicillin DH5α 
BRAF Q257R pDEST17 Ampicillin DH5α 
BRAF G464V pDEST17 Ampicillin DH5α 
BRAF S467A pDEST17 Ampicillin TOP10 
BRAF K483M pDEST17 Ampicillin TOP10 
BRAF K499E pDEST17 Ampicillin DH5α 
BRAF G534R pDEST17 Ampicillin DH5α 
BRAF N581D pDEST17 Ampicillin DH5α 
BRAF D594V pDEST17 Ampicillin TOP10 
BRAF G596V pDEST17 Ampicillin TOP10 
BRAF T599E/S602D pDEST17 Ampicillin DH5α 
BRAF V600E pDEST17 Ampicillin TOP10 
BRAF D638E pDEST17 Ampicillin DH5α 
MEK1 WT pDEST17 Ampicillin DH5α 
MEK1 F53S pDEST17 Ampicillin DH5α 
MEK1 F53L pDEST17 Ampicillin DH5α 
MEK1T55P pDEST17 Ampicillin DH5α 
MEK1 K97M pDEST17 Ampicillin DH5α 
MEK1 G128V pDEST17 Ampicillin DH5α 
MEK1 Y130C pDEST17 Ampicillin DH5α 
MEK1 S218D/S222D pDEST17 Ampicillin DH5α 
MEK1 constitutively active pDEST17 Ampicillin TOP10 
MEK2 WT pDEST17 Ampicillin DH5α 
MEK2 F57C pDEST17 Ampicillin DH5α 
MEK2 A62P pDEST17 Ampicillin DH5α 
MEK2 K101M pDEST17 Ampicillin DH5α 
MEK2 G132V pDEST17 Ampicillin DH5α 
MEK2 Y134C pDEST17 Ampicillin DH5α 
MEK2 S222D/S226D pDEST17 Ampicillin DH5α 
MEK2 K273R pDEST17 Ampicillin DH5α 
pT2Kmin-NP Dest RfA*  Ampicillin DH5α 
mitfa- BRAF WT pT2min-NP Dest Ampicillin Top 10 
mitfa- BRAF Q257R pT2min-NP Dest Ampicillin Top 10 
mitfa- BRAF S467A pT2min-NP Dest Ampicillin Top 10 
mitfa- BRAF D594V pT2min-NP Dest Ampicillin Top 10 
mitfa- BRAF G596V pT2min-NP Dest Ampicillin Top 10 
mitfa- BRAF V600E pT2min-NP Dest Ampicillin Top 10 
 
*







6.11. Capped mRNA production 
 
Capped mRNA synthesis was performed using AMBION
®
 mMESSAGE 
mMACHINE SP6 and T7 Ultra kits. The in vitro transcribed synthetic mRNA was 
capped with a 7-methyl guanosine, a structure that could only be incorporated at the 
5’ end of the construct.  
Linear purified DNA (as described above) that did not exceed 2Kb in length served 
as a template for in vitro transcription of sense mRNA following manufacturer’s 
instructions. A total volume of 20µl was achieved by assembling the reaction at 
room temperature, in the following order to avoid reagents precipitating out. 
 
 
2x NTP/Cap mix (pre-mixed to a 1:4 final ratio) 10 µl 
10x Enzyme Buffer mix 2 µl 
DNA linearised purified 6 µl 
T7/SP6 Enzyme mix 2 µl  
 
 
The reaction was incubated at 37ºC for 2hours and was stopped by adding 30µl 
ddH2O and 30µl of LiCl solution (7.5M LiCl in 50mM EDTA). The RNA was 
precipitated by transferring the mix at -20ºC for a minimum of 40 minutes. The 
samples were, then, centrifuged at maximum speed (13,200 rpm) at 4ºC for 15 
minutes. The supernatant was discarded and the resulting RNA pellet was washed 
with 70% EtOH to remove any residual ribonucleotides. The samples were 
centrifuged for a further 10 minutes at maximum speed. The EtOH was removed and 
the RNA pellet was re-suspended in 30µl ddH2O. The RNA concentration was 
determined using a NanoDrop 2000 spectrophotometer and the RNA quality was 
checked both by calculating the A260/A280 ratio on the NanoDrop and by running an 




6.12. Alcian Blue Staining of Cartilage 
 
Calculation of exact volumes was not necessary for the cartilage staining protocol, 
unless otherwise stated. It was important, however, that the embryos were always 
fully immersed in their equivalent solutions to avoid damage of the tissue, drying out 
and lack of staining.  
 
6.12.1. Embryo collection and fixing 
Embryos were collected at 5dpf and were transferred in a well of a 6-well plate, to 
ensure maximum solution penetration and to avoid embryos sticking together. After 
the maximum amount of embryo medium was removed, the embryos were 
immediately fixed in freshly prepared 4% PFA in PBS. The samples were fixed at 
room temperature with mild agitation for 7 hours. It was important that the embryos 
were not fixed for longer than 10 hours as that would affect the tissue permeability 
and, hence, the staining results. 
 
6.12.2. Post-fixing washes 
The PFA was discarded and the embryos were quickly rinsed in PBST before being 
transferred into a new well, to avoid PFA carry-over. The embryos were, 
subsequently, washed three times, for 5 minutes each, in PBST. If required, the 
embryos were stored overnight in PBST at 4ºC at this point. 
 
6.12.3. Staining 
The PBST was removed and the embryos were incubated in freshly made, syringe-
filtered 0.1% Alcian Blue solution for approximately 7 hours at room temperature. 
As the duration of this incubation step varied from 5-10 hours, depending on the 
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samples, the embryos were monitored every 30 minutes under a light microscope 
after 4 hours of staining were completed, to avoid over-staining. 
 
0.1% PBST (100ml) 
PBS 100 ml 
Tween- 20 100 µl 
 
0.1% Alcian Blue Staining Solution (100 ml) 
Alcian Blue 8GX (Sigma Aldrich) 100 mg 
100% EtOH 80 ml 
1M Glacial Acetic Acid 20 ml 
 
6.12.4. Post-staining washes 
The stain was discarded and the embryos were rinsed in 100% EtOH for a few 
seconds. The samples were, then, serially rehydrated in PBST in the following order, 
for 5 minutes each, at room temperature. 
 
70% EtOH; 30% PBST 
50% EtOH; 50% PBST 
30% EtOH; 70% PBST 
100% PBST 
 
The stained embryos were stored in 100% PBST at 4ºC overnight. 
 
6.12.5. Tissue clearing 
PBST was discarded and was replaced by 0.05% GIBCO
®
 Trypsin (Invitrogen) in 
PBS. The samples were incubated in trypsin at 30ºC for a minimum of 2 hours and 
were regularly monitored to avoid over-digestion of the embryos. The reaction was 




6.12.6. Bleaching, washes and storage 
After removing the trypsin, all residual embryo pigmentation was cleared by adding 
fresh bleaching solution. This step was rapid (approximately 5 minutes) and was 
performed under constant monitoring under a stereomicroscope at room temperature. 
The bleaching was halted when the eye pigmentation was completely gone. 
 
1% Bleaching Solution in 3% H2O2 (50 ml) 
KOH pellets 500 mg 
30% Hydrogen peroxide (Sigma) 5 ml 
PBST 45 ml 
 
To stop the bleaching reaction, the solution was replaced with PBST and the 
embryos were washed three times, for 5 minutes each time, in fresh PBST.  
 
The samples were, then serially mounted in glycerol at room temperature, in the 
following order. 
 
70% PBST; 30% Glycerol for 5 minutes  
50% PBST; 50% Glycerol for 5 minutes  
30% PBST; 70% Glycerol for 5 minutes 
 
The embryos were stably stored in the 70% Glycerol solution at 4ºC for a few 
months. 
6.12.7. Imaging 
The mounted embryos were micro-dissected with dissection forceps in order to 
remove all the tissue surrounding the craniofacial cartilage. Only the stained jaw 
structures were kept whilst the rest of the tissue was discarded. The mounted 
cartilage was imaged using a Nikon microscope and IP Lab imaging software and the 
images were edited using Adobe Photoshop
®
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Figure A-1 C-raf morpholino affects normal embryonic development 
 
Injection of wild-type zebrafish embryos with a C-raf MO promotes curling of the posterior 
structures, yolk extension defects (green arrow), close otolith proximity (blue arrow), development of 
a smaller head (red arrow) as well as an enlarged pericardium and mild atrio-ventricular anomalies 






Figure A-2 Cartilage staining of all the treated embryo groups 
 
Alcian blue staining of the jaw structures of all the embryos treated with increasing concentrations of PD0325901 
(horizontally) at different timepoints (vertically). The top panel of each group is a ventral image of the stained 
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The Ras/MAPK pathway is critical for human development and plays a central role in the formation and pro-
gression of most cancers. Children born with germ-line mutations in BRAF, MEK1 or MEK2 develop cardio-
facio-cutaneous (CFC) syndrome, an autosomal dominant syndrome characterized by a distinctive facial
appearance, heart defects, skin and hair abnormalities and mental retardation. CFC syndrome mutations in
BRAF promote both kinase-activating and kinase-impaired variants. CFC syndrome has a progressive pheno-
type, and the availability of clinically active inhibitors of the MAPK pathway prompts the important question
as to whether such inhibitors might be therapeutically effective in the treatment of CFC syndrome. To study
the developmental effects of CFC mutant alleles in vivo, we have expressed a panel of 28 BRAF and MEK
alleles in zebrafish embryos to assess the function of human disease alleles and available chemical inhibitors
of this pathway. We find that both kinase-activating and kinase-impaired CFC mutant alleles promote the
equivalent developmental outcome when expressed during early development and that treatment of CFC-
zebrafish embryos with inhibitors of the FGF-MAPK pathway can restore normal early development.
Importantly, we find a developmental window in which treatment with a MEK inhibitor can restore the
normal early development of the embryo, without the additional, unwanted developmental effects of the drug.
INTRODUCTION
Perception of the RAS-RAF-MEK-ERK mitogen-activated
protein kinase (Ras/MAPK) signalling components, known
for their role in signalling and cancer, has been altered by
the discovery that germ-line mutations underlie a series of syn-
dromes with overlapping features. These Ras/MAPK syn-
dromes include the genetic disorders neurofibromatosis Type
I, LEOPARD syndrome, Noonan syndrome, Costello syn-
drome, capillary malformation arteriovenous malformation
syndrome and cardio-facio-cutaneous (CFC) syndrome. The
overlapping clinical features, including heart defects, distinc-
tive facial appearances, skin and hair abnormalities, short
stature and mental retardation, propelled the discovery that
these syndromes are caused by germ-line mutations in the
same genetic pathway, and reflect a common underlying mol-
ecular pathogenesis through mutation of core components of
the Ras/MAPK signalling pathway. Characteristics that dis-
tinguish between the syndromes coupled with the now avail-
able sequence-based genetic testing, has been an important
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step forward in diagnosis and characterization of this group of
disorders (1).
With refined diagnostic tools in hand, there is a need to
understand the nature of the CFC mutations in vivo and
develop therapeutic approaches. Activated in most cancers,
the Ras/MAPK signalling pathway is among the key drug
targets for anti-cancer therapies (2). The pathway is activated
in tumour cells through many different ways, including
mutation of the components themselves, often through
gain-of-function mutations. For example, the BRAF oncogene
is mutated in over 60% of melanomas (3). The ‘addiction’ of a
broad spectrum of tumours to the continued activation of
Ras/MAPK signalling has made it a prime target for pharma-
cological intervention, and specific BRAF and MEK inhibitors
are currently in clinical trails (2,4–6). Although patients with
Costello syndrome are prone to developing neural crest malig-
nancies, it is not clear if CFC patients have an elevated risk of
developing cancer, with only a few individuals developing
neoplasms in different tissues (1). CFC BRAF mutations
have a wider mutation spectrum than BRAF-nevi/cancer
mutations, yet two notable similarities emerge. First, the spec-
trum of CFC and nevi/cancer mutations overlap, some with
identical mutations. Second, CFC and nevi/cancer disease
BRAF alleles result in both kinase-activating and
kinase-impaired activities in vitro (7–10). Although in vitro
functional assays have established the effects of the CFC
mutation on kinase activity, an outstanding question is how
both activating and inactivating BRAF mutations give rise to
the same clinical phenotype. We wanted to establish if CFC
allele mutations promote the same phenotypic outcome in
vivo, and which mutations are sensitive to currently available
MAPK-pathway inhibitors (11,12).
Animal models play an important role in furthering our
understanding of the pathogenesis associated with
Ras/MAPK syndromes disease alleles. Studies in transgenic
Drosophila have shown that both loss-of-function and
gain-of-function LEOPARD and Noonan syndrome PTPN11
mutations can give rise to similar developmental phenotypes
in the eye and wing veins of the fly, suggesting a rationale
for how different PTPN11 mutations can give rise to syn-
dromes with clinically overlapping phenotypes (13,14). In
zebrafish, loss of PTPN11 (SHP-2) and expression of
Noonan and LEOPARD syndrome alleles cause early cell
movement phenotypes and developmental features that
overlap with the principal features of the syndromes, including
growth and heart defects, craniofacial abnormalities and
ocular hypertelorism (15). Adult zebrafish and mouse
models of H-RasG12V reveal overlapping phenotypes with
Costello syndrome patients (16,17). Both models provide
insight into the syndrome. The zebrafish H-RasG12V model
suggests that oncogene-induced senescence contributes to the
pathogenesis of Costello syndrome (16), and the
H-RasG12V-induced cardiomyopathies in the mouse can be
prevented with treatment with standard anti-hypertensive
therapies (17). Thus, animal models can rapidly reveal the
nature of the human genetic mutation in vivo, their impact
upon development, and provide insight into evaluating new
therapeutic opportunities.
Cell culture studies have shown that CFC MEK mutant
alleles are sensitive to the widely used MEK inhibitor,
U0126 (12). Most CFC patients have mutations in BRAF,
and it has been predicted that BRAF CFC alleles might also
be sensitive to MEK inhibition (12). Given that MAPK signal-
ling plays an important role in cell movement in zebrafish gas-
trulation (18), we wanted to establish the effects of BRAF and
MEK CFC mutant alleles in early development. Here, we use
the zebrafish system to explore the function of a panel of 28
BRAF and MEK mutant alleles in development, and to
assess the potential of using small molecule inhibitors to
prevent these defects. We show that the expression of both
BRAF and MEK kinase-activating and kinase-impaired CFC
and melanoma alleles cause similar phenotypes with signifi-
cant cell movement defects in early embryogenesis. In
addition, we find that the cell movement phenotypes of both
the kinase-activating and kinase-impaired CFC alleles can be
prevented by treatment with specific MEK inhibitors. Treat-
ment is most effective within a developmental time window:
a 1 h treatment at the start of significant convergence–
extension cell movements is necessary and sufficient to
prevent the CFC induced developmental effects. FGF-MAPK
signalling is active during early embryogenesis, and therefore
we hypothesized that the inhibition of endogenous FGFR sig-
nalling might partially prevent the developmental effects of
CFC alleles in gastrulation. We show inhibition of upstream
signalling is also able to restore normal development for
CFC, except for the most active BRAF melanoma allele,
demonstrating the importance of overall activation of the
MAPK signalling during development. With sequencing-
based genetic tests available to identify individuals with
mutations, our work provides a rationale for varied kinase
activity in the CFC allele spectrum and will contribute to
the clinical discussion about the treatment strategy for individ-
uals with CFC syndrome using currently available MAPK-
pathway inhibitors.
RESULTS
CFC allele activity in zebrafish development
The Ras/MAPK pathway is highly conserved in vertebrates,
and we have used the zebrafish system to examine the func-
tional activity of CFC alleles and their response to chemical
inhibition (Fig. 1), based on the important role of the
FGF-MAPK pathway during early embryonic development.
Within the past two decades, the zebrafish system has
become established as a useful model for vertebrate develop-
mental biology and disease (19). Organogenesis in the trans-
parent embryos can be followed in vivo under the light
microscope, and specific genetic and chemical models of
human developmental syndromes have advanced our under-
standing of human disease and treatment (19–21).
Vertebrates share a conserved body plan that is established
through gastrulation, the critical process that involves extensive
cell movement and shapes the relatively unstructured early
embryo into a gastrula with conserved germ layers (18).
FGF-MAPK signalling contributes to the establishment of the
dorsoventral axis, in which the highest concentration of
FGF-signalling specifies the dorsal most part of the embryo
and acts as a local attractive centre for convergence–extension
movements within the gastrula (18). Expression of activated
2544 Human Molecular Genetics, 2009, Vol. 18, No. 14
FGF-RAS-RAF-MEK signalling in zebrafish embryo causes a
loss of localized FGF-concentration that would normally
promote convergence of cells towards the dorsal midline, but
does not affect the continued epiboly movements and thereby
results in an elongated embryo (22–24). Loss of the down-
stream ERK1 or ERK2 kinases in zebrafish also results in dis-
tinct convergence–extension cell migration defects during
gastrulation (25), as does the expression of Noonan and
LEOPARD syndrome SHP-2 alleles (15).
Building on these observations and coupled with the tract-
ability of the zebrafish system, we reasoned that the expression
of CFC mRNA in zebrafish embryos would allow us to rapidly
assess the functional significance of BRAF, MEK1 and MEK2
kinase-active and kinase-impaired variants within a develop-
mental context, and test the action of currently available
FGF-MAPK-pathway inhibitors on the CFC allele phenotypic
outcome (Fig. 1 and Table 1). We began by injecting mRNA
into the one-cell zebrafish embryo and closely monitoring
development of the effects of the high-kinase, most common
variant in melanoma, BRAFV600E, the kinase-impaired CFC/
melanoma variant, BRAFG596V and the most common
kinase-activating variant in CFC syndrome, BRAFQ257R.
Early cell-cleavage was not affected, and initial gastrulation
appeared normal. However, by 12 h post-fertilization (hpf),
the embryos were highly elongated (Fig. 1A). Later stages of
development showed that anterior embryonic structures still
formed, but that there was a lack of tail formation, similar to
ectopic MAPK signalling (22–24). In addition, the embryos
expressing the high-kinase BRAFV600E had a complete loss of
eye development (Fig. 1A). Importantly, injection of normal
human BRAF (wild-type, WT) into the embryo caused no evi-
dence of elongation, suggesting that the expression of BRAFWT
does not alter normal development, even when ectopically
expressed (Fig. 1A). Western blotting confirmed expression of
the myc-tagged BRAFWT and BRAF disease alleles (Fig. 1B).
Analysis of kinase-active and kinase-impaired CFC and
melanoma alleles
The Ras/MAPK signalling pathway is highly conserved in
humans and zebrafish. As in nevi/melanoma, the BRAF-CFC
mutations result in both kinase-activating and kinase-impaired
activities (2,7–9,26). Notably, all MEK1 and MEK2 CFC
mutations are kinase active (7,27) (K.A.R., unpublished
data). To assess the effects of the kinase-active and
kinase-impaired melanoma and CFC alleles in vivo, we gener-
ated a panel of 20 BRAF and MEK disease variants in addition
to the normal and engineered BRAF and MEK alleles
(7,27,28) (Figs 1, 2 and Table 1), and expressed each individu-
ally by mRNA injection in the zebrafish embryo. First, we
tested a panel of BRAF CFC and melanoma alleles, and
found all BRAF variants promote an elongated embryonic
phenotype, suggesting that in vivo, kinase-active and
kinase-impaired BRAF alleles can promote the same develop-
mental outcome (Fig. 2A, B and Table 1). To further test our
system, we expressed normal and CFC syndrome activating
MEK1 and MEK2 alleles, and also found that the disease
alleles, but not the normal MEKs (MEK1WT, MEK2WT), pro-
moted an elongated embryonic phenotype (Fig. 2C and
Table 1). Western blotting of zebrafish embryonic lysates for
total ERK protein and phospho-ERK confirmed that all
BRAF and MEK alleles caused ERK activation in the zebra-
fish embryo (Fig. 2B, D, E). Because the BRAFWT,
MEK1WT and MEK2WT expressing embryos developed nor-
mally, but both kinase-active and kinase-impaired alleles
caused altered embryonic development, this suggested to us
that the in vitro biochemical kinase activity might not
predict the potential for disease development. We found
both constitutively kinase-active and kinase-inactive BRAF
and MEK alleles to also promote an elongated embryonic
phenotype (Fig. 2 and Table 1), suggesting that additional
Figure 1. CFC syndrome alleles promote developmental changes during early embryogeneis. (A) RNA expression of CFC and melanoma variants BRAFQ257R
(kinase-activating, CFC), BRAFG596V (kinase-impaired, CFC and melanoma) and BRAFV600E (very high-kinase, melanoma) cause elongation of the developing
zebrafish embryo at 12 hpf, and severe developmental abnormalities at 24 and 48 hpf. In contrast, embryos expressing BRAFWT undergo normal development at
all stages. No differences were detected in WT or disease allele expressing 4 hpf embryos. (B) Western blotting of zebrafish extracts reveals expression of the
myc-tagged BRAF variants with the 9E10 antibody, and a-tubulin is a loading control.
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interactions in vivo, possibly with endogenous WT BRAF and
MEK, may be capable of altering normal development.
We observed control and CFC BRAFQ257R expressing
embryos in detail and noted initial changes to embryo shape
at 7.5–8.5 hpf (Fig. 3A). As FGF-MAPK signalling is critical
for cell movements during gastrulation, and Noonan and
LEOPARD mutant Shp2 alleles promote defective conver-
gence and extension cell movements (15), we examined
whether early gastrulation movements were affected by the
expression of BRAF and MEK disease alleles using in situ
hybridization markers (15,25). HggI (hatching gland, marker
of anterior–posterior axis) expression remained unaffected,
whereas dlx3 (edge neural plate marker, convergence
marker) was widely modified in the embryos injected with
the disease, but not normal, alleles. This indicates that the
CFC and melanoma alleles disrupt cell movements during gas-
trulation (Fig. 3B and C), similar to expression of activated
FGF-MAPK signalling in zebrafish development (22–24).
The convergence phenotypes appear more severe than the
Shp2 Noonan and LEOPARD syndromes alleles (15),
suggesting Shp2 mutations may act differently than BRAF
and MEK CFC syndrome alleles during gastrulation. The
ability to detect a clear phenotypic readout that could dis-
tinguish between BRAFWT and BRAF disease alleles,
allowed us to use the zebrafish as the basis for further investi-
gation of the CFC-pathway allele function.
BRAF kinase-active and kinase-impaired alleles can
promote an additive effect during development
Our findings, that CFC kinase-impaired mutant alleles behave
similar to kinase-active mutant alleles in vivo, are reminiscent
of the action of both gain-of-function Noonan and
loss-of-function LEOPARD Shp2 disease alleles to promote
ectopic wing vein growth in Drosophila (13,14), and cell
movement phenotypes in zebrafish (15). In zebrafish, Shp2
Noonan and LEOPARD mutant alleles are not additive, and
do not lead to an increase in the number of embryos with a
phenotype in early development (15). This suggests that
Noonan and LEOPARD Shp2 mutations induce the same phe-
notype by activating or inhibiting pathway signalling. We
investigated how BRAF kinase-activating and kinase-impaired
alleles promote similar phenotypes during embryogenesis. We
co-injected suboptimal levels of the kinase-active BRAFQ257R
allele, the kinase-active BRAFS467A or the kinase-impaired
BRAFG596V allele alone or with the BRAFWT allele (Fig. 4).
Co-injection of BRAF CFC mutant alleles with BRAFWT
did not significantly affect the number of embryos with a phe-
notype compared with the injection of the suboptimal BRAF
CFC allele alone. Only 60–66% of the embryos have an
early embryonic phenotype when expressing only one BRAF
CFC allele, or in combination with BRAFWT. In contrast,
co-injection of kinase-active BRAFQ257R with kinase-active
Table 1. Summary of the BRAF and MEK variants expressed in zebrafish
Gene Amino acid change Predicted activity Disease Developmental phenotype in zebrafish (n) Respond to treatment
BRAF Wild-type Wild-type NA No (0/40) NA
A246P ND CFC Yes (31/57) Yes
Q257R Kinase-activating CFC Yes (83/95) Yes
G464V Kinase-activating CFC Yes (25/45) Yes
S467A Kinase-activating CFC Yes (49/57) Yes
K483M Kinase-inactivating Engineered Yes (34/44) Yes
K499E Kinase-activating CFC Yes (23/44) Yes
G534R Kinase-activating CFC Yes (33/38) Yes
N581D ND CFC Yes (23/51) Yes
D594V Kinase-impaired Melanoma yes (43/56) yes
G596V Kinase-impaired CFC and Melanoma Yes (86/104) Yes
T599E/S602D Constitutively active Engineered Yes (36/73) Yes
V600E Kinase-activating Melanoma Yes (68/84) Yes CI-1040
no SU-5402
D638E ND CFC Yes (66/89) Yes
MEK1 Wild-type Wild-type NA No (0/40) NA
F53L Constitutively active Engineered Yes (16/33) Yes
F53S Kinase-activating CFC Yes (20/33) Yes
T55P Kinase-activating CFC Yes (26/45) Yes
K97M Kinase-inactivating Engineered Yes (45/62) Yes
G128V Kinase-activating CFC Yes (22/35) Yes
Y130C Kinase-activating CFC Yes (30/45) Yes
S218D/S222D Constitutively active Engineered Yes (45/55) Yes
DN3DD Constitutively active Engineered Yes (41/60) Yes
MEK2 Wild-type Wild-type NA No (0/40) N/A
F57C Kinase-activating CFC Yes (31/42) Yes
A62P Kinase-activating CFC Yes (25/39) Yes
K101M Kinase-inactivating Engineered Yes (39/52) Yes
G132V Kinase-activating CFC Yes (45/72) Yes
Y134C Kinase-activating CFC Yes (30/54) Yes
S222D/S226D Constitutively active Engineered Yes (33/49) Yes
K273R Kinase-activating CFC Yes (42/63) Yes
NA, not applicable; ND, not determined; n, number.
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BRAFS467A resulted in a significant enhancement of the
number of embryos with an elongated phenotype. In addition,
co-injection of kinase-active BRAFQ257R with kinase-impaired
BRAFG596V also resulted in a significant increase in the
number of elongated embryos. The number of embryos with
a phenotype induced by BRAFQ257R/S467A (91.9%) or
BRAFQ257R/G596V (88.2%) is consistent with the 82–87% of
embryos that develop a developmental phenotype when the
optimal dose is used (Table 1). Our results are consistent
with both the kinase-active and the kinase-impaired BRAF
CFC mutations acting as gain-of-function mutations during
development.
MEK inhibitors can prevent the effects of CFC alleles
We wanted to assess whether currently available MAPK-
pathway inhibitors might prevent the effects of CFC disease
alleles in development. Previous studies have shown that
Figure 2. Analysis and treatment of kinase-activating and kinase-impaired BRAF and MEK disease variants. (A) RNA expression of BRAF CFC and melanoma
variants, as well as engineered BRAF mutations, promotes an elongated embryo phenotype. RNA expression of wild-type BRAF has no effect on development.
The developmental phenotypes caused by the BRAF variants are prevented by treatment with the MEK inhibitor, CI-1040 and the embryo has a normal rounded
shape. (B) Western blotting of zebrafish lysates with anti-ERK and anti-phospho-ERK antibodies reveals a reduction in the ratio of phospho-ERK to total ERK
protein in treated embryos, and a-tubulin is a loading control. (C) RNA expression of CFC MEK variants, the MEK1 constitutively activating (DN3DD) and the
MEK2 kinase-inactivating K101M mutations promotes elongation in the developing embryo. Expression of wild-type MEK1 and MEK2 do not affect devel-
opment. The developmental phenotypes caused by the MEK alleles are prevented by treatment with the MEK inhibitors, CI-1040 and PD0325901. (D and
E) Western blotting of zebrafish lysates with anti-ERK and anti-phospho-ERK antibodies reveals downstream activity of phospho-ERK and confirms the
potency of the MEK inhibitors, and a-tubulin is a loading control.
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cancers with activated BRAF are highly sensitive to MEK
inhibitors (29) and that CFC MEK alleles in cell culture are
sensitive to the widely used MEK inhibitor, U0126 (12).
However, it was unknown whether the CFC kinase-activating
and kinase-impaired BRAF and MEK variants would be sen-
sitive to the inhibition of MEK during development. We
expressed BRAF CFC and melanoma alleles in developing
embryos as before, and at 4 hpf added CI-1040, a clinically
active MEK inhibitor that is the basis for new second-
generation MEK inhibitors (5,6) to the embryo medium. We
found that chemical inhibition of MEK was able to restore
normal development until 10.5 hpf in all embryos expressing
BRAF CFC and melanoma disease alleles (Fig. 2A). We
found a similar result when we expressed CFC and engineered
MEK1 and MEK2 alleles in zebrafish embryos, and treated
with CI-1040 or PD0325901, a derivative of CI-1040
(Fig. 2C). With both BRAF and MEK variants, western blot-
ting confirmed that the ratio of phosphorylated ERK to total
ERK protein was reduced after chemical inhibition of MEK
(Fig. 2B, D, E).
MEK signalling is critical for development, and we have
previously shown that prolonged treatment (up to day 4 pf)
with the pharmacological inhibition of MEK using CI-1040
causes severe axis, heart and craniofacial developmental
abnormalities (30), and we find a similar effect using
PD0325901 (C.A., E.E.P., unpublished data). Although we
were able to restore normal gastrulation in CFC embryos
with CI-1040 and PD0325901 (Fig. 2A and C), treated
embryos subsequently developed axis abnormalities associ-
ated with the effects of the inhibitor later in development
(30). To circumvent this problem, we exposed the most
common BRAFQ257R CFC allele expressing embryos to the
MEK inhibitor for 12 different treatments that varied for the
time of exposure. We found that although all experimental
treatments that involved adding the inhibitor early in develop-
ment prevented embryo elongation (10.5 hpf) (Fig. 5A treat-
ments A–F), a 1 h treatment within a 4.5–5.5 hpf
developmental window was sufficient to restore normal devel-
opment at 24 hpf (Fig. 5A treatment A), without the
additional, subsequent unwanted abnormalities caused by the
inhibitor (Fig. 5A treatments C–F). Treatment within this
early developmental window was necessary, as a 1 h treatment
later in development (Fig. 5B treatment F) was unable to
prevent CFC mutant allele phenotypes, as were the treatments
Figure 3. BRAF and MEK disease alleles promote cell movement phenotypes. (A) The most common CFC varient, BRAFQ257R, was expressed in developing
embryos, and the embryos imaged every hour. Development of the embryos begins to become affected by BRAFQ257R expression between 7.5 and 8.5 hpf. (B)
BRAF and (C) MEK disease variants promote significant changes in cell movement, as revealed by in situ hybridization. The gene expression domain of dlx3 is
altered for both expression pattern and intensity of signal, such that there is no dlx3 detected in the BRAFV600E expressing embryos. HggI expression remains
unaffected. The bottom panel shows the lateral view of the same embryos.
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that had CI-1040 throughout the experiment, with the excep-
tion of the 4.5–5.5 hpf developmental window (Fig. 5B
treatment B).
Distinguishing between BRAF alleles for sensitivity to
pathway inhibition
The ability to treat kinase-active and kinase-impaired CFC
embryos suggests correction of signalling downstream of the
CFC mutation is sufficient to restore normal development.
This is consistent with the sensitivity of cancers expressing
RAS and RAF high-kinase oncogenes to MEK inhibitors
(5,6,29), and the sensitivity of CFC MEK alleles to MEK inhi-
bition in cell culture (12). FGF-MAPK signalling plays an
important role during embryonic cell movements in zebrafish.
Unlike in a cancer cell with a BRAF mutation, a developing
animal with a BRAF or MEK CFC mutation also has endogen-
ous FGFR signalling. We hypothesized that total MAPK sig-
nalling may underlie CFC syndrome development and that
suppression of endogenous FGFR signalling could partially
suppress the activity of the effects of the downstream CFC
alleles. As with the MEK inhibitor, we treated 4 hpf
embryos expressing BRAF (Fig. 6A) and MEK (Fig. 6B)
CFC and melanoma mutant alleles with SU-5402, an inhibitor
of the FGF receptor 1 (FGFR1). Western blotting confirmed
reduction of phosphorylated ERK after SU-5402 treatment
(Fig. 6C). We found the development to be normal for all
treated embryos expressing BRAF and MEK disease alleles
at 10.5 hpf, with the exception of the very high-kinase activity
melanoma mutant BRAFV600E (Fig. 6A and B). The most
common mutation in melanoma and nevi, BRAFV600E is one
of the highest kinase activity mutants, has transforming
activity and is sufficient to promote nevi and melanoma devel-
opment, as well as other cancers, in animal models (3,26,31–
34). This suggests that total levels of MAPK signalling may be
responsible for the action of the CFC alleles, and reduction of
either endogenous FGF signalling or downstream MEK signal-
ling can prevent some of the pathological function of the
alleles.
DISCUSSION
Our study addresses the in vivo action of CFC mutant alleles
and may point to a potential therapeutic approach for individ-
uals with CFC syndrome. First, we have demonstrated that
CFC mutant alleles cause similar developmental phenotypes
in an in vivo zebrafish model system, despite their in vitro
kinase activity. Second, we have used our model system to
explore the therapeutic potential of small molecule inhibitors
to prevent the in vivo activity of CFC mutations during early
development. We have evaluated both the developmental
activity and the therapeutic potential of 18 human CFC and
three melanoma disease alleles, as well as three different
small molecule inhibitors, in 12 treatment conditions. In this
work, zebrafish embryos are injected at the single cell stage
with RNA of the human disease allele, or with control RNA,
and the phenotype of the embryo assessed by 10 h (Figs 1, 3
and 7A). Embryos normally express FGF-MAPK signalling
during development in a localized manner to shape the devel-
opment of the embryos during gastrulation (18). We found
BRAF and MEK kinase-active and kinase-impaired disease
variants interfere with convergence–extension cell move-
ments during gastrulation (Fig. 1), providing insight into
how similar clinical CFC phenotypes are caused by
kinase-activating and kinase-impaired alleles. Future studies
will reveal how the effects on early cell movement (Fig. 1)
correlate with disease allele penetrance and disease presen-
tation in humans.
In our in vivo animal system, and in the context of endogen-
ous signalling, we find CFC alleles with kinase-inactivating
mutations, as defined in vitro, promote the same phenotype
as kinase-active alleles. One possibility is that BRAF
kinase-impaired proteins interact with CRAF to stimulate
MEK-ERK signalling (9,10,35). Kinases frequently act
through dimerization, including BRAF and CRAF (10,36),
and crystal structures of MEK predict MEK1 and MEK2
self associate via a homodimerization interface to form
stable dimers (37). Such mechanisms may be at work in our
zebrafish studies, providing the molecular context for
kinase-impaired BRAF and MEK alleles to be able to
promote active signalling of the pathway, including the engin-
eered kinase-inactive alleles (36) as determined by in vitro
kinase assays (Fig. 3). Another possibility is that dysregulation
of Ras/MAPK signalling through gain-of-function or
loss-of-function mutations may cause similar disease pheno-
types (38). As an important example, the disease spectrum
associated with varying SHP-2 mutations in Noonan syndrome
and cancer argue against SHP-2 activity as the defining predic-
tor of disease outcome (39). Both loss-of-function and
gain-of-function mutations in SHP-2 lead to the clinically
Figure 4. BRAF kinase-active and kinase-impaired alleles can promote an
additive effect during development. Embryos co-expressing combinations of
suboptimal doses (15 pg) of kinase-active (BRAFQ257R, BRAFS467A) and
kinase-impaired (BRAFG596V) CFC alleles or BRAFWT mRNA were assessed
for the elongation phenotype at 10 hpf. The number of elongated embryos did
not change significantly upon expression of a single BRAF CFC allele (15 pg),
or in combination with BRAFWT (for a total of 30 pg). A significant increase
in the mutant phenotype was induced by co-injections of BRAFQ257R with
BRAFS467A (P , 0.0001) or BRAFQ257R with BRAFG596V (P ¼ 0.0003) com-
pared with the BRAF CFC allele co-injected with BRAFWT as indicated by x2
tests. The numbers in the bars indicates the percentages of elongated embryos;
n is the number of injected embryos.
Human Molecular Genetics, 2009, Vol. 18, No. 14 2549
similar LEOPARD and Noonan syndromes, and expression of
LEOPARD and Noonan syndrome alleles in zebrafish and
Drosophila produce equivalent developmental phenotypes
(15–17). Our work suggests that both kinase-active and
kinase-impaired CFC alleles are effectively gain-of-function
mutations and activate the pathway because combinations of
active and impaired BRAF mutant alleles can promote an
additive effect during early development (Fig. 4).
Designing new therapies for rare birth disorders is proble-
matic due to the great costs and research efforts of drug
development, and the required clinical safety and efficacy
testing for new therapeutics (40). Since the Ras/MAPK
pathway has been a prime target for cancer therapeutics,
application of these small molecule inhibitors presents a
possible therapeutic avenue, since the underlying molecular
dysfunction is common. Previously, the activity of CFC
MEK alleles has been shown to be sensitive to MEK inhibi-
tors in cells (12). Direct testing of the effects of anti-cancer
therapeutics on BRAF and MEK CFC characteristics in zeb-
rafish is an important next step in exploring the therapeutic
potential for CFC syndrome. Using our model, we have
tested the ability of FGF-MAPK inhibitors to prevent the
developmental effects of CFC and melanoma disease
alleles (Fig. 7B). We found that MEK inhibitors prevent
the cell migration defects caused by the disease alleles,
and also that additional developmental side-effects of the
drug could be avoided by treating the embryos within a
specific developmental time-window (Fig. 5A). These
results suggest that future studies in pre-clinical models of
CFC should explore if similar drug treatment time
windows may help ease the developmental abnormalities
and symptoms associated with CFC progression. However,
Figure 5. Identification of a zebrafish-CFC treatment window. (A) Six CI-1040 treatments (A–F) and a control treatment (G) for zebrafish embryos expressing
CFC variant BRAFQ257R reveal that all drug treatments restore normal development at 10.5 hpf (treatments A–F), whereas only treatments A and B restore
normal development both at 10.5 and 27.5 hpf. Other drug treatments (C–F) cause additional developmental defects at 27.5 hpf, most notably, reduced posterior
development. (B) Six additional drug treatments (A–F) and a control treatment (G) for zebrafish-CFC variant BRAFQ257R show that the 4.5–5.5 hpf develop-
mental window is necessary for the prevention of zebrafish-CFC early phenotypes. The percentage of embryos displaying the phenotype is given at the lower
right of each image (a minimal of n ¼ 30/experiment). Blue bars represent embryo medium, whereas red bars represent CI-1040 treatment.
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because CFC mutations affect gastrulation (Fig. 1–3), and
have an early developmental treatment window (Fig. 5),
application of MEK inhibitors for CFC syndrome patients
may be severely limited. Nonetheless, because CFC syn-
drome has a progressive phenotype, and many of the pheno-
typic effects develop post-natally, patients may still be
helped by systemic therapies after birth (1).
We also provide evidence that the developmental effects of
the disease alleles can be prevented by the inhibition
of endogenous FGFR-signalling, with the exception of one
of the highest kinase-activating melanoma mutations,
BRAFV600E (Fig. 6). We reason that as normal gastrulation
involves endogenous FGFR signalling, FGFR inhibition
reduces the total level of defective CFC BRAF or MEK signal-
ling, thereby preventing the altered cell movement phenotype.
This supports the idea that total MAPK signalling is important
in CFC development (Fig. 4), and also emphasizes the impor-
tance of testing the action of developmental syndrome mutant
alleles and inhibitors in a developing animal. In vitro, the CFC
BRAFQ257R and melanoma BRAFV600E mutant alleles both
promote similar high-kinase activity (7), and yet no individual
with CFC syndrome has been identified with a BRAFV600E
mutation. This demonstrates, for the first time, that the
BRAFV600E mutation is probably stronger in vivo than the
CFC mutations.
The high conservation of the MAPK signalling pathway
means that our CFC chemical-genetic studies in zebrafish
embryos will be relevant to the development of future pre-
clinical models of CFC. For example, mice exhibiting Apert-
like syndrome from dominant mutations in fibroblast growth
factor receptor-2 can be treated pre- and post-natally with
the small molecule MEK inhibitor, U0126 (41). We note,
however, that similar comprehensive CFC allele comparisons,
coupled with multiple treatment testing, within the short-time
span described here, is not currently feasible in mouse models.
This makes the zebrafish system a tractable tool for medical
and research geneticists to explore allele activity and thera-
peutic potential. This work establishes a foundation to
propel forward the clinical discussion and scientific strategy
for assessing the suitability of using currently available
cancer drugs to treat the progressive phenotypes of CFC in
children.
Figure 6. Treatment of BRAF, MEK1 and MEK2 variants with SU-5402. (A) The mutant phenotypes promoted by the RNA expression of BRAF variants are
prevented by pharmacological treatment with the FGFR1 inhibitor SU-5402, with the exception of the developmental phenotype caused by BRAFV600E.
(B) Similarly, the elongation promoted by MEK1 and MEK2 disease variants is prevented by SU-5402 treatment. (C) Western blotting of total zebrafish
lysates for ERK and phospho-ERK protein shows that SU-5402 treatment causes reduction of ERK phosphorylation, with a-tubulin as a loading control.
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MATERIALS AND METHODS
Animal husbandry
Adults and zebrafish embryos were raised and maintained at
28.58C. Embryos were acquired by pair matings of AB and
TL zebrafish lines.
Cloning and RNA production
Patient and engineered BRAF, MEK1 and MEK2 DNA were
cloned into pENTR 3C (Invitrogen), and using the Gatewayw
(Invitrogen) technology the DNA sequences were subcloned
into the pDEST17 (Invitrogen) vector. Expression vectors
were linearized, and in vitro transcription of synthetic
capped mRNA was performed using the T7 RNA polymerase
mMESSAGE mMACHINE Kit (Ambion).
Microinjection of embryos
Injections were performed on WT zebrafish embryos using a
nitrogen-powered Picospritzer III microinjector (Intracel) con-
jugated to a Nikon SMZ 1000 stereomicroscope. One-cell
stage embryos were injected with 35 pg (optimal) or 15 pg
(suboptimal) of capped mRNA and were monitored until
throughout the first 24 h of development.
Pharmacological inhibition of FGF and MAPK signalling
To test the prevention of the mRNA-promoted phenotype,
4 hpf embryos injected with mRNA were treated with small
molecule inhibitors. To inhibit FGFR1 activity, embryos
were incubated in SU5402 (Calbiochem) at 1 mM in E3
embryo medium (42) at 28.58C in the dark. To inhibit
MEK1/2, embryos were treated with 1 mM CI-1040 and 1or
7 mM PD-0325901 (University of Dundee) in E3 embryo
medium at 28.58C as previously described (30).
Whole-mount RNA in situhybridization
Embryos collected at the tail-bud stage were fixed overnight in
4% parafolmaldehyde/PBS at 48C, were hand-dechorionated
and dehydrated overnight in methanol at 2208C. In vitro tran-
scribed digoxigenin-labelled antisense RNA probes were syn-
thesised (Roche). Dlx3 and HggI riboprobes (15) and
whole-mount in situ hybridization were carried out following
previously described protocols (43). Anti-digoxigenin anti-
serum alkaline phosphatase was incubated in a 1:5000 dilution
overnight and the samples were washed in BCL3 solution (1 M
Tris pH 9.5, 5 M NaCl, 0.5 M MgCl2, 20% Tween 20). The
embryos were, subsequently, stained in 500 ml of BM Purple
alkaline phosphatase (Roche) for 30–45 min and the reaction
was stopped in 20 mM EDTA/PBS. Processed embryos were
imaged using a Nikon SMZ1500 stereomicroscope in conjunc-
tion with a Nikon Coolpix 5400 camera.
Protein blotting
Embryo buffer was removed, and tail-bud stage embryos were
frozen at 2808C. Samples were ribolyzed for 5 s in protein
extraction buffer [2 M Tris pH 7.5, 5 M NaCl, 1% NP40, Na
deoxycholate, 10% SDS, 0.5 M NaF, 1 M b-glycosyl phos-
phate, protease inhibitor cocktail tablet (Roche)]. The
protein content was measured and the samples were normal-
ized. Total protein extracts were analyzed by western blotting,
probed with antibodies raised in rabbit [p44/42 MAPK
(1:2000) (Cell Signaling)] and in mouse [phospho p44/42
Figure 7. Evaluation of CFC-disease variant in vivo activity and potential treatment. Schematic representation of the zebrafish-based approach designed to
examine the in vivo significance of BRAF and MEK CFC disease mutations. (A) Microinjection of BRAF or MEK CFC variant mRNA into the single-cell
zebrafish embryo promoted an elongated zebrafish embryo at 10 hpf that gives rise to an animal with severe development defects, including axis formation,
and heart defects at 24 hpf (red arrow). (B) Treatment of CFC-microinjected embryos with inhibitors of the FGF-MAPK signalling pathway (green) restores
normal development to the CFC-zebrafish embryo, possibly by restoring appropriate total levels of MAPK-signalling (green arrows).
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MAPK (E10) (1:2000), c-myc (9E10) (1:2000) (Sigma),
a-tubulin B-5-1-2 (1:50000) (Santa Cruz)]. Secondary anti-
bodies conjugated to horseradish peroxidase were used to
detect the proteins.
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